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SUMMARY 
 
Staphylococcus aureus is one of the leading causes of hospital acquired infections. The ability 
of S. aureus to acquire resistance to a diverse range of antimicrobial compounds, results in 
limited treatment options, particularly in methicillin-resistant S. aureus. A mechanism by 
which S. aureus develops reduced susceptibility to antimicrobials is through the formation of 
small colony variants (SCVs). Reduced antimicrobial susceptibility in S. aureus SCVs is not 
related to ‘classical’ mechanisms of resistance, but occurs as a direct result of the 
development of the SCV phenotype. S. aureus SCVs are frequently associated with defects in 
the bacterial electron transport chain and these defects are responsible for the characteristics 
associated with the SCV phenotype. 
 
This study aimed to investigate and characterise the selection of S. aureus SCVs in the 
presence of various antibiotics and also to examine their biofilm forming capabilities.   Four 
members of the aminoglycoside family of antibiotics were shown to select for S. aureus 
SCVs. In addition, a broad range (X 0.25 MIC – X 4 MIC) of aminoglycoside concentrations 
were shown to select for S. aureus SCVs. Characterisation of these isolates revealed that 
differences in auxotrophy, biochemical profiles, carotenoid production, haemolysis, levels of 
intracellular ATP, mutation frequency and reversion rate were present. Members of the 
tetracycline family of antibiotics were also shown to select for S. aureus SCVs. Tetracycline 
selected S. aureus SCVs show attenuated catalase, coagulase and heamolysis activity and 
reduced production of extracellular DNase and lipase and reduced susceptibility to various 
antimicrobial agents. As SCVs have been linked to persistent and recurrent infections their 
ability to form biofilms was also investigated. A range of S. aureus SCVs isolated from 
various backgrounds were shown to form greater biofilms in comparison to parent strains, 
which was attributed to increased production of polysaccharide intracellular adhesin. In 
addition S. aureus SCV biofilms displayed a more pronounced reduction in antimicrobial 
susceptibility, which was attributed to a reduction in antimicrobial penetration through SCV 
biofilms. 
 
Limited discovery of novel antibiotics in recent years and the observation that S. aureus SCVs 
can be selected for by various antimicrobial compounds highlights the need for novel 
antimicrobial compounds. Accordingly, an investigation into the susceptibility of S. aureus to 
various plant compounds was undertaken. Both S. aureus SCVs and parent strains showed 
susceptibility to five plant antimicrobials tested, of which SCVs were more susceptible to 
cinnamon bark, green tea and oregano. Resistance to these plant antimicrobials could not be 
induced and synergistic relationships between certain plant antimicrobials and antibiotics 
were demonstrated. Finally, formation of SCVs in bacterial species other than S. aureus was 
examined. Gentamicin induced SCV selection in Escherichia coli, Pseudomonas aeruginosa 
and S. epidermidis as well as chloroamphenicol and ciprofloxacin in E. coli and tetracycline 
in S. epidermidis. SCVs from these bacterial species shared common characteristics 
associated with the SCV phenotype including altered growth and biochemical profiles, 
auxotrophy for compounds involved in electron transport, reduction in expression of 
virulence factors and reduced antimicrobial susceptibility. Additionally all SCVs showed an 
increased capacity to form biofilms. 
 
The ability of certain antibiotics to select for SCVs and their increased capacity to form 
biofilms suggest that SCV are an important adaptation to aid survival and persistence in times 
of stress. Reduced susceptibility to commonly used antibiotics in SCVs signifies that the 
development of new antimicrobial compounds is required. Harnessing naturally occurring 
plant antimicrobials and their synergistic relationship with antibiotics may offer a novel 
approach to treating antibiotic resistant infections whilst overcoming antibiotic selection for 
SCVs. 
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CHAPTER 1: GENERAL INTRODUCTION  
1.1 Staphylococcus aureus  
The term ‘staphylococcus’ (from the Greek ‘staphyle’ meaning bunch of grapes) was 
originally coined by Sir Alexander Ogston to describe the grape like clusters of 
bacteria found in the pus of acute abbesses (Newsom, 2008; Ogston, 1882). To date 
there are 35 recognised species of Staphylococcus all of which are Gram-positive, 
non-motile, non-spore forming and grow optimally under aerobic conditions 
(Peacock, 2005). The majority of species grow at a temperature range of 18-40°C and 
have a high salt tolerance, defined as the ability to grown in the presence of 10 % w/v 
sodium chloride.  
 
Shortly after the discovery of the Staphylococcus genus, Anton J Rosenbach isolated a 
strain of staphylococci and named it Staphylococcus aureus due to the pigmented 
appearance of its colonies. S. aureus is a coccoid shaped bacterium that occurs singly, 
in pairs, short chains or grape like clusters (Figure 1.1). Approximately 20-30 % of 
the general human population are carriers of the bacterium, which is commonly found 
on the skin and mucous membranes (particularly the nose; Kluytmans et al., 1997). 
The golden pigment of some S. aureus on rich medium is due to the presence of 
carotenoids which are thought to protect cells from oxidants, produced by the immune 
system (Liu et al., 2005). The production of catalase and coagulase are two important 
characteristics that allow differentiation from other bacterial genera and species. 
Catalase production differentiates S. aureus from Streptococcus species and coagulase 
production allows differentiation from coagulase negative staphylococci (CoNS) such 
as S. epidermidis.  
1.1.1 Features of the S. aureus genome  
S. aureus strains Mu50 and N315 were the first to be sequenced and published in 2001 
(Kuroda et al., 2001). As of Summer 2011, the genomes of 25 different S. aureus strains have 
been sequenced (National Centre for Biotechnological Information, 2011). All the sequenced 
genomes are between 2.7 and 3 million base pairs (bp) in size and have a low G+C content 
(between 32.7 and 32.9 %). Their genomes contain a single circular chromosome which  
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A)
B)
 
 
 
Figure 1.1 Arrangement and morphology of S. aureus cells A) - Scanning electron 
micrograph of S. aureus exhibiting typical cocci morphology with the presence of 
irregular grape-like clusters. B) - Transmission electron micrograph showing S. 
aureus daughter cells which have divide and are yet to split apart.  A) Scale bar 
represents 10 µm, magnification X 4000. B) Scale bar represents 1 µm, magnification 
X 31,000. 
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encodes approximately 2700 coding sequences as well as structural and regulatory 
RNAs (Holden & Lindsay, 2008). Bacterial genomes are composed of a core genome, 
comprising of genes essential for growth and functionality coupled with an auxiliary 
set of genes (Frost et al., 2005). The S. aureus genome comprises approximately 75% 
genes involved in processes such as central metabolism and other housekeeping 
functions (Lindsay & Holden, 2004). This gene set is highly conserved between 
strains and makes up the core genome. The auxiliary gene set is composed of genes 
associated with virulence and drug resistance, which are frequently carried on mobile 
genetic elements (MGEs; Holden & Lindsay, 2008). MGEs consist of bacteriophages, 
genomic islands, plasmids and transposons all of which can move between the 
genomes of bacteria via the process of horizontal gene transfer (HGT). Analysis of 
closely related orthologues indicates that the genetic background of S. aureus has 
been vertically transmitted from a common ancestor that subsequently diverged to 
Bacillus and Staphylococcus species (Ito et al., 2003).  
1.1.2 S. aureus infections  
S. aureus commonly colonises humans as a commensal; however under certain 
conditions S. aureus behaves as an opportunistic pathogen and is the frequently the 
causative agent of various human diseases. As such it is of the most intensively 
studied bacterial species (Plata et al., 2009). S. aureus infections have been linked to a 
diverse range of medical conditions including skin, soft-tissue, respiratory, bone, 
joint, and endovascular disorders (Lowy, 1998) and are associated with prolonged 
hospital stay, increased morbidity and mortality, as well as increased healthcare costs 
(Que & Moreillon, 2010).  Pathogenesis requires the combination of various virulence 
factors including; secreted proteins, cell surface-bound proteins and cell surface 
components (Tenover & Gorwitz, 2000). These factors are regulated by a network of 
interacting genetic and environmental factors.  
1.2 Antibiotic resistance  
1.2.1 Origins of antibiotic resistance  
Antibiotics have revolutionised medicine in many respects; their introduction as a 
means to combat bacterial infection is regarded as one of the most important events in 
medical history (Davies & Davies, 2010; Overbye & Barrett, 2005). The discovery of 
penicillin by Sir Alexander Fleming in 1928 marked the birth of the antibiotic era. 
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Following the clinical success of penicillin, the development of chloramphenicol, 
tetracycline, erythromycin, rifampicin and vancomycin was achieved between 1940 
and 1960 (Yoneyama & Katsumata, 2006). However, resistance to two of the first 
commonly used antibiotics (penicillin and streptomycin) was reported in clinical 
isolates a few years after their introduction (Barber & Rozwadowskadowzenko, 1948; 
Waksman et al., 1945). Before the introduction of penicillin in the 1940s as a 
therapeutic agent, a bacterial penicillinase was identified (Abraham & Chain, 1940) 
revealing that bacterial resistance mechanisms were components of natural microbial 
populations rather than purely a consequence of human medical intervention (Bentley 
et al., 2002; D'Costa et al., 2006). Resistance elements are predicted to have been 
circulating in bacterial populations for millennia rather than emerging since the advent 
of the antibiotic era (Wright, 2007). This is strengthened by the fact that the majority 
of antibiotics originate from soil dwelling actinomycetes and resistance elements for 
self-protection are often clustered in antibiotic biosynthetic operons (Bentley et al., 
2002; Cundliffe et al., 2001). Accordingly the mechanisms of resistance to many 
antibiotics in clinical isolates have their origins in the environmental resistome 
(Alonso et al., 2001). 
 
Bacteria have the ability to adapt and adjust to changes in their environment and have 
subsequently developed protective mechanisms to reduce their susceptibility to 
antibiotics (Hogberg et al., 2010). Although this reduced susceptibility can be 
achieved via spontaneous mutation and alteration of the target gene, the majority of 
antibiotic resistance genes are acquired through HGT. Antibiotic resistance genes are 
commonly carried on mobile genetic elements such as bacteriophages, plasmids and 
transposons, allowing them to be transferred among bacteria. HGT has facilitated the 
spread of antibiotic resistance genes via gene exchange processes such as conjugation, 
transduction and transformation. The liberal widespread use of antibiotics (between 
100,000 and 200,000 tonnes per annum worldwide) has provided the requisite 
conditions to mobilise resistance genes that circulate in the environmental, into 
pathogenic bacteria (Wise, 2002; Wright, 2007). Consequently resistance to every 
antibiotic ever used in clinical practice has now been reported (Payne et al., 2007). 
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1.2.2 The cost of antibiotic resistance  
A recent conservative estimate on the cost of antibiotic resistance to member states of 
the European Union (EU) was €1.5 billion with approximately 25,000 patients in the 
EU dying each year from infections caused by multi drug resistant pathogens (So et 
al., 2010). In both Europe and the USA the most problematic pathogens associated 
with antibiotic resistance and nosocomial infections are; Enterococcus faecium, S. 
aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa 
and Enterobacter species which have been termed the ESKAPE pathogens (Rice, 
2008). Rice (2008) reported that this collection of pathogens are of exceptional 
importance as they represent paradigms of pathogenesis, transmission, and resistance. 
Currently rational and prudent use of antibiotics coupled with strict and meticulous 
hygiene policies are employed to combat the threat posed by antibiotic resistance 
(World Health Organisation, 2001). However these policies alone cannot solve the 
problem of antibiotic resistance and development of novel antibiotics is crucial for the 
future of healthcare systems across the world (Hogberg et al., 2010)  
1.2.3 Antibiotic resistance in S. aureus and the spread of methicillin-resistant  
S. aureus  
Before the antibiotic era, prognosis for patients with staphylococcal infections was 
poor. For example, a study in a Boston hospital in 1941 reported that the mortality 
rate of patients with S. aureus bacteremia was 82% (Skinner & Keefer, 1941). The 
introduction of penicillin in the 1940s greatly improved the prognosis and decreased 
mortality rates for patients that had succumb to staphylococcal infections. Soon after 
the introduction of penicillin, approximately 60% of S. aureus hospital isolates in the 
UK were reported as penicillin resistant (Barber & Rozwadowskadowzenko, 1948). 
Penicillin resistant strains carried a gene (blaZ) encoding a ß-lactamase, which 
inactivates penicillin through hydrolysis of the ß-lactam ring (Projan & Ruzin, 2006). 
The 1950s saw the spread of virulent penicillinase-producing strains that disseminated 
through hospitals (Shanson, 1981). This was followed by the development of 
semisynthetic penicillins such as methicillin, which resisted the action of ß-lactamase 
enzymes due to the presence of an acyl side chain, preventing hydrolysis (Gilmore et 
al., 2008; Kirby & Bulger, 1964; Rolinson et al., 1960). Similarly to penicillin, the 
introduction of methicillin was closely followed by the development of resistance. 
The first case of methicillin-resistance in S. aureus was reported in Britain in 1961, 
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(Barber, 1961) but resistance remained at low frequencies through the 1960s 
(approximately 1% of hospital isolates in the UK) and therefore methicillin was 
viewed as clinically effective (Parker & Hewitt, 1970). Outbreaks of methicillin-
resistant S. aureus (MRSA) began to be observed in hospitals in the 1960s (Barrett et 
al., 1968; Benner & Kayser, 1968; Colley et al., 1965) and the late 1960s and 1970s 
saw the spread of MRSA across international borders (Lowy, 2003). This was 
followed by a decline in the prevalence of MRSA in the late 1970s and 1980s due to 
the implementation of infection control policies and the introduction of gentamicin 
(Ayliffe, 1997).  
 
In the following decades epidemic strains of MRSA disseminated worldwide and 
various individual MRSA strains became prevalent in geographically distinct areas of 
the globe (Chambers & Deleo, 2009). Outbreaks of MRSA are of great concern as the 
prognosis for infected patients is worse than those infected with methicillin-sensitive 
S. aureus (MSSA). Meta analysis of S. aureus cases over a 20 year period, showed a 
significant increase in mortality was associated with MRSA bacteremia (Cosgrove et 
al., 2003). Differences in mortality have been attributed to the lower availability of 
bactericidal drugs to treat MRSA and the underlying healthcare problems in the old 
and sick rather than enhanced virulence of MRSA strains (Lowy, 2003). Furthermore, 
the cost of treating MRSA patients is twice that of treating patients with MSSA 
infections (Capitano et al., 2003), which is attributed to the increasing costs of 
vancomycin as well as implementing patient isolation practices within hospitals 
(Gilmore et al., 2008). MRSA is still prevalent and a major concern in hospitals today 
and is responsible for 19,000 deaths a year in the US (Klevens et al., 2007). This 
accounts for more deaths than the combined number of deaths from patients suffering 
from acquired immunodeficiency syndrome (AIDS) and tuberculosis (Boucher & 
Corey, 2008). 
 
The glycopeptide, vancomycin is the antimicrobial of choice for treatment of MRSA patients. 
Those who cannot tolerate vancomycin can be treated with fluroquinolones, trimethoprim 
sulfamexazole or clindamycin (Lowy, 1998). However S. aureus can also become resistant to 
these antimicrobial agents through various mechanisms (Table 1.1). In recent years other 
novel antibiotics such as linezolid and daptomycin have suffered a similar fate with resistance 
being reported soon after their introduction (Figure 1.2).  
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Figure 1.2 The development of antibiotics and progression of antibiotic resistance in S. aureus  
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Table 1.1 Mode of action of antibiotics and mechanism of resistance in S. aureus. Adapted from al - Masaudi et al., (1991), Jensen & 
Lyon  (2009) and Woodford (2005) 
 
Antibiotic Mechanism of action Resistance mechanism(s) Gene(s) Genomic Location 
Aminoglycosides Protein synthesis – inhibit 
translocation 
 
AMEs – inactivation of antibiotic 
 
aac, aph, 
ant 
 
 
Chromosome, plasmids 
and transposons 
ß-lactams (Penicillin) 
 
 
 
 Semisynthetic ß-
lactams (Methicillin) 
Peptidoglycan synthesis –
inhibits cell wall synthesis 
enzymes 
 
Peptidoglycan synthesis – 
inhibits cell wall synthesis 
enzymes 
 
Enzymatic hydrolysis of ß-lactam 
ring 
 
 
Modified PBP2a with reduced 
affinity for ß-lactams 
 
blaZ 
 
 
 
mecA 
Plasmid and transposons 
 
 
 
Chromosome  
 
Chloramphenicol Protein synthesis – inhibit 
transpeptidation  
Chloramphenicol aceltyransferase 
– inactivation of antibiotic 
 
cat Plasmid 
Daptomycin Cell membrane depolarisation 
via leakage of potassium and 
other cellular components 
 
Not completely understood – 
mutations in RNA polymerase ß-
subunit implicated 
 
rpoB Chromosome 
Quinolones DNA synthesis – inhibit DNA 
gyrase 
 
Alteration in QRDR, reducing 
affinity of enzyme-DNA complex 
for fluroquinolones 
grlA/B,  Chromosome 
Fusidic acid Protein synthesis – forms a 
stable complex with elongation 
Decreased affinity of the G factor 
for the antibiotic. Impermability 
fusA, fusB Chromosome and 
plasmid  
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factor G and ribosome 
inhibiting translocation 
 
and efflux also implicated 
 
Glycopeptides Cell wall synthesis – prevent 
incorporation of late 
peptidoglycan precursors into 
the peptidoglycan matrix 
VISA – thickening of cell wall 
 
VRSA -  alteration in composition 
of precursors resulting in reduced 
affinity for vancomycin 
 
- 
 
 
vanA 
 
 
 
 
 
Plasmid 
Macrolides, 
Lincosamides and 
Streptogramin B 
Protein synthesis – stimulates 
dissociation of peptidly-tRNA 
during elongation 
 
Methylation of adenine on 23S 
component – reduced affinity for 
antibiotics 
 
ermA, ermB, 
ermC 
 
 
 
Plasmid and transposons 
Mupirocin Protein synthesis – inhibits 
isoleucyl-tRNA synthestase 
preventing incorporation of 
isoleucine into nascent peptides 
 
Alteration of target site 
 
Acquisition of novel isoleucyl-
tRNA synthestase 
ileS 
 
 
mupA 
Chromosome 
 
 
Plasmid 
Oxazolidinones Protein synthesis – prevent 
formation of the 70S ribosomal 
initiation complex 
 
Alteration of domain V component 
of the 23S rRNA 
23S rRNA Chromosome 
Rifampicin RNA polymerase – binds to ß-
subunit of DNA dependant 
RNA polymerase 
 
Alteration of target site rpoB Chromosome 
Tetracycline 
 
Protein synthesis – inhibit 
binding of aminoacyl-tRNAs  
Tetracycline efflux proteins – 
energy dependent efflux of 
tet(K), tet(L) 
 
Chromosome and 
plasmid 
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tetracycline 
 
Ribosomal protection protein – 
promotes release of bound 
tetracycline 
 
 
 
tetA(M)           
 
 
Transposons 
Trimethoprim Tetrahydrofolic acid synthesis – 
competes with DHFR inhibiting 
reduction of dihydrofolate acid 
to tetrahydrofolic acid 
Chromosomal mutations, reduced 
affinity for trimethoprim 
 
Acquisition of unique DHFR with 
reduced affinity for trimethoprim 
dfrB 
 
dfrA,  
Chromosome 
 
Plasmid 
 
 
AMEs - aminoglycoside modifying enzymes; DHFR - dihydrofolate reductase; PBP - penicillin binding protein; QRDR - quinolone resistance 
determining region;  VISA - vancomycin intermediate S. aureus; VRSA -  vancomycin resistant S. aureus  
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1.2.4 Mechanism of methicillin-resistance in S. aureus  
Methicillin was the first synthetic penicillin to be developed and is resistant to 
hydrolysis by ß-lactamase enzymes (Kirby & Bulger, 1964; Rolinson et al., 1960). 
Methicillin binds to penicillin binding proteins (PBP) in sensitive S. aureus strains 
and inhibits cross linking of peptidoglycan, resulting in cell lysis (Wise & Park, 
1965). S. aureus possess several PBPs that are responsible for catalysing cross-linking 
reactions between peptidoglycan polymers, one of the final steps in bacterial cell wall 
assembly (Chambers, 1988). MRSA strains posses an additional PBP called PBP2a 
(also known as PBP’) which confers resistance to methicillin and all other ß-lactam 
antibiotics (Brown & Reynolds, 1980; Georgopapadakou et al., 1982). PBP2a has a 
low affinity for ß-lactam antibiotics (Hartman & Tomasz, 1984) and thus can continue 
to catalyse the formation of cross-bridges in bacterial cell wall peptidoglycan in the 
presence of ß-lactams (Berger-Bachi & Rohrer, 2002; Hartman & Tomasz, 1984). 
PBP2a is thought to have initially evolved by recombination of two genes: an 
inducible type I penicillinase gene and a PBP gene of E. coli, resulting in a β-lactam-
inducible MRSA PBP (Song et al., 1987). The genetic basis of this resistance is the 
mecA gene which encodes PBP2a. mec DNA is known to be present in S. aureus 
(Sjostrom et al., 1975), however additional DNA is present in MRSA strains (Beck et 
al., 1986; Hiramatsu et al., 2001). mecA is believed to have originated in the animal 
related staphylococcal species S. fleurettii, the sequence of which is nearly identical to 
the mecA region found in MRSA strains (Tsubakishita et al., 2010).  mecA is found on 
a mobile genetic island (GI) termed the staphylococcal cassette chromosome, mec 
(SCCmec) and is a well-developed vehicle for transmission of genes among 
staphylococcal species (Ito et al., 1999; Katayama et al., 2003).  
1.2.5 Staphylococcal chromosome cassette mec 
SCCmec is a 21 – 67 kb fragment of DNA that integrates into the S. aureus 
chromosome at a unique site (attBscc), near the origin of replication (Chambers & 
Deleo, 2009; Hiramatsu et al., 2001). attBscc is highly conserved among clinical 
strains of S. aureus and is found within an opening reading frame of unknown 
function (orfX; Ito et al., 1999). The integration off SCCmec near the origin of 
replication may provide an advantage allowing the instant utilisation of imported 
antibiotic resistance genes (Ito et al., 2003). SCCmec is a variable genetic element, 
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but contains conserved elements such as the mec operon (composed of mecA and its 
regulatory genes) and the cassette chromosome recombinase complex ccr (Holden et 
al., 2004; Ito et al., 2001). The ccr genes encode recombinases crucial for excision of 
the cassette from the chromosome and subsequent integration in the correct 
orientation (Katayama et al., 2000). Different types of SCCmec have been classified 
according to the class of the mec gene complex and the type of ccr complex that they 
contain (Table 1.2). Currently three distinct ccr genes have been identified; ccrA, ccrB 
and ccrC which are regarded as phylogenetically diverse as they share less than 50% 
DNA sequence similarity (Ito et al., 2009).  
 
The regions of SCCmec which border the ccr and mec complexes are know as 
junkyard (J) regions and are divided into three regions. J1 ranges from the 
chromosome right junction to the ccr genes, and J2 ranges from the ccr genes to mec 
complex (Ito et al., 2003). Finally, the J3 region is located between the mec complex 
and the left extremity of SCCmec. Various insertion sequences (IS), transposons, and 
plasmids have been found in SCCmec, including Tn554, IS1272, IS431, pUB110, 
pT181, and p1258; many of which carry resistance to other classes of antimicrobial 
agents (Table 1.2).  
1.2.6 Community-acquired MRSA 
Although MRSA is widely regarded as a nosocomial problem there are increasing 
reports of outbreaks and transmission in the community. Community-acquired MRSA 
(CA-MRSA) infections refer to those caused outside the hospital setting and are 
prevalent in previously healthy individuals. CA-MRSA is commonly associated with 
skin and soft tissue infections (such as furunculosis) but has also been associated with 
severe necrotising pneumonias (Zetola et al., 2005). Such infections have been 
associated with certain groups of society including injected drug users (Huang et al., 
2008), men who have sex with men (Diep et al., 2008) and people who engage in 
contact sport (Lindenmayer et al., 1998). CA-MRSA strains differ from hospital 
acquired strains as they show susceptibility to many antibiotics. This is due to the fact 
that they carry the type IV SCCmec element which carries no additional resistance 
genes (Said-Salim et al., 2003). The presence of additional virulence genes is thought 
to contribute to the pathogenicity of CA-MRSA. Genome sequencing of CA-MRSA 
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Table 1.2 Classification of SCCmec types in MRSA. (Chambers & Deleo, 2009; Deurenberg & Stobberingh, 2008; Ito et al., 2001; Ito et 
al., 2003; Ito et al., 2009) 
 
SCCmec Type Size (kb) ccr genes  mec complex Additional resistance 
elements  
SCCmec I 34 ccrA1, ccrB1 Class B  
SCCmec II 53 ccrA2, ccrB2 Class A puB110, Tn554 
SCCmec III 67 ccrA3, ccrB3 Class A pI258, pT181, Tn554, ΨTn554 
SCCmec IV 21-24 ccrA2, ccrB2 Class B  
SCCmec V 28 ccrC Class C  
SCCmec VI 24 ccrA4, ccrB4 Class B  
SCCmec VII 41-49 ccrC Class C  
SCCmec VIII 32 ccrA4, ccrB4 Class A Tn554 
 
Five (A–E) different classes of mec elements have been defined, of which three (A–C) are common in SCCmec. pUB110 carriers the ant (4’) 
gene providing resistance to several aminoglycosides. Tn554 encodes ermA providing constitutive and inducible macrolide–lincosomide–
streptogramin B (MLS) resistance. Additional resistances to cadmium, mercury and tetracycline are observed in SCCmec III via ΨTn554, pI258 
and pT181 respectively.  
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strain MW2 revealed the presence of additional virulence genes, including the 
presence of additional toxins such as the Panton-Valentine leukocidin (PVL) toxin 
(Baba et al., 2002). The increasing prevalence of community-acquired MRSA coupled 
with the substantial morbidity and mortality associated with these infections suggests 
that CA-MRSA has the potential to cause serious issues in public health (Yamamoto 
et al., 2010).  
1.2.7 Searching for novel antibiotics targets 
The dramatic increase in the emergence of antibiotic resistance coupled with the 
current difficulties facing the pharmaceutical industry means there is a pressing need 
for the development of new approaches to antibiotic discovery.  One such approach 
encompasses a new generation of screening methods. Screening novel antibiotics 
against an Escherichia coli strain that possesses resistance to commonly used 
antibiotics preselects any hits to be of a potential novel class of antimicrobial agent 
(Gullo et al., 2006). Secondly, the utilisation of techniques such as in vivo expression 
technology (IVET) and signature tagged mutagenesis (STM) may prove useful in 
novel candidates through identifying genes that are essential for the infection process 
(Alksne & Projan, 2000; Chiang et al., 1999). Yoneyama & Katsumata (2006) point 
out that the expression profiles of pathogens during infection in vivo vary greatly in 
comparison to those recreated in rich media in vitro. Therefore the use of techniques 
that can potentially identify these targets may provide novel targets for antibiotic 
development. 
 
Utilising the wealth of knowledge generated from microbial genome sequencing 
projects offers great potential in generating leads for novel antibiotics. Analysis of 
pathogen genome sequences allows for the identification of conserved enzymes that 
are essential for bacterial growth and replication (Fischbach & Walsh, 2009). A study 
by Rosamond & Allsop (2000) analysed the genomes of several respiratory pathogens 
for essential conserved genes, not present in humans. Through detailed bioinformatic 
analysis three possible candidates were selected as potential targets for the 
development of novel respiratory tract antibiotics. Finally identification of novel 
ecological niches inhabited by antibiotic producing bacteria may yield previously 
unidentified bioactive compounds (Wright & Sutherland, 2007). Abyssomicin C 
(which inhibits bacterial p-aminobenzoic acid biosynthesis) has been isolated from a 
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recently identified marine actinomycete bacterium (Bister et al., 2004). Other sources 
of novel antibiotic producing bacteria include bacterial symbionts of insects 
(Kaltenpoth et al., 2005) and arthropods (Gebhardt et al., 2002). Re-examining the 
soil dwelling actinomycetes may hold potential in the discovery of novel antibiotics as 
it has been predicted that ~ 2% of the antibiotics produced by Streptomyces have been 
identified (Baltz, 2005). Potential new targets for novel antibiotics include peptide 
deformylase (PDF) (Yuan et al., 2001), bacterial fatty acid synthesis (Payne et al., 
2001), the non-mevalonate pathway (Yoneyama & Katsumata, 2006) and signalling 
networks (two component systems and quorum sensing pathways) (Barrett & Hoch, 
1998). 
1.3 Molecular typing of MRSA 
Molecular typing of MRSA strains is an important tool in tracing outbreaks and cases 
of transmission. Various molecular epidemiological techniques have been employed 
to type and track isolates including; macrorestriction of chromosomal DNA 
(generated via restriction enzyme digestion) and profiling via pulse field gel 
electrophoresis (PFGE), nucleotide polymorphisms in the mecA gene and Tn554 
insertion patterns  (Oliveira et al., 2002). The need for more rapid methods has seen 
the development of several polymerase chain reaction (PCR) based methods including 
coagulase gene typing, random amplified polymorphic DNA (RAPD) and repetitive 
element sequence-based PCR (rep-PCR; Weller 2000). 
1.3.1 Pulse field gel electrophoresis  
Restriction enzymes (such as SmaI) are used in PFGE to digest bacterial genomes; 
strain-specific banding patterns are then generated using a specialised form of 
electrophoresis (Tenover et al., 1997). PFGE is considered to be a highly 
discriminatory typing method for studying outbreaks and hospital-to-hospital 
transmission of MRSA isolates (Deurenberg et al., 2007). This technique has been 
used to investigate the spread of clones through European countries (Deplano et al., 
2000) as well as to trace the source, transmission, and spread of nosocomial infections 
(Ichiyama et al., 1991). PFGE is reproducible and highly discriminatory typing 
method, but criticisms of the technique include its speed and the lack of a common 
nomenclature (Deurenberg et al., 2007; van Belkum et al., 1998).  
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1.3.2 Random amplified polymorphic DNA 
RAPD uses low stringency PCR with short arbitrary primers to amplify portions of 
genomic DNA followed by the separation of resulting fragments by electrophoresis 
(Williams et al., 1990). RAPD has been used to investigate a nosocomial outbreak of 
a non-phage typeable MRSA strain (Tambic et al., 1997) and the use of multiple 
primers has been demonstrated to improve discriminatory power (Cheeseman et al., 
2007).   Although RAPD is considered simpler and less time consuming, comparison 
with PFGE reveals that RAPD is less discriminatory (Saulnier et al., 1993).  
1.3.3 Multilocus sequencing  
MLST was first applied to Neisseria meningitidis in order to overcome the problems 
associated with traditional and molecular typing methods (Maiden et al., 1998). 
MLST differs from PFGE as it is a sequence-based technique and exploits the 
differences in the nucleotide sequence of several house keeping genes. Fragments         
(~ 450 bp) of these house keeping genes are sequenced and a single polymorphism 
results in the assignment of a new allele number. The combination of the seven alleles 
generates an allelic profile, which translates into a single sequence type (ST; Enright 
& Spratt, 1999). The discriminatory power of MLST was validated through 
comparison with PFGE profiles and the power of MLST as an epidemiological 
monitoring tool has been facilitated by an easily accessible online database which is 
expanded as novel STs are identified (Urwin & Maiden, 2003). MLST has been 
successfully applied to S. aureus using the seven housekeeping genes; carbamate 
kinase (arcC), shikimate dehydrogenase (aroE), glycerol kinase (glp), guanylate 
kinase (gmk), phosphate acetyltransferase (pta), triosephosphate isomerase (tpi), and 
acetyl coenzyme A acetyltransferase (yqiL)  (Enright et al., 2000). MLST has proved 
instrumental in analysing and tracing the origins and evolutionary history of MRSA 
(Enright et al., 2002; Oliveira et al., 2002).  
1.4 Small colony variants  
The first incidence of small colony variants (SCVs) was reported in 1910 when an 
irregular form of Eberthella typhosa (now known as Salmonella enterica) was 
observed (Jacobsen, 1910; Proctor, 2001). SCVs have been observed in several 
bacteria species and have been extensively studies in S. aureus.  
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1.4.1 S. aureus small colony variants  
S. aureus SCVs are slow growing, morphological variants that exist as a 
staphylococcal subpopulation and often arise after exposure to antimicrobial 
chemotherapeutics (Proctor et al., 2006). The phenotypic trait of slow growth leads to 
the development of microcolonies which are approximately 10 times smaller than 
wildtype S. aureus colonies (Proctor et al., 1995). S. aureus SCVs also demonstrate a 
number of other characteristics that are atypical for S. aureus including reduced α-
toxin production, delayed coagulase activity, the production of non pigmented 
colonies and deficiencies in certain biochemical reactions (Balwit et al., 1994; Proctor 
et al., 1995; von Eiff et al., 2000). S. aureus SCVs have been associated with 
persistent and recurrent infections and SCVs with defects in the components of the 
bacterial electron transport chain (ETC) and the biosynthesis of thymidine have been 
consistently recovered.  
1.4.1.1 Electron transport deficient SCVs  
Electron transport chain deficient SCV isolates are commonly auxotrophic for haemin 
and menadione (McNamara & Proctor, 2000; Proctor et al., 1995; Proctor & Peters, 
1998). Both play crucial roles in bacterial electron transport (Figure 1.3). Haemin is 
required for the biosynthesis of cytochromes which accepts electrons from 
menaquinone and completes the ETC. Menadione is isoprenylated to form 
menaquinone and is the acceptor of electrons from nicotinamide adenine dinucelotide 
(NADH) and flavin adenine dinucelotide (FADH2; von Eiff et al., 2001b). Haemin 
and menaquinone are both used in aerobic electron transport and mutations in their 
biosynthetic genes results in a disrupted ETC and blockage of oxidative respiration. 
Haemin and menaquinone are synthesised by the heme and men operons respectively 
(Tien & White, 1968), and mutations in genes of these operons result in the SCV 
phenotype (Bates et al., 2003; von Eiff et al., 1997b).  
1.4.1.2 Haemin and menadione auxotrophy  
S. aureus hemB mutants display typical characteristics associated with the SCV 
phenotype including micro colonies, reduced coagulase activity and reduced 
susceptibility to aminoglycosides. However, these characteristics can be reversed by 
growing hemB mutants in the presence of haemin, or by complementing the mutant 
with intact hemB (von Eiff et al., 1997b). Mutation of the menD gene (encoding 2-
succinyl-6-hydroxy-2, 4-cyclohexadiene-1-carboxylate synthase) also results in 
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mutants displaying characteristics associated with the SCV phenotype (Bates et al., 
2003; Kohler et al., 2008). Without oxidative respiration SCVs can only produce ATP 
through fermentation, which is significantly less efficient, resulting in ATP shortage 
in SCVs. ATP is required for various essential cellular functions including cell wall 
biosynthesis, the generation the electrochemical gradient and carotenoid biosynthesis 
(Figure 1.3). As a result of reduced ATP production SCVs display slower growth 
(hence smaller colonies), reduced uptake of aminoglycosides and cationic peptide 
transport and decreased pigment formation.  
 
Analysis of SCVs recovered from the clinical environment has identified further 
mutations in the heme and men operons. Haemin auxotrophy has been linked to 
mutations in hemH which is involved in the final step in haemin biosynthesis (Schaaff 
et al., 2003). The genetic basis for clinically isolated menadione auxotrophy in 
clinically isolated SCVs has also been demonstrated. DNA sequencing of the nine 
genes involved in menadione biosynthesis from osteomyelitis isolates revealed 
mutations in the gene encoding naphthoate synthase menB (Lannergard et al., 2008). 
In both studies, supplementation with haemin or menadione resulted in reversion to 
the wildtype phenotype. 
1.4.1.3 Thymidine dependent SCVs (TD-SCVs) 
TD-SCVs are frequently recovered from cystic fibrosis (CF) patients that have 
received long term treatment with trimethoprim sulphamethoxazole (SXT; Gilligan et 
al., 1987; Kahl et al., 1998). TD-SCVs share characteristics with electron transport 
deficient SCVs, such as reduced α-toxin production and lack of pigmentation (Kahl et 
al., 1998). TD-SCVs frequently display reduced susceptibility to SXT and show 
increased persistence in CF patients in comparison to wildtype strains (Kahl et al., 
2003b). In terms of their morphology TD-SCVS exhibit two distinct phenotypes when 
grown on Columbia sheep blood agar; either a ‘fried egg’ morphology (translucent 
edges surrounding a smaller, elevated pigmented centre) or pinpoint colonies 
(approximately 10 times smaller than wildtype S. aureus; Kahl et al., 2005). 
Transmission electron microscopy (TEM) revealed abnormal cell size and 
morphology (Figure 1.4). TD-SCVs are up to 8 times larger than wildtype cells due to 
‘swollen cells’ with uncompleted cross walls (Kahl et al., 2003a). Thymidine 
auxotrophy in TD-SCVs is due to mutations in thyA (which encodes thymidylate  
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Figure 1.3 Relationship between electron transport, ATP production and 
characteristics associated with the SCV phenotype in S. aureus (adapted from 
Proctor et al., 2006) Reduced ATP production results in reduced cell wall and protein 
bioysythesis resulting in reduced growth rate and production of microcolonies. ATP is 
also required for carotenoid biosynthesis, hence SCVs produce non-pigmented 
colonies. Reduced antibiotic susceptibility to aminoglycosides and cationic peptides is 
observed due to a reduction in electrochemical gradient, required for the uptake of 
these compounds.  
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Figure 1.4 TEM images of SCVS exhibiting ‘fried egg’ morphology (A, B and C), 
pinpoint SCVs (D and E) and wildtype S. aureus (F) Incomplete cell walls, 
irregular cell size and empty cells are represented by the arrows in A-E. Regular cell 
wall separation can be seen in wildtype S. aureus (F). Images reproduced from Kahl 
et al. (2003a).  
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synthase in S. aureus) and this mutation is also responsible for reduced SXT 
susceptibility (Besier et al., 2007). SXT interferes with tetrahydrofolic acid which acts 
as a co-factor for thymidylate synthase (Besier et al., 2007). Thymidylate synthase 
plays a role in DNA synthesis, catalysing the synthesis of deoxythymidine 
monophosphate (dTMP) from deoxyuridine monophosphate (dUMP). Analysis of 
clinical TD-SCVs and a thyA knock-out mutant revealed that a series of different 
mutations in thyA are responsible for the TD-SCV phenotype. Mutations in thyA 
permits TD-SCVs to bypass the SXT inhibited pathway. Thymidine is still required 
by TD-SCVs as it is essential for DNA synthesis. In order to compensate for the lack 
of thymidine, TD-SCVs increase expression of nupC, which is responsible for the 
transport of nucleotides into the cell (Chatterjee et al., 2008; Saxild et al., 1996).  If 
large amounts of thymidine are present TD-SCVs can revert to the wildtype form 
(Kahl et al., 1998) accounting for the phenotypic switching observed in TD-SCVs.  
 
Mutations in thyA have also been linked to hypermutability in TD-SCVs (Besier et al., 
2008a). Clinical TD-SCVs isolates were analysed for mutations in the methyl-directed 
mismatch repair (MMR) system. The MMR system is composed of a series of genes 
(mutS, mutL, mutH, and uvrD,) which are responsible for DNA repair in S. aureus 
(Miller, 1996). Hypermutability is associated with a truncation in mutL in TD-SCVs. 
This leads to replication errors (due to a defective DNA mismatch repair system), that 
combined with the selective pressure of SXT favour the emergence of mutations in the 
thyA gene and the formation of the TD-SCV phenotype (Besier et al., 2008a). Another 
characteristic associated with TD-SCVs is enhanced post-stationary phase survival 
(Chatterjee et al., 2007). Thymidine auxotrophy in TD-SCVs results in a delay in 
tricarboxylic acid (TCA) cycle function, preventing entry into the death phase. 
Chatterjee et al., (2007) further established that TD-SCVs utilise contrasting 
metabolic pathways during stationary phase in comparison to hemB mutants.  
 
Although TD-SCVs are frequently isolated from CF patients, patients suffering from 
other medical conditions are known to harbour TD-SCVs (Besier et al., 2008b). In all 
cases, patients were suffering from various chronic infections and had been 
administered long term SXT treatment. Similarly to TD-SCVs isolated from CF 
patients, sequence analysis showed mutations in thyA were responsible for the SCV 
phenotype. Besier et al. (2008) also showed that dTMP (a metabolite of thymidine) 
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was found in the majority of specimens analysed. The level of dTMP is crucial to the 
phenotypic appearance of S. aureus SCVs as high concentrations result in reversion to 
the wildtype phenotype (Zander et al., 2008).  
1.4.1.4 CO2 Auxotrophy   
Auxotrophy for CO2 has been reported in S. aureus SCVs (Hale, 1951; Thomas, 
1955). Growth in the presence of CO2 restores pigment and α-toxin activity (Thomas, 
1955), similar to the supplementation with auxotrophic compounds observed in ETC 
deficient SCVs. Recently a Spanish hospital reported the isolation of CO2-dependent 
SCVs of S. aureus in which auxotrophy for CO2 was confirmed by growth in 5% CO2 
for 18 hours (Gomez-Gonzalez et al., 2010). SCVs were isolated from a range of 
patients suffering from infections such as catheter-related bacteremia, and wound and 
respiratory infections. The authors concluded that they were unaware of any 
alterations in bacterial metabolism that may cause this type of variant or the genetic 
mechanism for reversion to a rapidly growing form. Auxotrophy for CO2 is rarely 
reported in S. aureus SCVs, however the isolation of CO2 auxotrophs suggests that 
specific atmospheric requirements may be needed to isolate and characterise these 
variants (Pinto & Merlino, 2011). 
1.4.2 SCV formation 
The mechanisms behind the formation/generation of SCVs are yet to be fully 
understood. Regulatory as well as genetic events might be involved, especially since 
many SCVs are unstable and form revertants growing as large colonies. Schaaff et al., 
(2003) have examined whether an increased mutation rate favours the formation of 
SCVs by comparing E.coli wildtype with mutS - mutants (part of the damage-directed 
MMR crucial for proofreading during DNA replication; Horst et al., 1999). Results 
showed that the emergence of spontaneous SCVs was 556-fold higher in the mutS - 
mutants than in the wildtype strain, concluding that a high mutation rates favours the 
emergence of SCVs. These finding are similar to those observed in TD-SCVs (see 
section 1.4.1.3), suggesting that mutations may play a role in the formation of SCVs. 
The widely reported ability of antimicrobials such as aminoglycosides to select for 
SCVs (Balwit et al., 1994; Musher et al., 1977) suggests that certain antimicrobials 
may induce SCV formation. Recently, aminoglycoside-induced SCV formation has 
 23 
been linked to the activity of an alternative sigma factor in S. aureus (see section 
1.4.8.2).  
1.4.3 Infections associated with S. aureus SCVs  
A range of human infections have been associated with S. aureus SCVs (Table 1.3), 
many of which have been linked to persistent and recurrent outbreaks. In humans 
cystic fibrosis and osteomyelitis infections have been frequently attributed to the 
presence of S. aureus SCVs, as well as bovine mastitis in dairy cattle (von Eiff et al., 
1997; Kahl et al., 1998; Atalla et al., 2008).  
1.4.3.1 Cystic fibrosis  
TD-SCVs are frequently recovered from CF patients and has been linked to treatment 
with SXT (see section 1.4.1.3). SCVs have the ability to replace wildtype strains in 
the CF environment and demonstrated increased levels of persistence (Kahl et al., 
2003b). Transcriptional analysis of TD-SCVs showed low levels of expression of the 
accessory gene regulatory (agr; which acts as a genetic control for various virulence 
factors) and increased expression of genes regulated by the alternative sigma factor, 
σ
B
 (Moisan et al., 2006). Altered transcriptional profiles may serve as an optimised 
adaptation to the CF lung, facilitating increased persistence in comparison to wildtype 
strains (Proctor et al., 2006). 
1.4.3.2 Osteomyelitis  
S. aureus SCVs have also been isolated from patients being treated for osteomyelitis, 
which is often treated with beads that provide a slow release of an antimicrobial (von 
Eiff et al., 2001b). SCVs isolated from osteomyelitis patients frequently display, 
auxotrophy for haemin and/or menadione and up to a 32 fold greater gentamicin 
minimum inhibitory concentration (MIC; von Eiff et al., 1997a). Analysis of patient 
case history revealed that patients infected with S. aureus SCVs were more likely to 
undergo relapses of osteomyelitis, strengthening the link between SCVs and recurrent 
infection. As gentamicin treatment for S. aureus SCV infection is no longer effective 
in osteomyelitis patients, treatment with hydroxyapatite cement (HAC) loaded with 
vancomycin has been trialled in animals (Joosten et al., 2005). HAC/vancomycin-  
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Table 1.3 Isolation of S. aureus small colony variants from human infections  
 
Source information  Auxotrophy  SCV associated observations Reference 
Patients treated with penicillin CO2 - Sherris, (1952) 
Sepsis and osteomyelitis patients Menadione and thymidine  Reduced aminoglycoside susceptibility Acar et al., (1978) 
Septic arthritis patient  Menadione  Reduced aminoglycoside susceptibility Spearman et al., (1996) 
Osteomyelitis patients treated with 
gentamicin beds 
Haemin and/or menadione  Clonal PFGE profiles, SCVs associated with 
recurrent infections  
von Eiff et al., (1997a) 
CF patients  Haemin, thymidine, 
and/or menadione 
Clonal PFGE profiles, resistance to antifolate 
agents  
Kahl et al., (1998) 
Sepsis in an AIDS patient  Thymidine and 
menadione  
Reduced antibiotic susceptibility, delay in 
identification resulting in patient mortality  
Seifert et al.,  (1999) 
Persistent wound infection treated 
with clindamycin  
Haemin and menadione  Misidentified as CoNS Abele-Horn et al., (2000) 
Patient with Darier’s disease  Haemin  Reduced antibiotic susceptibility, increased 
intracellular persistence  
von Eiff et al., (2001a) 
Recurrent ventriculoperitoneal shunt-
related meningitis   
Haemin  Clonal PFGE profiles, misidentified as CoNS by 
automated identification systems  
Spanu et al., (2005) 
Prosthetic joint infection  - Clonal PFGE profiles, SCV infection resulted in 
removal of prosthetic device  
Sendi et al., (2006) 
 
AIDS – acquired immunodeficiency syndrome; CoNS – coagulase negative staphylococci; CF – cystic fibrosis; PFGE – pulse field gel electrophores
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treated animals showed eradication of infection and furthermore HAC/vancomycin 
treatment did not induce SCV formation. 
1.4.3.3 Bovine mastitis  
Bovine mastitis is commonly associated with dairy cattle and is defined as 
‘inflammation of the mammary gland’ (Bradley, 2002). Although limited studies are 
available, the presence of S. aureus displaying the SCV phenotype has been detected 
in S. aureus positive milk samples produced by cows suffering from chronic mastitis 
(Atalla et al., 2008). Persistent infection in bovine mastitis may be due to the ability 
of SCVs to persist for longer periods in bovine mammary epithelial cells, creating a 
reservoir of bacteria for persistent or relapsing infections (Atalla et al., 2010a). 
Antibody-mediated (AMIR) and cell-mediated immune responses (CMIR) display 
marked differences in cows infected with SCVs in comparison to those infected with 
wildtype S. aureus (Atalla et al., 2010b). A lack of immune activation in the host is 
thought to aid SCV persistence in cows with chronic mastitis. 
1.4.4 Identification and susceptibility testing of SCVs  
As S. aureus SCVs display many characteristics that are abnormal for wildtype strains 
they pose difficulties in identification and isolation in the laboratory (Figure 1.5). The 
production of non-pigmented, non-hemolytic colonies on solid agar may lead to          
S. aureus not being detected. Additionally, SCVs can be missed as they are easily 
overgrown by wildtype S. aureus due to a much slower dividing rate of SCVs (180 
minutes for SCVs and 20 minutes for wildtype; von Eiff et al., 2001b). Lack of 
coagulase production and reduced haemolytic activity mean staphylococcal SCVs and 
are often misidentified as CoNS (McNamara & Proctor, 2000; Seaman et al., 2007). A 
study evaluating commonly used media for recovery of S. aureus showed that SCVs 
often failed to produce the phenotypic characteristics required in order to obtain a 
positive S. aureus culture result (Kipp et al., 2005). In order to avoid misidentification 
the extension of conventional culture techniques is desirable. It was concluded that 
laboratories should be specifically looking for SCVs in samples from patients who 
have received long-term therapy or when an infectious disease has been unusually 
persistent. Suspected SCVs that provide abnormal standardised testing results should 
be confirmed as S. aureus by testing the species-specific genes (von Eiff, 2008). A 
non-conventional diagnostic approach using a 16S rRNA-directed in situ 
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hybridisation technique has been shown to be successful in correctly identifying SCVs 
as S. aureus (Kipp et al., 2003).  
1.4.5 Reduced antimicrobial susceptibility in SCVs 
Reduced antimicrobial susceptibility in SCVs does not result from the classical 
mechanisms of antimicrobial resistance such as production of β-lactamases (to 
inactivate β-lactam based antibiotics) or efflux pumps (to pump antimicrobials out 
from the cell; al Masaudi et al. 1999). The mechanism of reduced susceptibility 
relates to characteristics associated with the SCV phenotype. For example, reduced 
aminoglycoside susceptibility is related to the lack of a functional electron transport 
chain (Figure 1.3). The uptake of positively charged aminoglycoside molecules 
requires the presence of a differential charge to be present across the bacterial 
membrane (Kohanski et al., 2010). In aerobically growing bacteria this is present due 
to the presence of an electrochemical gradient (due to an active ETC). In SCVs 
however, interruption of the ETC reduces the electrochemical gradient across the 
bacterial membrane, decreasing the uptake of aminoglycosides (Proctor, 2006). 
Interruption of the ETC is also responsible for reduced susceptibility to cell wall 
specific antibiotics as limits on ATP production reduce cell wall biosynthesis which is 
associated with a four fold increase in the MIC of cell wall specific antibiotics 
(McNamara & Proctor, 2000). Finally, the survival of S. aureus SCVs within host 
cells reduces the effectiveness of antibiotics that have a limited ability to penetrate 
eukaryotic cells, such as ß-lactams and vancomycin (Darouiche & Hamill, 1994).  
 
Various antimicrobial agents can select for SCVs which result in reduced 
susceptibility to these selecting compounds through unique mechanisms. Pan et al., 
(2002) discovered that exposure of S. aureus to sparfloxacin and a ciprofloxacin 
derivative gave rise to SCVs which exhibited reduced susceptibility to 
fluroquinolones. In order to identify a genetic basis for the mutations that gave rise to 
reduced fluroquinolone susceptibility the quinolone resistance-determining region 
(QRDR) of the gyrA, gyrB, grlA, or grlB genes were sequenced. No alterations in the 
sequence of the QRDRs were detected. The reduced fluroquinolone susceptibility may 
be related to depletion of intracellular ATP levels which is known to protect against 
quinolone killing via reducing gyrase-mediated DNA cleavage (Li & Liu, 1998).  
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Triclosan, a synthetic bisphenol antimicrobial agent, has also been shown to select for 
S. aureus SCVs (Seaman et al., 2007). The target of triclosan is enoyl reductase 
(encoded by fabI) responsible for bacterial fatty acid bioysythesis (Sivaraman et al., 
2004). Mutations in fabI have been shown to result in reduced triclosan susceptibility 
in S. aureus (Fan et al., 2002).  Sequencing of fabI in S. aureus SCVs however 
revealed 100% sequence similarity with wildtype susceptible fabI sequences, 
suggesting a novel mechanism for reduced triclosan susceptibility. Despite the 
aforementioned examples, there are examples where reduced antimicrobial 
susceptibility is in S. aureus SCVs is due to mutations in the target gene. Norstrom et 
al., (2007) identified novel mutations in fusA (translation elongation factor) and rplF 
(ribosomal protein L6) in SCVs selected for in the presence of fusidic acid. These 
mutations gave rise to reduced fusidic acid susceptibility through altering the 
structural conformations of translation elongation factor EF-G on the ribosome. 
1.4.6 Construction of mutants representing the SCV phenotype  
Several mutants have been artificially generated in order to provide insights into the 
SCV phenotype. von Eiff et al. (1997b) constructed a stable S. aureus SCV by 
interrupting the hemB gene with an erythromycin cassette. The resulting mutants 
displayed a classic SCV phenotype with reduced coagulase and pigment production, 
reduced susceptibility to aminoglycosides and increased intracellular persistence. The 
same methodology has been used to interrupt the S. aureus menD gene, resulting in a 
stable menadione auxotrophic SCV (Bates et al., 2003). Both mutants have been used 
to further the understanding of the SCV phenotype and to demonstrate the link 
between deficiencies in electron transport and SCV characteristics.  
1.4.6.1 Microarray and protein profiling analysis of hemB- and menD- mutants   
Microarrays allow the production of a ‘gene expression profile’ or ‘signature’ for a 
particular organism under certain environmental conditions and provide high levels of 
data output to investigate bacterial metabolism (Ehrenreich, 2006; Lucchini et al., 
2001). Seggewiss et al., (2006) performed a comparative, genome-wide transcriptome 
analysis of the S. aureus hemB- mutant. A difference in the expression of 170 genes 
was recorded with 122 genes significantly up-regulated in the hemB- mutant in 
comparison to the parent strain. Glycolytic and fermentation pathways were 
upregulated in the hemB- mutant due to deficiencies in the ETC. Similar expression  
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Figure 1.5 Cycling of the SCV phenotype and identification issues Antibiotic treatment of S. aureus infections can select for SCVs. Reduced 
expression of virulence factors may lead clinicians to believe antibiotic therapy has eradicated infection and antibiotic therapy ceases. Removal 
of the antibiotic selective pressure that maintains SCV phenotype, permits reversion to the virulent wildtype form 
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profiles have been generated from microarray analysis of SCV menD- mutants, 
although genes involved in nitrate respiration and fermentation pathways were further 
upregulated in the menD- mutant (Kohler et al., 2008). 
 
Phenotype microarray (PM) technology consists of preconfigured well arrays in 
which each well tests a different cellular phenotype (Bochner et al., 2001). Individual 
wells are continuously monitored and results are combined with bioinformatic 
software to allow high throughput screening of cellular phenotypes. PM technology 
has been applied to hemB- and menD- SCV mutants to screen over 1,500 phenotypes 
(von Eiff et al., 2006). Analysis showed that both mutants were defective in utilizing a 
variety of carbon sources. The menD- mutant was found to be more metabolically 
restricted than the hemB- mutant as more metabolic pathways in   S. aureus utilise 
menaquinone than haemin. An absolute protein quantification approach by 
Kriegeskorte et al., (2011) showed an agreement with previous microarray studies; 
1019 cytoplasmic proteins in S. aureus were identified of which 154 were 
differentially regulated in SCVs. Proteins involved in the TCA cycle were down 
regulated as well as certain virulence markers. Notably, differences in the expression 
of proteins involved in glycolysis were observed between SCV isolates, suggesting 
that variation exists in SCVs isolated from different environments.  
1.4.6.2 Virulence and persistence of hemB- and menD- mutants in animal 
models  
Incorporating SCVs into several established animal models has provided insights into   
S. aureus SCV host/pathogen interactions. Both hemB- and menD- mutants have been 
investigated in a rabbit model of endocarditis to study virulence and rates of infection 
(Bates et al., 2003). The capacity to induce experimental endocarditis was similar in 
the two mutants when compared to the wildtype parent strain.  This was surprising as 
SCVs produced reduced amounts of α-toxin and exhibit reduced rates of growth. The 
menD- mutant accumulated at lower densities than the hemB- mutant and parent 
strains, which may be related to its slower growth rate of the menD- mutant. The 
nematode Caenorhabditis elegans has also been used to study host/pathogen 
interactions of both the hemB- and menD- mutants. In contrast to the rabbit model of 
endocarditis, both mutants (as well as clinically derived SCVs) were shown to be less 
virulent in nematodes than parental strains (Sifri et al., 2006). Reduced exoprotein 
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production due to the loss of a functional electron transport chain was suggested to be 
responsible for the reduced virulence of SCVs. Finally, the hemB- mutant also been 
examined in a murine model of septic arthritis (Jonsson et al., 2003). In contrast to 
other animal model results that concluded that the hemB- mutant was more virulent in 
comparison to parent strains. Mice inoculated with the hemB- mutant developed more 
severe clinical arthritis which was linked to higher protease production and decreased 
adhesive properties of the hemB- mutant, enhancing invasiveness. Although the 
animal models discussed show varying degrees of virulence it is clear that SCVs are 
associated with altered virulence profiles. Alterations in the expression of virulence 
factors are considered key to increased intracellular persistence of S. aureus SCVs, 
allowing the ability to cause persistence and recurrent infections. 
1.4.7 Intracellular persistence  
SCVs have the potential to persist in the presence of antimicrobials via methods that 
extend beyond classical mechanisms (see section 1.4.5). One such method is 
encompassing the intracellular environment known as the ‘intracellular milieu’. 
Bacteria have to meet several criteria in order to be able to survive intracellulary, 
including; not killing the host cell by inducing apoptosis, resisting intracellular host 
defences, not activating the host immune system and the ability to replicate in the host 
cytoplasm (Sendi & Proctor, 2009). Assays have demonstrated that SCVs fulfil these 
criteria by persisting intracellulary in endothelial cells (Balwit et al., 1994; von Eiff et 
al., 1997b), and persisting in keratinocytes in a patient suffering from Darier’s disease 
(a inherited rare cutaneous disease; von Eiff et al., 2001a; Copper & Burge 2003). 
SCVs isolated from the Darier’s disease patient were shown to persist >100 fold more 
in comparison to the normal phenotype.  
 
The intracellular milieu itself can trigger the emergence of SCVs in S. aureus (Vesga 
et al., 1996). Intracellular bacteria were shown to develop the SCV phenotype at a 
much greater rate than bacteria not exposed to an intracellular environment in bovine 
endothelial cells. Tuchscherr et al., (2010) showed that during infection in endothelial 
cells SCVs exhibit increased expression of fibronectin-binding proteins (FnBPs; 
aiding host cell invasion) and avoid activation of the host cell immune system. The 
latter is linked to the down regulation of virulence factors such as haemolysins, which 
when produced by S. aureus induce inflammation and tissue destruction. The lack of 
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expression of virulence factors, and reduction of damage to host cells in SCVs can be 
correlated to low levels of RNAIII and agr which act as genetic controls to various 
virulence factors (Proctor et al., 2006). The study by Tuchscherr et al., further 
illustrated that SCVs were able to persist in endothelial cells for prolonged periods of 
time (in comparison to wildtype S. aureus), which was attributed to differences in 
gene expression.  
 
Another recent study by Tuchscherr et al., (2011a) highlighted the importance of the 
SCV phenotype when S. aureus is exposed to intracellular conditions. Over the course 
of infection in various in vivo and in vitro models, the S. aureus phenotype gradually 
changed to favour the SCV phenotype. However, SCVs recovered were shown to be 
extremely unstable, reverting to the wildtype form following subculture. These studies 
suggest that S. aureus has the ability to adopt different phenotypes, adapting to hide or 
attack host cells in certain conditions. The switch to the SCV phenotype appears to 
serve as an adaptation for persistence in S. aureus and the intracellular milieu may act 
as reservoir for recurrent infections as patients infected with SCVs can experience 
disease free periods, lasting several years only for the infection to re-emerge years 
later (Proctor & Peters, 1998; Tuchscherr et al., 2011a).  
1.4.8 Global regulators of S. aureus with relevance to the SCV phenotype  
1.4.8.1 Accessory gene regulator (agr) 
The agr system consists of two divergently transcribed loci which are controlled by 
two promoters (Peng et al., 1988). These neighbouring promoters (P2 and P3) 
regulate the transcription of two transcripts RNAII and RNAIII, respectively (Novick 
et al., 1993). The P2 transcript contains four genes agrB, D, C, and A, of which agrB 
and agrD together produce an autoinducing peptide (AIP; Novick et al., 1995). AIP 
increases transcription from the agr promoters P2 and P3 corresponding to an increase 
in transcription of the effector molecule RNA III. agr is responsible for the regulation 
of 138 genes in S. aureus of which approximately 20 are putative virulence 
determinants (Dunman et al., 2001). These include cell wall associated factors (that 
facilitate attachment to the host) and secreted exotoxins that aid in the invasion 
process. Due to this role in the regulation of virulence factors, agr plays an important 
role in the infection process. During the initial stages of infection agr activity is low 
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and adhesion factors are expressed, but as infection progresses agr activity increases 
inducing the production of exotoxins (Otto, 2001).  
 
Due to the absence of certain virulence factors in SCVs, the role of agr in SCVs has 
been investigated. Analysis of thymidine auxotrophic SCVs isolated from CF patients 
and SCV isolates from bovine mastitis has revealed that levels of agr expression are 
reduced or almost absent in SCVs (Atalla et al., 2008; Kahl et al., 2005). agr controls 
the expression of α-hemolysin, which correlates to the lack of α-hemolysin frequently 
observed in SCVs. The expression of the exoprotein coagulase is also regulated by the 
agr locus (Atalla et al., 2011) and reduced expression of agr correlates with the lack 
of or complete absence of coagulase activity observed in SCVs.  
1.4.8.2 Sigma B  
Alternative sigma factors in bacteria are involved in regulating gene expression in 
response to environmental signals such as changes in temperature or pH shifts 
(Hecker et al., 2007; Kullik et al., 1998).  Three alternative sigma factors have been 
identified in S. aureus; sigma A (Deora & Misra, 1996) sigma B (Wu et al., 1996) and 
sigma H (Morikawa et al., 2003), all of which are closely related to their respective 
forms in Bacillus subtilis. Regulation of σB is modulated by rsbU, rsbV, rsbW gene 
products which sit in a chromosomal cluster along with sigB (Bronner et al., 2004). 
Under non stress conditions RsbW acts as an anti-sigma factor and holds σB in an 
inactive complex (Pane-Farre et al., 2006). Under stress conditions RsbV is 
dephosphorylated by RsbU and forms a RsbV–RsbW complex. This permits the 
release of free σB, which binds to RNA polymerase to form an active σB-holoenzyme 
(Bronner et al., 2004). Microarray based analysis has shown that σB influences the 
expression of 251 genes, 198 of which are positively influenced (Bischoff et al., 
2004). Cell envelope biosynthesis, signalling pathways and various virulence factors 
were among some of the diverse cellular processes influenced by σB. Numerous 
studies have examined σB activity in S. aureus SCVs. A collection of TD-SCVs 
isolated from CF patients exhibited decreased σB activity in comparison to isogenic 
wildtype strains (Kahl et al., 2005). σB activity in these strains however was restored 
upon supplementation with thymidine suggesting that regulatory mechanisms are 
responsible for the various alterations observed. In contrast, another study showed 
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SCVs isolated from CF patients exhibited increased σB activity in compassion to 
parent strains (Moisan et al., 2006). Increased σB activity was correlated to 
persistence in eukaryotic host cells which was impaired in a σB deficient mutant. 
Mitchell et al. (2008) demonstrated that this may be related to increased expression of 
FnBPs, (which are positively influenced by σB) which permits increased adhesion of 
S. aureus to host tissues.  
 
Recently σB has been implicated in the emergence of SCVs following exposure to 
aminoglycosides (Mitchell et al., 2010a). Sub-inhibitory concentrations of gentamicin 
and tobramycin significantly increased the frequency SCV formation in S. aureus 
strains with σB+ background, where-as fewer SCVs were recovered from a  σB- 
constructed mutant (Mitchell et al., 2010a). Quantitative PCR (qPCR) also 
demonstrated that sub-inhibitory concentration of gentamicin and tobramycin induced 
σB activity. Exposure to 4-hydroxy-2-heptylquinoline-N-oxide (HQNO; an 
antistaphylococcal exoproduct produced by P. aeruginosa; Machan et al., 1992) has 
also been shown to select for S. aureus SCVs via a σB dependent mechanism. 
Exposure to HQNO resulted in a concomitant activation σB of and repression of agr 
(Mitchell et al., 2010b). Additionally, elevated σB levels were responsible for 
increased FnBP expression and increased biofilm formation.  
1.5 SCVs in bacterial species other than S. aureus  
Although S. aureus SCVs are the most extensively studied, SCVs have been isolated 
from a broad range of Gram-negative and Gram-positive bacteria including 
Pseudomonas aeruginosa (Haussler et al., 1999b; Haussler et al., 2003b), E. coli 
(Lewis et al., 1991), CoNS such as S. epidermidis, and S. capitis (von Eiff et al., 
1999) E. faecalis (Wellinghausen et al., 2009) and Burkholderia pseudomallei 
(Haussler et al., 1999a). Notably, the majority of these species are of significant 
medical importance in conditions such as cystic fibrosis (CF), nosocomial infections 
and device related infections. Research bias in favour of clinically-important species 
many account for the reporting of SCVs in the aforementioned groups and little is 
know about SCVs in the environment. Despite this bias, there is paucity of 
publications on SCVs in species other than S. aureus. SCVs of these species share 
some of the characteristics associated with S. aureus SCVs, including auxotrophy 
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(Funada et al., 1978; Wellinghausen et al., 2009), reduced susceptibility to 
aminoglycosides (Gerber & Craig, 1982; Haussler et al., 1999a), and altered 
biochemical profiles (Langford et al., 1989; Voureka, 1951). 
 35 
1.6 Project aims  
 
• Investigate the ability of various aminoglycosides to select for S. aureus SCVs across a 
range of concentrations.  
 
• Characterise aminoglycoside selected SCV isolates to determine if variation is present 
among SCV isolates and if any variation is influenced by the concentration of selecting 
aminoglycosides. 
 
• Investigate if the tetracycline group of antibiotics can select for S. aureus SCVs and to 
characterise any tetracycline selected SCVs.  
 
• Examine biofilm formation in S. aureus SCVs and compare biofilm formation with parent 
strains.  
 
• Examine biofilm susceptibility to antimicrobials and the effects of antimicrobial agents 
on biofilm mass and cells within biofilms. 
 
• Identify if a difference in antimicrobial susceptibility of biofilms formed by S. aureus 
SCV and parent strains is present. If a relationship is present, elucidate a mechanism for 
difference in susceptibility. 
 
• Investigate the anti-staphylococcal effects of various plant compounds produced by the 
CASE sponsor, Cultech Ltd, and compare SCV and parent susceptibilities.  
 
• Investigate if resistance to these compounds can be induced and if they have a synergistic 
relationship with clinically used antibiotics.  
 
• Identify if antibiotics can select for bacterial species other than S. aureus and characterise 
any antibiotic selected SCVs using species specific assays. 
 
• Examine biofilm formation in SCVs of other bacterial species. 
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2 CHAPTER 2: AMINOGLYCOSIDE SELECTION FOR 
STAPHYLOCOCCUS AUREUS SMALL COLONY VARIANTS 
2.1 Introduction  
2.1.1 Aminoglycoside classification and mode of action 
Gentamicin, neomycin, streptomycin and tobramycin are all examples of amino 
sugars that are members of the aminoglycoside family. Aminoglycosides have a 
backbone structure which is made up of an aminocyclitol ring saturated with amine 
and hydroxyl substitutions (Shakil et al., 2008). Aminoglycosides can be 
distinguished on the basis this aminocyclitol ring. For example, streptomycin contains 
streptidine as its aminocyclitol unit (Figure 2.1), where as gentamicin, kanamycin and 
neomycin are 2-deoxystreptamine containing aminoglycosides (Magnet & Blanchard, 
2004).  
 
Aminoglycosides exhibit activity against a range of clinically important pathogens 
including Escherichia coli, Salmonella spp., Shigella spp., Pseudomonas spp., 
Staphylococcus aureus and some streptococci (Vakulenko & Mobashery, 2003). 
Aminoglycosides display good synergetic activity with other antibiotic classes (such 
as β-lactams) and are therefore used in the treatment of a range of bacterial infections 
including meningitis, pneumonia, tuberculosis and even plague (Nakamura et al., 
2000; Shakil et al., 2008). Aminoglycosides bind to the 16S rRNA, at the tRNA 
acceptor A site and interfere with protein synthesis (Magnet & Blanchard, 2004). The 
exact mechanism of action of aminoglycosides is uncertain and multiple mechanisms 
may be involved. It has been suggested that the binding of aminoglycosides induces 
the misreading of messenger RNA producing defective proteins, but aminoglycosides 
may also interfere with initiation complexes (Wirmer & Westhof, 2006). 
Aminoglycoside uptake in Gram-positive bacteria takes place in two distinct phases. 
Firstly, energy-independent binding of aminoglycosides to phospholipids and teichoic 
acids occurs. This is followed by an energy-dependent transport across the 
cytoplasmic membrane, provided a sufficient membrane potential (∆Ψ) is present 
(Taber et al., 1987).  
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Gentamicin Neomycin
Kanamycin Streptomycin
Streptidine 
2-deoxystreptamine 
 
 
Figure 2.1 Chemical structure of aminoglycosides used in this study. Adapted 
from Klostermeier et al., (2004).  
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2.1.2 Aminoglycoside resistance  
Streptomycin was the first aminoglycoside to be discovered following its isolation 
from the actinomycete Streptomyces griseus in 1944 and was shown to be active 
against Mycobacterium tuberculosis (Schatz & Waksman, 1944{Schatz, 1944 #773)}. 
The antibiotic was later shown to be clinically effective in the treatment of 
tuberculosis (Hinshaw et al., 1946). Resistance however was reported just two years 
later (Youmans et al., 1946). Currently resistance to aminoglycosides can be acquired 
by four different mechanisms: i) alteration of the target; ii) interference with transport 
of the antibiotic; iii) enzymatic inhibition of the antibiotic; iv) substitution of the 
target (Veyssier & Bryskier, 2005).   
2.1.2.1 Aminoglycoside resistance in S. aureus  
Aminoglycoside resistance is common in staphylococci and has been surveyed by the 
SENTRY Antimicrobial Surveillance Programme (Schmitz et al., 1999). Nineteen 
European hospitals were surveyed and found that 23% of S. aureus isolates were 
resistant to gentamicin, 29% to tobramycin, 31% to kanamycin and 21% to 
streptomycin.  High level aminoglycoside resistance in S. aureus can be conferred by 
mutations in the 30S domain of the bacterial ribosome, leading to altered 
aminoglycoside binding (Schito, 2006). However, the most common mode of 
resistance is through aminoglycoside modifying enzymes (AMEs) which inactivate 
many aminoglycosides of therapeutic importance (Jensen & Lyon, 2009). AMEs can 
be grouped into three categories according to their mode of action on the 
aminoglycoside substrate; acetyltransferase (AAC), phosphotransferase (APH) and 
nucleotidyltransferase (ANT; Woodford, 2005). Aminoglycosides are chemically 
modified by AMEs (through covalent modification of specific amino or hydroxyl 
functions), which results in poor binding to the ribosome (Mingeot-Leclercq et al., 
1999).  AMEs are often located on plasmids, transposons and integrons permitting 
lateral transfer of aminoglycoside resistance among certain bacterial populations 
(Shakil et al., 2008).   
2.1.2.2 Reduced aminoglycoside susceptibility in S. aureus small colony variants  
Small colony variants (SCVs) however do not follow these ‘classical mechanisms’ of 
resistance. Reduced susceptibility to aminoglycosides in SCVs is due to a failure to 
accumulate aminoglycosides intracellulary (Miller et al., 1980). As SCVs are 
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defective in electron transport, SCVs display a reduced ∆Ψ. Reduced ∆Ψ across the 
bacterial membrane results in a lowered uptake of positively charge compounds such 
as aminoglycosides (Proctor & Peters, 1998). Monitoring ∆Ψ in S. aureus parent and 
SCV strains Baumert et al. (2002) showed that following the accumulation of glucose, 
∆Ψ in SCVs dropped rapidly. The reduction in ∆Ψ was directly linked to a 10-30 fold 
reduction in aminoglycoside susceptibility. Low level or complete absence of ∆Ψ in 
anaerobic bacteria confers intrinsic resistance to aminoglycosides (Bryan et al., 1979) 
highlighting the importance of ∆Ψ for aminoglycoside susceptibility.  
2.1.3 Aminoglycoside selection for S. aureus SCVs 
Various classes of antimicrobial agents have been demonstrated to select for S. aureus 
SCVs most notably aminoglycosides and trimethoprim-sulfamethoxazole (SXT) 
(Gilligan et al., 1987; Kahl et al., 1998). Other antibiotics such as fusidic acid 
(Norstrom et al., 2007), members of the fluroquinolones (pazufloxacin and 
sparfloxacin; Mitsuyama et al., 1997; Pan et al., 2002) and biocides such as triclosan 
(Seaman et al., 2007) have all been shown to induce SCV formation. Extracellular 
products produced by other bacteria have also been implicated in the formation of S. 
aureus SCVs. 4-hydroxy-2-heptylquinoline-N-oxide (HQNO) and pyocyanin 
produced by P. aeruginosa both interfere with the S. aureus electron transport chain 
(ETC) and have been demonstrated to select for SCVs in vitro (Biswas et al., 2009; 
Hoffman et al., 2006).   
 
Aminoglycosides are the most commonly reported antimicrobial to be associated with 
the selection of S. aureus SCVs, with cases of both in vivo and in vitro selection for 
SCVs being documented. In the clinical setting SCVs are often recovered from 
patients who are being treated for osteomyelitis (von Eiff et al., 1997), which is often 
treated by surgical placement of gentamicin beads in bones where infection is present. 
The use of gentamicin beads provides a steady release of antimicrobial to the site of 
infection over the course of weeks or months if required (Evans & Nelson, 1993). It is 
hypothesised that the slow release of low levels of gentamicin into the infected area is 
an efficient way to select for SCVs (von Eiff et al., 1998). Several studies have 
demonstrated aminoglycosides can readily select for SCVs in vitro (Balwit et al., 
1994; Kaplan & Dye, 1976; Musher et al., 1977). SCVs selected for by 
aminoglycosides in vitro share characteristics with those isolated from patients 
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receiving aminoglycoside treatment. Aminoglycoside selected SCVs are frequently 
auxotrophic for haemin and menadione (Balwit et al., 1994; von Eiff et al., 1997), 
which relates to defects in the ETC and ATP generation (see section 1.4.1.1). 
 
2.1.3.1 Molecular mechanisms for aminoglycoside induced SCV selection 
The formation of SCVs in S. aureus has been postulated to involve underlying 
regulatory and genetic mechanisms. Schaaff et al. (2003) demonstrated that mutations 
are involved in the emergence of aminoglycoside selected SCVs. Sequencing of the 
haemin operon of a gentamicin selected, stable haemin auxotroph revealed the 
presence of a deletion in the hemH gene. Mutation in hemH leads to the inactivation 
of last step of haemin biosynthesis and is responsible for the auxotrophy for haemin 
displayed. Global regulators have also been demonstrated to play a role in SCV 
formation. Recently the alternative transcription sigma factor, sigma B (σB) has been 
implicated in the formation of SCVs (Mitchell et al., 2010a). S. aureus strains with a 
σ
B+ and σB- background were exposed to subinhibitory concentrations of gentamicin 
and gene expression was monitored. Emergence of SCVs was promoted in the 
presence of aminoglycosides in the σB+ strain; however SCVs were not detected from 
the σB- strain. Additionally the presence of aminoglycosides in the exponential phase 
of growth significantly increased the expression of σB and correlated with the 
emergence of SCVs.    
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2.1.4 Aims  
Although aminoglycosides such as gentamicin are known to select for S. aureus 
SCVs, little is known about the effect of different aminoglycosides and different 
concentrations on SCV selection. Differences in auxotrophy have been reported in 
aminoglycoside selected SCVs, no study has conducted analysis on variations that 
may exist in SCVs selected from different aminoglycoside concentrations. Therefore 
the aims of this study were to: 
 
• Examine the ability of gentamicin, kanamycin, neomycin and streptomycin to 
select for S. aureus SCVs 
• Examine the effect of aminoglycoside concentration on growth rate  
• Determine SCV selection frequencies in the presence of various aminoglycoside 
concentrations 
• Confirm SCV isolates are S. aureus via species specific multiplex PCR 
• Characterise SCV isolates on the basis of auxotrophy, ATP concentration, 
heamolysis, carotenoid biosynthesis, and reversion rate 
• Examine and compare mutation frequency in SCV isolates 
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2.2 Materials and methods 
2.2.1 Bacterial strains  
S. aureus American Type Culture Collection (ATCC) strain 25923 and epidemic 
methicillin-resistant S. aureus (EMRSA) strain 15 were included in this study in order 
to represent well characterised MSSA and MRSA strains respectively. Both strains 
are susceptible to a range of aminoglycosides according to published CLSI guidelines. 
Strains were maintained at -80°C in Mueller Hinton (MH) broth supplemented with     
8% dimethyl sulfoxide (DMSO) and re-isolated on MH agar plates when required.  
2.2.2 Preparation of aminoglycoside stock solutions  
Gentamicin, kanamycin, neomycin and streptomycin were all obtained from Sigma 
Aldrich (UK). Manufactures potencies were used to determine amounts of each 
aminoglycoside powder required to produce a 10,000 mg/L solution. All powders 
were dissolved in sterile deionised water, dissolved thoroughly (through vortex 
mixing) and filter sterilised with a 0.2 µm filter (Minisart, UK). Reduced strength 
stock solutions were made where required in deionised water and all stock solutions 
were stored at 4°C for a maximum of 14 days.  
2.2.3 Determination of minimum inhibitory concentrations  
Minimum inhibitory concentrations (MICs) were determined according to Clinical 
Laboratory Standard Institute (CLSI) guidelines (CLSI, 2006). Cation adjusted 
Mueller Hinton (CAMHB) was used for MIC determination and stock solutions of 
CaCl2 and MgCl2 were prepared and added to MH broth to ensure each batch 
contained the correct concentrations of CaCl2 (20 mg/L) and MgCl2 (10 mg/L). 
Individual S. aureus colonies (3-4) were inoculated into CAMHB and incubated at 
37°C with shaking at 150 rpm. Cultures were grown to the end of logarithmic phase 
and cell densities were adjusted to match the turbidity of a 0.5 McFarland standard at 
625 nm. The range of antimicrobial concentrations to be tested was decided and 
concentrations were made in CAMHB at double the required concentration to allow 
for dilution by the inoculum.  Microtitre well plates (Fisher, UK) were inoculated with 
100 µL of required antimicrobial concentrations and 100µL of inoculum to provide a 
test inoculum of 5 X 105 CFU/mL. Microtitre plates were incubated at 37°C without 
shaking and the MIC was recorded as the lowest concentration that inhibited visible 
growth after 18 hours.  
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2.2.4 Determination of minimum bactericidal concentrations  
Minimum bactericidal concentrations (MBC) were determined according to CLSI 
guidelines (CLSI, 1999) with recommendations from Peterson & Shanholtzer (1992). 
All non-turbid wells from MIC experiments were further examined to determine 
MBCs. Wells were stirred gently with a pipette tip and 100 µL aspirated onto the 
surface of an antimicrobial free MH agar plate. In order to avoid carryover of 
antimicrobial agents, samples were dispensed onto the centre of a MH agar plate and 
streaked down the centre to allow the broth to be absorbed into the agar. The 
inoculum was then spread over the plate with a sterile glass rod. Plates were then 
incubated at 37°C and examined for growth after 24 and 48 hours. Following 
incubation, plates were analysed for growth and the number of colony forming units 
(CFU) recorded. The MBC was recorded as the lowest concentration that provided a 
99.9% reduction from the initial inoculum.  
2.2.5 SCV selection assays  
Aminoglycosides were prepared in CAMHB at concentrations of X 0.25 MIC, X 0.5 
MIC, MIC, X 2 MIC and X 4 MIC and dispensed into wells of a microtitre well plate. 
S. aureus strains ATCC 25923 and EMRSA 15 were grown in CAMHB as described 
previously (section 2.2.3), and dispensed into wells contain aminoglycosides to 
achieve a starting inoculum of 5 X 105 CFU/mL. Aminoglycoside concentrations 
were prepared to double the final concentration to allow for dilution by the inoculum 
and control wells containing aminoglycoside free CAMHB were also included. 
Microtitre plates were incubated for 24 hours at 37°C without shaking. Following 
incubation, wells were analysed for the presence of SCVs by aspirating 100 µL of 
individual well contents onto MH agar containing the defined MIC for the 
aminoglycosides tested. Agar plates were inverted and incubated for 48 hours at 37°C. 
Additionally serial dilutions of wells were prepared in phosphate buffered saline and 
plated onto aminoglycoside free MH agar to calculate the number of wild type CFU. 
Suspect SCVs were subjected to coagulase analysis using Staphylase test kit (Oxoid 
Ltd, UK). Several colonies of suspected SCVs were smeared onto a test circle on a 
reaction card. A drop of test reagent was added and colonies mixed into reagent using 
a sterile wire loop. The presence of agglutination indicated the colonies being tested 
were coagulase positive, whereas the absence of agglutination was recorded as 
coagulase negative. Microcolonies that were coagulase negative were recorded as 
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SCVs and the SCV formation frequency was calculated as the number of SCVs per 
CFU counts on aminoglycoside free MH agar.   
2.2.6 S. aureus growth characteristics in the presence of aminoglycosides  
Growth dynamics in a range of aminoglycoside concentrations were examined using a 
Bioscreen C analyser (ThermoFisher UK). Aminoglycoside concentrations and           
S. aureus cells were prepared as described previously (section 2.2.3) and inoculated 
into honeycomb bioscreen plates (Growth Curves Ltd, Finland). Plates were incubated 
for 48 hours at 37°C with shaking for 5 seconds before every optical density 
measurement at intermediate intensity. Optical density was read using the wideband 
filter (450 – 580 nm) every 10 minutes. Aminoglycoside free CAMHB was used to 
obtain growth curves in the absence of aminoglycosides which served as controls.  
2.2.7 DNA extraction 
S. aureus DNA was extracted using the GenElute Bacterial Genomic DNA Kit (Sigma 
Aldrich, UK). Overnight S. aureus parent and SCV cultures were pelleted by 
centrifuging at 10,000 rpm in microfuge tubes. 200µL of lysis buffer (consisting of 
200 U/mL lysostaphin and 2 x 106 U/mL lysozyme) was used to resuspend pellets, 
which were subsequently incubated for 30 minutes at 37°C. Proteinase K solution   
(20 µL) was then added followed by addition of 200 µL of manufacturers specific 
lysis solution. Samples were vortexed thoroughly in order to create a homogenous 
mixture and incubated at 55°C for 10 minutes. DNA binding columns were optimised 
for binding using ethanol, followed by the addition of the previously prepared lysate. 
Samples were centrifuged at 8,000 rpm for 1 minute, followed by 2 additional 
washing steps before eluting bound DNA by the addition of 200 µL manufactures 
elution solution. Finally sample were centrifuged for 1 minute at 10,000 rpm and the 
remaining elute (regarded as pure genomic DNA) stored at 4ºC until required.  
2.2.8 Species confirmation  
As S. aureus SCVs are frequently difficult to identify a modified version of the 
quadriplex PCR protocol developed by Zhang et al. (2004) was employed to confirm 
that SCV isolates were in fact S. aureus. PCR targeted 16S rRNA (Staphylococcus 
genus specific), nuc (S. aureus species specific), and mecA (a determinant of 
methicillin resistance) using the primers in Table 2.1.  
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All PCR reagents were supplied by Qiagen (UK). PCR was carried out in 25 µL 
reactions with 2 µL template DNA (approximately 50 ng/µL) being added to a 23 µL 
PCR mixture consisting of; sterile polished deionised water, 1 X Coralload buffer, 1 X 
Q solution, 1.5 mM MgCl2, 0.12 µM each 16S rRNA and mecA primers, 0.04 µM 
each nuc primer, 200 µM dNTPs, and 1 unit Taq DNA polymerase. PCR was 
conducted in a Flexigene Thermal Cycler (Techne Ltd., UK) with the following cycle; 
5 min at 94°C, followed by 10 cycles of 94°C for 40 seconds, 68°C for 40 seconds, 
and 72°C for 1 min and 25 cycles of 94°C for 1 min, 58°C for 1 min, and 72°C for 2 
min, and a  final hold at 72°C for 10 min. PCR products (12 µL) were run on 2% w/v 
agarose (Sigma Aldrich, UK) gels and were visualised with ethidium bromide (0.5 
µg/mL final concentration in TAE buffer; 40 mM Tris-acetate, 1 mM EDTA) for 30 
minutes. Molecular standards were run on gels using Hyperladder I (Invitrogen, UK).  
2.2.9 Analysis of SCV isolates  
For the purpose of following experiments, where required SCV and parent strains 
were grown in MH broth at 37°C with shaking at 150 rpm. Parents were incubated for 
24 hours whereas SCVs were incubated for 48 hours to allow sufficient growth.  
2.2.9.1 Biochemical analysis 
API STAPH strips (Biomerieux, France) were used to analysis the ability of SCV 
isolates to ferment certain carbohydrates and to examine enzyme production. A direct 
colony suspension of SCV and parent cells was prepared in API STAPH suspension 
medium (Biomerieux, France) and 100 µL added to all tubes. Anaerobic conditions 
were created by the overlaying of mineral oil to ADH and URE tests. Parent test strips 
were incubated at 37°C for 24 hours where as the incubation period was extended to 
48 hours for SCV isolates. Positive/negative results were read based on colour 
changes outlined by the API STAPH guide. The catalogue of the enzymatic reactions 
tested and resulting colour changes are listed in Appendix 1.   
2.2.9.2 Haemolytic assay of growth medium  
Haemolytic activity of parent and SCV strains was analysed using the method of 
Brouillette et al., (2004). Optical density of cultures was measured at 650 nm and 
recorded. Cultures were then centrifuged at 10,000 rpm for 5 minutes and the 
supernatant collected. 1 mL of supernatant was incubated with 5 mL of sheep red 
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Table 2.1 Primers used in multiplex PCR for species confirmation of SCVs  
 
Primer 
 
Sequence (3’- 5’) 
Staph756F AACTCTGTTATTAGGGAAGAACA 
Staph750R CCACCTTCCTCCGGTTTGTCACC 
MecA1 GTAGAAATGACTGAACGTCCGATAA 
MecA2 CCAATTCCACATTGTTTCGGTCTA 
Nuc1 GCGATTGATGGTGATACGGTT 
Nuc2 AGCCAAGCCTTGACGAAC TAAAGC 
 
 
Lyophilised primers were obtained from MWG Eurofins (Germany). 100 pmol stocks 
were obtained by the addition of nuclease free H2O.  
 47 
blood cells (Oxoid, UK) for 1 h at 37 °C to allow lysis. Red blood cell debris was 
pelleted by centrifugation and released haemoglobin was measured at 540 nm. 
Haemolytic activity was estimated based on the ratio of OD540/OD650. 
2.2.9.3 Reversion rates 
Rates of reversion were calculated using the method of Seaman et al., (2007). Ten 
SCV colonies were suspended in 3 mL of 0.9% NaCl and used to inoculate an 
antibiotic free MH agar plate. After 48 hours growth at 37°C the number of wildtype 
colonies was counted and the frequency of reversion was determined as the number of 
wildtype CFU per SCV.  
2.2.9.4 Carotenoid production 
Carotenoid production was quantified using a methanol extraction protocol 
(Morikawa et al., 2001). Cells were pelleted by centrifuged at 10,000 rpm for 5 
minutes and washed once with PBS. Cells were resuspended in 200 µl methanol and 
heated at 55°C for 3 minutes. The supernatant was removed from the cell debris after 
spinning for 1 minute at 13,000 rpm and methanol added to yield a final volume of 1 
mL. Absorption spectra of the methanol extracts were measured in a quartz cuvette 
and the absorbance at 465 nm was recorded.  
2.2.9.5 Quantification of intracellular ATP  
In order to compare levels of ATP between SCVs and parents an enzyme based 
luciferase assay was employed. The BacTiter-Glo™ Microbial Cell Viability Assay 
(Promega, UK) quantifies ATP using mono-oxygenation of luciferin to produce a 
light signal which can be detected using a luminometer. Cultures were adjusted to 1 X 
107 CFU/mL and 100 µL added to individual wells of 96 microtitre well plates. 
BacTiter-Glo reagent (100 µL) was added to each well and gently shaken for 5 
minutes at room temperature. Control wells contained no bacteria and were used to 
determine background luminescence. Luminescence was detected using relative light 
units (RLU) with a LUMIstar OPTIMA plate reader (BMG, UK). RLU/ATP was 
determined from a standard curve using dilutions of ATP standard (Promega, UK) and 
the concentration of ATP per mL was calculated. 
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2.2.9.6 Auxotrophy profiles  
SCVs are commonly auxotrophic for haemin, menadione and thymidine (individually 
or a combination), therefore the auxotrophy profiles of various SCV isolates were 
examined. Stock solutions (1,000 mg/L) of haemin, menadione and thymidine (Sigma 
Aldrich, UK) were prepared by dissolving powders in DMSO (haemin) or sterile 
deionised H2O (menadione and thymidine). Stock solutions were stored at 4°C for a 
maximum of 14 days. Lawns of SCVs were prepared by spreading 100µL of 
overnight culture onto the surface of a MH agar plate. Sterile filter paper discs plated 
in the centre of the plate and 10 µL of haemin, menadione or thymidine stock 
solutions added to filter discs and plates were incubated for 48 hours. SCVs were 
confirmed as auxotrophic if a zone of wildtype like growth (i.e. large colonies, 
restoration of pigment) was present surrounding the filter disc.  
2.2.9.7 Mutation frequency to rifampicin resistance   
For the measurement of mutation frequency to rifampicin resistance of SCV and 
parent strains the method of Besier et al., (2008a) was applied. Cultures were pelleted 
by centrifugation at 10,000 rpm for 5 min and resuspended in 1 mL MH broth. A 100 
µL sample of this suspension was plated onto MH agar plates as well as MH agar 
containing rifampin at a concentration of 100 mg/L. After 48 hours incubation at 
37°C, CFU were counted and mutation frequencies determined by dividing the 
number of CFU on rifampicin-supplemented agar by the number of CFU on 
rifampicin-free agar. Colonies growing on rifampicin containing plates were streaked 
onto another rifampicin containing in order to prove the stability of the mutants. 
2.2.9.8 Statistical analysis  
Minitab statistical software 16 was used to investigate significant difference between 
parent and SCV isolates. Provided the data met the requirement of being normally 
distributed and showed equal variance, data was subject to 2 sampled t tests with 95% 
confidence intervals. If the assumptions of the t test were violated the Mann-Whitney 
test (non-parametric( with 95% confidence intervals was applied.  
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2.3 Results  
2.3.1 MIC and MBCs 
S. aureus strains ATCC 25923 and EMRSA 15 were tested for their susceptibilities to 
the aminoglycosides gentamicin, kanamycin, neomycin and streptomycin. Both 
strains were found to be sensitive to all aminoglycosides tested (Table 2.2). MIC 
values for the four aminoglycosides tested were 2-4 times greater for EMRSA 15 in 
comparison to ATCC 25923. ATCC 25923 MBCs for gentamicin, kanamycin and 
neomycin were 2 times greater than MIC values where as the MBC for streptomycin 
was 4 times greater than the MIC. During MBC testing however SCVs were 
frequently detected and values shown in Table 2.2. These represent 99.9% elimination 
of wildtype and do not account for the selection of SCVs.     
2.3.2 Minimum small colony variant prevention concentration (MSCVPC)  
As SCVS were frequently detected at concentrations deemed bactericidal for wildtype             
S. aureus the term minimum concentration that prevents formation of SCVs during 
routine MIC and MBC testing (MSCVPC) was implemented. During MBC testing, 
plates regularly contained a mixture of wildtype and SCV colonies (Figure 2.2). As 
the antibiotic concentration was increased wildtype colonies were completely 
eradicated leaving only SCV colonies. CLSI guidelines stipulate that a 99.9% 
reduction from the ‘original’ inoculum is required to achieve MBC criteria. 
Consequently the MBC was recorded as the lowest concentrations at which 99.9% of 
wildtype were eliminated and MSCVPC was introduced to cover the concentration at 
which SCVs were not detected. The MSCVPC varied for each aminoglycoside but 
was always within the range of being equal to 2 times greater than the MBC (Table 
2.2).  
2.3.3 SCV selection frequencies  
All four aminoglycosides were successful in isolating SCVs although differences in 
frequencies after exposure to different concentrations and between strains were 
observed (Table 2.3). Notably the presence of subinhibitory concentrations (X 0.25 
and X 0.5 MIC) of all aminoglycosides significantly increased the recovery of SCVs 
in comparison to untreated control conditions (P = < 0.01). SCVs were recovered 
from control conditions that were plated on kanamycin and streptomycin in both  
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Table 2.2 Aminoglycoside MICs, MBCs and MSCVPC (mg/L) for S. aureus 
ATCC 25923 and EMRSA 15 determined by broth microdilution 
 
 
 
 
Modal MIC, MBC and MSCVPC values are presented. Modal values were obtained 
from three independent replicates and three independent biological replicates. 
 
 
 
 
 
 
 
 
 
 
MIC MBC  MSCVPC MIC  MBC  MSCVPC 
Gentamicin 0.25 0.5 1 1 2 4 
Neomycin 0.5 1 2 2 5 10 
Kanamycin 2 4 8 4 12 20 
Streptomycin 2 8 8 4 20 30 
                                             ATCC 25923                                  EMRSA  15 
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A) B) C)
 
Figure 2.2 Characteristics associated with S. aureus SCVs recovered following aminoglycoside exposure A) - Presence of parent and SCV 
colonies (arrow) recovered following MBC testing; B) - Restoration of wildtype growth and pigmentation around a filter disc impregnated with 
haemin indicating haemin auxotrophy; C) - Agglutination positive S. aureus (top) and agglutination negative S. aureus SCVs (bottom). The 
differences in colony size, pigmentation and coagulase activity demonstrate the difficulties in identifying S. aureus SCVs using traditional 
methods.   
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strains and from only EMRSA 15 in the case of neomycin. Interestingly 
concentrations of aminoglycosides that are inhibitory (exceeded MIC) to ATCC 
25923 and EMRSA 15 were also found to select for SCVs. Exposure of EMRSA 15 
to all tested combinations across the range of aminoglycoside gave rise to SCVs, 
expect for X 4 MIC gentamicin (Table 2.3). In contrast SCVs were not detected from 
ATCC 25923 after to exposure to any aminoglycosides at X 4 MIC concentration. 
Exposure to X 4 MIC for EMRSA 15 proved to be the most efficient concentration in 
selecting for SCVs for neomycin, kanamycin and streptomycin.  
2.3.4 Identification of SCVs as S. aureus using multiplex PCR 
Amplification of 16S rRNA and nuc genes was successfully employed to ensure that 
all SCVs were S. aureus and not contaminants (Figure 2.3). SCV isolates recovered 
following exposure to various aminoglycoside concentrations show the presence of 
16S rRNA (756 bp) and nuc (279 bp), which can also be observed in the parent strain 
(Figure 2.3). Additionally the presence of mecA (310bp) can be observed in SCV 
isolates recovered from EMRSA 15, permitting discrimination between MRSA and 
MSSA strains.    
2.3.5 Reversion rates  
The rate at which SCVs reverted to the parent form varied according to the 
aminoglycoside concentration applied. SCV isolated at X 2 and X 4 MIC of the four 
aminoglycosides tested were deemed as stable isolates as no revertants were detected 
(Table 2.4). SCVs isolated from X 0.25 MIC of all aminoglycosides showed high 
rates of reversion, and reversion rates were significantly higher than reversion rates at 
X 0.5 MIC (P = < 0.05). As aminoglycoside concentrations increased, the frequency 
at which revertants from both strains were detected decreased. For example the 
reversion frequency of EMRSA 15 SCV isolated from X 0.5 MIC neomycin exposure 
(2.2 X 10-4) was significantly higher than the reversion frequency of EMRSA 15 SCV 
isolated from MIC neomycin exposure (8.4 X 10-5; P = < 0.05). Comparison of SCVs 
selected from different aminoglycosides revealed no significant difference in 
reversion rates.  
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Table 2.3 SCV selection frequencies (expressed as SCVs per CFU) after 24 hours exposure to increasing concentrations of 
aminoglycosides  
 
 Control 
25923           E15 
X 0.25 MIC 
25923         E15 
X 0.5 MIC 
25923         E15 
MIC 
25923         E15 
X 2 MIC 
25923         E15 
X 4 MIC 
25923         E15 
Gentamicin  
ND ND 2.1 X 10-4 8.7 X 10-4 3.5 X 10-2 2.5 X 10-3 6.2 X 10-2 2.1 X 10-2 2.1 x 10-1 2.5 X 10-1 ND ND 
Neomycin 
ND 1.1 X 10-6 8.3 X 10-4 3.2 X 10-5 2.6 X 10-3 3.9 X10-3 1.7 X 10-2 4.2 X 10-2 2.6 X 10-1 8.5 X 10-1 ND 2.5 X 10
2
 
Kanamycin 
2.7 X 10-6 6.2 X 10-6 5.1 X10-5 2.1 X 10-5 2.1 X 10-2 7.6 X 10-3 8.4 X 10-2 1.6 X 10-2 5.4 X 10-1 5.9 X 10-1 ND 3.2 X 10
2
 
Streptomycin  
1.5 X 10-6 7.3 X 10-5 4.2 X 10-4 8.9 X 10-5 5.9 X 10-3 5.7 X 10-3 5.3 X 10-3 7.5 X 10-3 2.3 X 10-1 4.2 X 10-2 ND 4.8 X 10
2
 
 
25923 – ATCC 2923; E15 – EMRSA 15; ND – SCVs not detected 
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Figure 2.3 Multiplex PCR of SCV isolates recovered from various concentrations of gentamicin L - Hyperladder 1; A1 – ATCC 253923 WT; A2 - 
ATCC 25923 SCV X 0.25 G; A3 - ATCC 25923 SCV X 0.5 G; A4 - ATCC 25923 SCV MIC G; A5 - ATCC 25923 SCV X 2 MIC G; B1 – EMRSA 15 WT; 
B2 – EMRSA 15 SCV X 0.25 G; B3 – EMRSA 15 SCV X 0.5 G; B4 – EMRSA 15 SCV MIC G; B5 – EMRSA 15 SCV X 2 MIC G. Multiplex PCR 
confirmed SCV isolates as S. aureus. The presence of the additional band in EMRSA 15 SCV isolates is attributed to the presence of mecA (310bp). 
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Table 2.4 Reversion frequencies (expressed as CFU per SCV) of SCV isolated from increasing aminoglycoside concentrations  
 
 
 X 0.25 MIC 
25923         E15 
X 0.5 MIC 
25923         E15 
MIC 
25923         E15 
X 2 MIC 
25923         E15 
X 4 MIC 
25923         E15 
Gentamicin  5.8 X 10-2 3.5 X 10-2 2.2 X 10-3 2.7 X 10-4 1.2 X 10-6 4.1X 10-5 S S NT NT 
Neomycin 3.1 X 10-1 7.1 X 10-1 6.1 X 10-4 2.2 X10-4 5.7 X 10-5 8.4 X 10-5 S S NT S 
Kanamycin 4.2 X10-2 5.3 X 10-2 5.1 X 10-3 4.1 X 10-4 4.2 X 10-6 5.4 X 10-6 S S NT S 
Streptomycin  6.3 X 10-2 5.6 X 10-2 4.6 X 10-3 5.2 X 10-4 3.6 X 10-5 2.6 X 10-5 S S NT S 
 
25923 – ATCC 2923; E15 – EMRSA 15; S – stable isolates (no revertants detected); NT – not tested. Large rapidly growing pigmented colonies were 
recorded as revertants.   
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2.3.6 Growth rates in the presence of aminoglycosides  
Parent strains ATCC 25923 and EMRSA 15 displayed typical S. aureus growth rates 
when grown in unmodified MH broth (Figure 2.4). The presence of X 0.25 MIC 
gentamicin and kanamycin significantly increased the lag phase in strain ATCC 
25923 (P = < 0.001). The same conditions in strain EMRSA 15 however resulted in 
growth profiles similar to unmodified conditions. As S. aureus strains were exposed 
to increasing concentrations of aminoglycosides lag phase duration increased in a 
concentration dependant manner (Figure 2.4). For example, exposure to X 0.5 MIC 
gentamicin concentration resulted in an average 9 hour lag phase duration where as 
exposure to X 2 MIC gentamicin concentration resulted in an average lag phase 
duration of 16.5 hours. Exposure of ATCC 25923 to X 2 MIC gentamicin and 
kanamycin resulted growth profiles with a significantly lower growth rate in 
comparison to other concentrations (P = < 0.05), similar to the growth rate of SCVs. 
Sampling of wells following the completion of growth rates analysis confirmed the 
presence of a S. aureus SCVs population in gentamicin and kanamycin concentrations 
of X 2 MIC for ATCC 253923. Although concentrations of X 4 MIC gentamicin and 
kanamycin resulted in no change in optical density, sampling of EMRSA 15 exposed 
to X 4 MIC kanamycin revealed the presence of a SCV population. SCVs were not 
detected for ATCC 25923 exposed to X 4 MIC for gentamicin and kanamycin and 
EMRSA 15 at X 4 MIC gentamicin. This is in agreement with MSCVPC obtained 
previously, as X 4 MIC values are equal to MSCVPC values.  
2.3.7 Biochemical profiles  
Contrasting biochemical profiles between parent and SCV isolates were observed for 
both strains, and biochemical profiles of EMRSA 15 and corresponding SCV isolates 
are shown in Table 2.5. Parent strains displayed the ability to ferment a range of 
carbohydrates as well as production of alkaline phosphatase, arginine dihydrolase and 
urease enzymes. All SCV isolates were unable to ferment mannitol where as SCVs 
selected from higher aminoglycosides concentrations were unable to ferment lactose, 
maltose and sucrose (Table 2.5). Furthermore, loss of enzymatic activity was also 
observed in several SCV isolates. Alkaline phosphatase activity was not detected in 
SCVs isolated from X 2 MIC gentamicin and kanamycin and X 4 MIC kanamycin. 
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Figure 2.4 Growth rates of ATCC 25923 and EMRSA 15 in varying concentrations of gentamicin and kanamycin A1) - ATCC 25923 gentamicin;             
A2) - ATCC 25923 kanamycin; B1) - EMRSA 15 gentamicin; B2) - EMRSA 15 kanamycin. Generally increasing aminoglycoside concentration results in an 
increase in lag phase duration and a reduction in final optical density. Data is the mean of three independent replicates.   
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Table 2.5 Biochemical profiles of EMRSA 15 and corresponding SCVs selected for in the presence of different concentrations of gentamicin and 
kanamycin 
 
 
Differences between SCV and parents are shaded in grey. G - Gentamicin; K – Kanamycin; + - Positive (enzyme activity, fermentation of carbohydrate); - = 
Negative (lack of enzyme activity, inability to ferment carbohydrates); NT – not detected. Test abbreviations are shown in Appendix 1. 
  G              K       G              K       G              K       G              K       G              K  
GLU + + + + + + + + + NT + 
FRU + + + + + + + + + NT + 
MNE + + + + + + + + + NT + 
MAL + + + + + - + - - NT - 
LAC + + + + + + + - - NT - 
TRE + + + + + + + + + NT + 
MAN + - - - - - - - - NT - 
XLT - - - - - - - - - NT - 
MEL - - - - - - - - - NT - 
NIT + + + + + + + + + NT + 
PAL + + + + + + + - - NT - 
VP + + + + + + + + + NT + 
RAF - - - - - - - - - NT - 
XYL - - - - - - - - - NT - 
SAC + + + - + - + - - NT - 
MDG - - - - - - - - - NT - 
NAG + + + + + + + + + NT + 
ADH + + + + + + + + + NT + 
URE + + + + + + + + + NT - 
Parent  SCV X 0.25 MIC SCV X 0.5 MIC SCV X MIC SCV X 2 MIC SCV X 4 
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A lack of urease activity was also observed in SCV isolated from X 4 MIC 
kanamycin. 
2.3.8 Carotenoid production  
Methanol extraction of carotenoids revealed similar absorbance values corresponding 
to similar levels of carotenoids in parent strains (ATCC 25923 = 0.20 ± 0.01, EMRSA 
15 = 0.22 ± 0.007). All SCV isolates produced lower amounts of carotenoid in 
comparison and differences in the amount of carotenoid produced by SCV isolates 
was observed according to the concentration of the selecting aminoglycoside (Figure 
2.5). SCVs isolates from both strains following exposure to MIC, X 2 MIC and X 4 
MICs of gentamicin and kanamycin were significantly reduced in comparison to 
parent strains (P = < 0.001). Complete absence of carotenoid was observed in 
EMRSA 15 SCVs recovered from exposure to X 2 MIC gentamicin and X 2 and X 4 
MIC kanamycin (Figure 2.5).  
2.3.9 Intracellular ATP concentrations  
Similar intracellular ATP concentrations were recorded for parent strains (Figure 2.6). 
Overall SCV isolates contained lower intracellular ATP levels in comparison to parent 
strains (Figure 2.6). ATP concentrations decreased as the concentration of the selected 
aminoglycoside increased. Average ATP concentrations of SCV isolates from both 
strains following exposure to MIC,  X 2 MIC and X 4 MIC gentamicin and 
kanamycin concentrations were significantly reduced in comparison to parent strains 
(P = < 0.001).  
2.3.10 Auxotrophy profiles  
Auxotrophy was confirmed if SCVs appeared as fast growing pigmented colonies 
around filter discs impregnated with haemin, menadione or thymidine. Auxotrophy 
was detected in 26/40 (65 %) isolates examined in this study (Figure 2.7). Haemin 
auxotrophy was the most frequently auxotrophy detected with 12/40 (30%) of 
isolates. Auxotrophy for a combination of haemin and menadione was the second 
most frequent auxotrophy detected with 10/40 isolates (25%) displaying this 
auxotrophy profile. The remaining isolates in which auxotrophy was identified were 
menadione auxotrophs (5/40; 10%). Auxotrophy for thymidine was not detected in 
any of the SCV isolates tested.  
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Figure 2.5 Carotenoid production in SCVs isolated following exposure to different aminoglycoside concentrations A) - ATCC 25923; B) - 
EMRSA 15. Carotenoid production was completely absent in SCV isolated from higher aminoglycoside concentrations. Results are the means of 
three independent replicates and three biological replicates. Error bars represent standard error. 
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Figure 2.6 Intracellular ATP concentrations of SCVs isolated following exposure to different aminoglycoside concentrations A) - ATCC 25923; B) - 
EMRSA 15. SCVs isolated following exposure to MIC, X 2 and X 4 MIC aminoglycoside concentrations contained significantly lower levels of intracellular 
ATP in comparison to parent strains. Results are the means of three independent replicates and three biological replicates. Error bars represent standard error 
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Gentamicin
Kanamycin
Neomycin
Streptomycin 
 
Hemin Menadione Hemin + Menadione No auxotrophy detected 
 
 
Figure 2.7 Auxotrophy profiles of SCV isolates following exposure to different 
concentrations of four aminoglycosides A complete absence of thymidine 
auxotrophy was observed. Number of isolates examined; gentamicin n = 8, 
kanamycin n = 11, neomycin n = 10 and   streptomycin n = 11. 
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2.3.11 Mutation frequency to rifampicin resistance  
Differences in mutation frequency were observed between SCV isolates and parent 
strains. SCV isolate isolated from exposure to X 0.25, X 0.5 and X MIC gentamicin 
and kanamycin concentrations displayed mutation frequencies significantly greater 
than parent strains (P = < 0.05; Table 2.6). ATCC  25923 SCV isolates recovered 
from exposure to X 2 MIC gentamicin and EMRSA 15 SCV isolates recovered from 
exposure to X 2 MIC gentamicin and  X 2 and X 4 MIC kanamycin concentrations 
displayed significantly higher mutation rates than SCV isolates recovered following 
exposure to lower aminoglycoside concentrations and corresponding parent strains            
(P = < 0.05). In SCV isolates where the mutation frequency to rifampicin resistance 
was > 10-7 isolates were termed as hypermutators due to their high mutation 
frequencies (Table 2.6). 
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Table 2.6 Mutation frequency to rifampicin resistance of SCV isolates and 
corresponding parent strains  
 
Gentamicin isolates  
 
Isolate ATCC 25923 EMRSA 15  
Parent  2.1 X 10-10  1.5 X 10-10 
SCV X 0.25  1.9 X 10-9 1.8 X 109 
SCV X 0.5 8.9 X 10-9  7.2 X 10-9 
SCV X MIC 2.1 X 10-9 6.7 X 10-8 
SCV X 2 MIC 8.5  X 10-6 8.1 X 10-6 
 
 
Kanamycin isolates  
 
Isolate ATCC 25923 EMRSA 15  
Parent  2.1 X 10-10 1.5 X10-10 
SCV X 0.25  7.8 X 10-9 1.2 X 10-9 
SCV X 0.5 5.9 X 10-9 7.8 X 10-9 
SCV X MIC 5.4 X 10-9 2.1 X 10-8 
SCV X 2 MIC 2.2 X 10-6 6.1 X 10-6 
SCV X 4 MIC - 2.6 X 10-6 
 
 
Mutation frequencies are the mean of three independent replicates. Isolates were 
regarded as strong hypermutators if mutation frequency was greater that 10-7 and are 
shown in bold.  
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2.4 Discussion 
Aminoglycosides (particularly gentamicin) have been demonstrated to select for 
SCVs of S. aureus, as well as other bacterial species, including E. coli (Lewis et al., 
1991) and Pseudomonas aeruginosa (Langford et al., 1989). This study highlights the 
ability of gentamicin, neomycin, kanamycin and streptomycin to select for                    
S. aureus SCVs at various concentrations. To our knowledge this is the first study that 
has compared SCV selection and corresponding isolates following exposure to 
various aminoglycosides across a broad range of concentrations.  
 
One of the important implications of this work relates to aminoglycoside 
susceptibility testing of S. aureus. CLSI guidelines stipulate that MICs are defined as 
‘the lowest concentration of antimicrobial agent that inhibits growth of the organism 
in microdilution wells as detected by the untrained eye’ (CLSI, 2006). In well plate 
susceptibility testing this is based on the absence of turbidity following incubation. 
The results of this study clearly highlight certain shortcomings of this form of 
susceptibility testing as concentrations exceeding aminoglycoside MICs, resulted in 
the growth of S. aureus through the formation of SCVs. CLSI guidelines state that an 
incubation time of 16-20 hours should be adhered to before reading MICs. However, 
in this study increases in absorbance were frequently detected following 15 or more 
hours incubation which may not be sufficient to be detected by laboratory personal 
when recording MICs by eye. Aminoglycoside susceptibility testing for S. aureus and 
other bacterial species should therefore take into consideration the formation/selection 
of SCVs. Increasing the incubation time to 48 hours will allow changes in optical 
density (caused by the growth of SCVs) to be recorded. Furthermore, SCVs were 
often recovered from aminoglycoside concentrations that exceeded concentrations 
that were bactericidal for parent S. aureus. We therefore implemented the term 
‘minimum SCV prevention concentration’. The application of the MSCVPC may 
have applications in susceptibility testing as it ensures the elimination of the whole 
population regardless of whether the test compound has led to the selection of SCVs.  
 
The phenotypic appearance of aminoglycoside selected SCVs on solid agar also 
presents identification difficulties. Contrasting colony size and the lack of 
pigmentation observed in SCVs may result in the conclusion that S. aureus is not 
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present. Mannitol salt agar is a selective, differential medium that has been used for 
the isolation of S. aureus (Sharp & Searcy, 2006). The observation that SCV isolates 
in this study failed to ferment mannitol and observations of other mannitol 
fermentation deficient SCVs (Atalla et al., 2008) suggests that SCVs will not be able 
to grow on mannitol salt agar and may go undetected. Furthermore rapid identification 
tests such as the presence of coagulase (to differentiate between S. aureus and CoNS) 
are subject to limitations when testing SCVs due to their lack of coagulase activity. In 
this study molecular identification was used to successfully confirmed SCV isolates as          
S. aureus. Molecular identification overcomes the failings of phenotypic testing 
concerning the identification of SCVs. The use of multiplex PCR also allows the 
identification of the presence of resistance determinants (such as mecA) which may be 
an important consideration when considering treatment of S. aureus infections. If an 
SCV infection is suspected applying molecular identification can provide important 
evidence regarding the causative agent.   
 
In total 40 different isolates were recovered following the application of various 
aminoglycoside selection conditions. Various differences were observed between 
these isolates. Contrast in levels of intracellular ATP between SCV isolates and 
parents was observed. No correlation between the concentration of the selecting 
aminoglycoside and the resulting auxotrophy was observed. Reduced ATP production 
in SCVs is related to defects in electron transport (Proctor et al., 2006). In this study 
we were able to identify auxotrophy for haemin, menadione or a combination of both 
in 65% of isolates. Haemin and menadione have crucial roles in electron transport as 
discussed previously (see section 1.4.1.2). The reduced levels of ATP in SCVs can be 
linked to auxotrophy for these compounds. In the remaining SCV isolates in which it 
was not possible to determine auxotrophy profiles defects in other complexes or 
components of the electron transport chain may be responsible for the SCV 
phenotype. Possible candidates include defects in unsaturated fatty acid biosynthesis 
or in the F0F1-ATPase. Unsaturated fatty acid biosynthesis is required to form the 
isoprenoid tail that is added to form menaquinone (Collins & Jones, 1981; Kaplan & 
Dye, 1976), so a defect in the production of this lipid would disrupt formation of the 
electron transport chain. Mutations or inhibition of the F0F1-ATPase (which is 
required for ATP generation) have also been suggested to produce the SCV phenotype 
(McNamara & Proctor, 2000). Mutations in the genes involved in the biosynthesis of 
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the F0F1-ATPase can generate SCVs in E. coli (Jensen & Michelsen, 1992), therefore 
the same may be apparent in S. aureus.  
 
Differences in intracellular ATP concentrations were apparent between isolates and a 
correlation between the selecting aminoglycoside concentration and levels of ATP 
observed.  SCVs selected at higher aminoglycosides concentrations had lower levels 
of intracellular ATP in comparison to those isolated at lower concentrations. As the 
electron transport chain is SCVs is not fully operational, an upregulation of glycolytic 
and fermentative pathways is required in order to generate ATP (Kohler et al., 2003). 
However in order to utilise other carbohydrates, a fully functional tricarboxylic acid 
cycle (TCA cycle) is required. Differences in carbohydrate utilisation were observed 
in the SCVs isolated in this study, which has been reported previously using 
phenotypic microarray profiling (von Eiff et al., 2006). The failure to ferment 
carbohydrates can be related to accumulation of NADH, which occurs as a result of 
defects in electron transport (Proctor, 2006). The differences in biochemical profiles 
between the isolates in this study may therefore by related to more pronounced defects 
in TCA cycle function. For example isolates that have lost the ability to ferment 
multiple carbon sources may show a further, down regulation of enzymes involved in 
TCA cycle blocking the fermentation of certain carbohydrates (Proctor, 2006). 
Another plausible explanation is that reduction in cellular ATP indirectly blocks the 
uptake of complex carbohydrates and also indirectly blocks the steps of the 
phosphotransferase systems inhibiting the utilisation of lactose, mannitol, maltose and 
sucrose (Reizer et al., 1988). Further pronounced deficiencies in ATP availability may 
explain why SCVs isolated following exposure to higher aminoglycoside 
concentrations may show further deficiencies in carbohydrate utilisation.    
 
The deficiencies in ATP production appear to correlate with deficiencies in carotenoid 
production. SCVs isolated at higher aminoglycoside concentrations showed 
undetectable carotenoid production, whereas as isolate recovered from a lower 
aminoglycoside concentration showed carotenoid production similar to parent strains. 
In order to drive carotenoid biosynthesis and produce pigment, S. aureus, must 
expend energy and process ATP as well as a functional ETC to function (Proctor, 
2000). The lower ATP levels observed in S. aureus SCVs results in the variation in 
carotenoid production observed in this study. Although the presence of pigmentation 
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in S. aureus protects cells from oxidative stress (Clauditz et al., 2006), SCVs may 
expend the limited available energy for essential cellular process such as cell wall 
biosynthesis at the cost of pigment production.  
 
Several isolates showed high levels of mutational resistance towards rifampicin and 
were deemed hypermutators. These isolates were recovered from the higher 
aminoglycoside concentrations tested. Hypermutability is considered to be a key force 
in driving bacterial evolution and bacteria displaying the associated increases in 
mutation frequency are recovered from cystic fibrosis (CF) patients (Oliver et al., 
2000). CF patients infected with hypermutable isolates can suffer from increased 
infection duration and isolates often display raised levels of antibiotic resistance 
(Macia et al., 2005; Mena et al., 2007). The hypermutator phenotype has been linked 
to defects in the methyl-directed mismatch repair (MMR) system (Oliver et al., 2002), 
allowing for adaptation (through increasing mutation frequency) whilst reducing the 
risk of accumulating deleterious mutations (Jolivet-Gougeon et al., 2011). The 
hypermutator phenotype in SCV isolates observed in this study may aid persistence 
and long term survival. SCV isolates recovered from higher aminoglycosides 
concentrations in this study also show reduced energy levels. Coupled with the 
observation that the hypermutator phenotype permits a fitness disadvantage (Jolivet-
Gougeon et al., 2011), SCV isolates are severely impaired. The hypermutator 
phenotype may provide a survival mechanism through the SCV phenotype allowing 
long term persistence and the development of antibiotic resistance.  
 
The alternative sigma factor, σB is an important regulator in S. aureus influencing the 
expression of many genes including various virulence factors (Bischoff et al., 2004), 
many of which show altered levels of expression in SCVs (Kohler et al., 2003). σB 
has been implicated in the formation of SCVs following aminoglycoside exposure 
(Mitchell et al., 2010a) and sustained σB activity in S. aureus SCV isolates has been 
associated with ‘locking’ SCVs into a constant state of colonisation (Mitchell et al., 
2008). It is feasible that expression of σB varies between the aminoglycoside select 
SCV isolates examined in this study. Several isolates from higher aminoglycoside 
concentrations showed a lack of reversion to the wildtype form. However SCVs 
isolate from lower aminoglycoside concentrations were associated with higher 
reversion frequencies. σB expression therefore may directly correlate to the 
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concentration of the selecting aminoglycoside and isolates selected for in the presence 
of higher aminoglycoside concentrations may display a sustained rate of increased σB 
expression maintaining the SCV phenotype.  
 
This study highlights the ability of a range of aminoglycosides to select for SCVs and 
that formation of the SCV phenotype provides a survival mechanism to bypass the 
inhibitory effects of aminoglycosides. Through analysis of various isolates it is 
proposed that aminoglycoside selection directly impacts on energy availability and σB 
expression. Differences in energy levels results in differences in carotenoid 
biosynthesis and carbohydrate utilisation. σB expression may correlate with 
aminoglycoside in a concentration dependant manner and serve as a governing global 
regulator influencing SCV characteristics. The observation of hypermutability 
suggests that the SCV phenotype in various isolates may be further geared towards 
survival and persistent in order to over overcome environmental stress. On the outset 
the variants are observed as slow growing variants with attenuated virulence where as 
in real terms they have the characteristics for persistence and antibiotic resistance. 
With this in mind the analogy ‘a wolf in sheep’s clothing’ is useful in characterising 
the SCV phenotype. 
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2.5 Conclusions  
• Increasing aminoglycoside concentrations increase the duration of lag time in             
S. aureus and prolonged incubation can result in the growth of S. aureus through 
the formation of SCVs 
• Examining SCV selection in the presence of aminoglycosides revealed that 
aminoglycoside susceptibility testing of S. aureus may be hindered through the 
formation of S. aureus SCVs, resulting in the implementation of a ‘minimum SCV 
prevention concentration’  
• Multiplex PCR targeting S. aureus specific genes is a useful tool in overcoming 
the uncertainty surrounding SCV identification and can be used to confirm SCVs 
as S. aureus  
• S. aureus SCVs can be selected for following exposure to kanamycin, gentamicin, 
neomycin and streptomycin at a range of concentrations including those that 
exceeding MBC 
• Auxotrophy for haemin and menadione is responsible for the disruption of the 
electron transport chain and the SCV phenotype in the majority of aminoglycoside 
selected SCVs  
• Variation in carbohydrate utilisation, carotenoid production and levels of 
intracellular ATP are apparent in SCVs selected in the presence of 
aminoglycosides   
• SCV isolates selected at higher aminoglycoside concentrations can be classified as 
hypermutators and these isolates also show a high level of stability  
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3 CHAPTER 3: TETRACYCLINE SELECTION FOR 
STAPHYLOCOCCUS AUREUS SMALL COLONY VARIANTS 
3.1 Introduction  
3.1.1 History of tetracycline  
The tetracycline group of antibiotics, discovered in the 1940s exhibit antimicrobial 
activity against a broad range of Gram-negative and positive microorganisms (Chopra 
& Roberts, 2001). Chlortetracycline was the first member of the family to be isolated 
(from Streptomyces aureofaciens) and is classed as a first generation tetracycline 
along side oxytetracycline and tetracycline (Roberts, 1996). These compounds were 
discovered by systematic sampling of fermentation products of spore forming soil 
bacteria and were rapidly introduced into clinical practice (Thaker et al., 2010). This 
was followed by the development of minocycline and doxycycline constituting the 
second generation tetracyclines, followed by the development of the glycylcyclines 
e.g. tigecycline (third generation tetracyclines; Chopra & Roberts, 2001). Second and 
third generation tetracyclines are the products of semi-synthesis, i.e. synthetic organic 
manipulation of natural product antibiotic scaffolds (Thaker et al., 2010).  
 
Several aspects of the tetracyclines make them excellent therapeutic agents; they 
exhibit good oral absorption and low toxicity, are relatively inexpensive and most 
importantly they are active against common pathogens (Schnappinger & Hillen, 
1996). Tetracyclines have been used for the clinical treatment of a wide range of 
infections including respiratory tract infections and sexually transmitted diseases, as 
well in the management of acne (Zhanel et al., 2004).  
3.1.2 Mode of action 
The antimicrobial activity of tetracyclines is achieved via inhibition of bacterial 
protein synthesis. Several tetracycline binding sites on the ribosome are present, but 
the key binding appears to be in the region of the tRNA acceptor site (Anokhina et al., 
2004). ‘Typical’ tetracyclines (such as tetracycline and doxycycline) bind to the 
bacterial 30S ribosomal subunit and exert bacteriostatic activity via preventing the 
attachment of aminoacyl t-RNA to the ribosomal receptor site (Roberts, 1996). 
‘Atypical’ tetracyclines exhibit bactericidal activity (Chopra, 1994) and studies in E. 
coli demonstrated that they are poor inhibitors of protein synthesis and are thought to 
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target the cytoplasmic membrane interfering with membrane permeability (Oliva et 
al., 1992).   
3.1.3 Mechanisms of resistance  
The use of tetracyclines has declined in recent decades due to the emergence of 
resistant strains of bacteria (Griffin et al., 2010). The first incidence of tetracycline 
resistance was reported in Shigella dysenteriae in 1953 (Roberts, 1996). Four different 
mechanisms of bacterial resistance to the tetracyclines have been identified (Figure 
3.1). These include: 1) protection of the antibiotic target i.e. the ribosome; 2) 
reduction of tetracycline intracellular concentration via efflux; 3) inactivation of the 
tetracycline molecule by modifying enzymes; and 4) target modification 
(Schnappinger & Hillen, 1996). Tetracycline resistance is normally due to the 
acquisition of new genes often associated with either a mobile plasmid or transposon 
(Roberts, 1996). Tetracycline resistance genes are diverse in sequence and recent 
analysis reported that 1,189 tetracycline genes have been reported in more than 84 
genera and 354 species of Gram-positive and Gram-negative bacteria (Liu & Pop, 
2009). 
3.1.3.1 Ribosomal protection proteins  
Ribosomal protection proteins (RPPs) were first identified in streptococci, in which 
the TetM protein was shown to provide resistance to tetracycline (Burdett, 1986). 
RPPs are soluble cytoplasmic proteins that display sequence similarity with the 
elongation factors involved in protein synthesis (Zakeri & Wright, 2008).  RPPs are 
thought to interact with the protein at the base of the ribosome disrupting the primary 
tetracycline binding site, causing tetracycline molecules to be released from the 
ribosome (Burdett, 1996; Roberts, 2005). There are various different RPPs spanning 
Gram positive and Gram negative bacterial genera, where Tet(O) and Tet(M) are the 
most prevalent and the best studied classes (Zakeri & Wright, 2008). RPPs are 
approximately 72.5 kDa in size and the genes encoding them are divided into three 
groups based on the amino acid sequence of encoded proteins (Connell et al., 2003; 
Taylor & Chau, 1996). Group-1 includes tet(M), tet(O), tet(S), tet(W), tet(32), and 
tet(36), whereas Group-2 includes tetB(P). Finally Group-3 is contains a smaller 
number and includes tet(Q) and tet(T) (Thaker et al., 2010).  
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Figure 3.1 Bacterial mechanisms employed for resistance to the tetracycline class 
of antibiotics. Efflux, ribosomal protection proteins are widespread in bacteria, 
mediated through horizontal gene transfer whereas target mutation and inactivation 
have been sparsely reported. Adapted from Zakeri & Wright (2008) and Thacker et 
al., (2010) 
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3.1.3.2 Efflux mediated resistance  
Efflux mediated resistance reduces the concentration of tetracycline in the cytoplasm 
via the tet efflux genes coding for 46 kDa membrane associated proteins that export 
tetracycline out of the cell (Chopra & Roberts, 2001). Efflux predominantly occurs 
via proteins that are members of the major facilitator superfamily (MFS) group of 
membrane transporters (Paulsen et al., 1996). Energy-dependent removal of 
tetracyclines involves the exchange of a proton for a tetracycline-cation complex via 
these membrane associated transporters (Butaye et al., 2003). Since the original 
reports of efflux mediate tetracycline resistance in E. coli (McMurry et al., 1980), 
several other classes of tet efflux genes have been described. The first group includes 
tet(A)–(E), (G), (H), (J), and (Z) as well as tet(30) (Roberts, 2005). Classes A, B, D, 
and H are associated with non-conjugative transposons or transposon-like elements 
where as classes C, E, and G are often found on plasmids (Roberts, 1996). The other 
group of the tet efflux genes (including tet(K) and tet(M)) are distributed among 
Gram-positive bacteria including Bacillus and Staphylococcus species. The substrate 
spectrum of the Tet efflux proteins present in bacteria commonly includes 
tetracycline, oxytetracycline, chlortetracycline and doxycycline, but not minocycline 
and glycylcyclines (Schnappinger & Hillen, 1996).  
3.1.3.3 Enzymatic inactivation  
The first tetracycline inactivating enzyme to be discovered was tet(X) from a strain of 
Bacteroides fragilis, although it did not convey resistance in its host (Speer et al., 
1991). The tet(X) gene product is a 44-kDa cytoplasmic protein that chemically 
modifies tetracycline (Chopra & Roberts, 2001). Tet(X) is monooxygenase enzyme 
that acts on first and second generation tetracyclines, but it is also active against the 
recently approved third generation tetracycline; tigecycline (Moore et al., 2005; Yang 
et al., 2004). To date tet(X) has not be found amongst clinically-derived bacterial 
strains (Moore et al., 2005), however the fact that it was originally found on a mobile 
genetic element (Speer et al., 1991) suggests that it can be passed between bacteria 
via horizontal gene transfer. Two other genes tet(34) and tet(36) have been proposed 
as tetracycline inactivators, but their exact mechanism of tetracycline inactivation is 
not fully understood (Thaker et al., 2010).  
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3.1.3.4 Target modification  
Target modification is the least prevalent of all tetracycline resistance mechanisms. 
Studies using tetracycline resistant propionibacteria (Propionibacterium acnes) 
revealed that single base mutations in the 16S rRNA sequence were responsible for 
tetracycline resistance (Ross et al., 1998). Several studies have also shown that 
substitutions in the primary binding site of the 16S rRNA of Helicobacter pylori can 
mediate tetracycline resistance (Gerrits et al., 2002; Trieber & Taylor, 2002).  
3.1.3.5 Tetracycline resistance in S. aureus 
Two mechanisms of tetracycline resistance have been identified in S. aureus. Active 
efflux via tet(K) and tet(L) and ribosomal protection mediated via tet(M) (Fluit et al., 
2005). Both tet(K) and tet(L) confer resistance to tetracycline and chlortetracycline, 
but in the majority of cases tetracycline efflux in S. aureus is mediated by tet(K), 
which is commonly carried on the 4.4 kb plasmid pT181 (Guay et al., 1993; 
Werckenthin et al., 1996). The conjugative transposon Tn5801 carries tet(M) which 
mediates tetracycline and minocycline resistance through ribosomal protection 
(Kuroda et al., 2001). A survey regarding the distribution of S. aureus tetracycline 
resistance mechanisms in various European hospitals concluded that tet(K) and tet(M) 
were the most prevalent resistance mechanisms (Fluit et al., 2005). 
3.1.4 Tigecycline  
Tigecycline belongs to a recently developed derivative of the tetracycline class of 
antibiotics know as the glycylclines (Stein & Craig, 2006). Tigecycline is a structural 
derivative of minocycline, differing from it by the long side chain at the 9 position of 
carbon atom of the D ring of the tetracyclic nucleus (Seputiene et al., 2010). The 
molecular basis of tigecycline action is similar to the tetracyclines, binding to the 
ribosome 30S subunit and preventing attachment of aminoacylated tRNAs to the 
ribosomal A site (Bauer et al., 2004). Tigecycline however posseses an advantage 
over the first and second generation tetracyclines as it can overcome the previously 
described mechanisms of tetracycline resistance. Ribosomal protection resistance is 
overcome as tigecycline remains bound to ribosomes that have been modified by 
tet(M) (Petersen et al., 1999). Secondly the long side chain of tigecycline makes the 
molecule a poor substrate for tetracycline efflux pumps (Someya et al., 1995).  
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A broad spectrum of human pathogens including penicillin resistant S. pneumonia, 
vancomycin-resistant enterococci, methicillin-resistant S. aureus (MRSA) and 
vancomycin-intermediate S. aureus are all widely susceptible (Noskin, 2005). 
Tigecycline is primarily bacteriostatic with time dependent activity against MRSA 
and other Gram-positive pathogens (Stryjewski & Corey, 2009). Although tigecycline 
resistance has been reported in medically important pathogens such as Enterococcus 
faecalis and (Werner et al., 2008) and Acinetobacter baumannii  (Navon-Venezia et 
al., 2007) tigecycline resistance is yet to be reported in clinical isolates of S. aureus. 
However in vitro studies have shown increased expression of a member of the 
multidrug and toxin extrusion (MATE) family of efflux pumps (mepA) can result in 
reduced tigecycline susceptibility (McAleese et al., 2005).  
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3.1.5 Aims 
Various antimicrobial agents are known to select for S. aureus SCVs; however no 
study has examined the ability of the tetracycline class of antibiotics to do so. 
Therefore the aims of this study were to:   
• Determine if members of the tetracycline class of antibiotics can select for              
S. aureus SCVs and compare selection frequencies between various strains 
• Characterise any SCVs on the basis of auxotrophy, growth rate, MIC profiles and 
S. aureus specific enzymes 
• Compare morphology differences of SCVs and parent stains using transmission 
electron microscopy 
• Determine whether SCVs display clonality with parent strains through random 
amplified polymorphic DNA analysis   
• Sequence the S. aureus 16S rRNA of any SCVs to identify mutations that may be 
responsible for reduced tetracycline susceptibility  
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3.2 Materials and methods 
3.2.1 Bacterial strains 
In this study four S. aureus strains that demonstrated susceptibility to a range of 
tetracyclines were included. S. aureus American Type Culture Collection (ATCC) 
strain 25923 and National Collection of Type Cultures (NCTC) strain 6571 were 
chosen as they represent well characterised methicillin-sensitive reference stains. 
Epidemic methicillin-resistant S. aureus (EMRSA) strain 15 and N315 were chosen to 
represent well studied clinical MRSA strains. Strains were maintained at -80°C in 
Mueller Hinton (MH) broth supplemented with 8 % dimethyl sulfoxide (DMSO) and 
re-isolated on MH agar plates when required. 
3.2.2 Preparation of tetracycline stock solutions 
Doxycycline, tetracycline and oxytetracycline were obtained from Sigma Aldrich 
(UK). Antibiotic stocks (10,000 mg/L) were prepared by adding 100 mg of the 
required antibiotic to 10 mL of sterile deionised water. Solutions were dissolved 
thoroughly by vortex mixing and where required 1 M NaOH was added dropwise to 
aid dissolving. Solutions were filter sterilised by passing them through 0.2 µm filters 
(Minisart, UK), and diluted to reduced strength stock solutions in sterile deionised 
water. Stocks solutions were maintained at 4°C for a maximum of 14 days.  
3.2.3 Determination of minimum inhibitory concentrations  
Minimum inhibitory concentrations (MICs) were determined as described previously 
(section 2.2.3). 
3.2.4 Tetracycline SCV selection assays  
Overnight S. aureus cultures grown in cation adjusted Mueller Hinton broth 
(CAMHB) were diluted to achieve a starting density of 5 X 105 CFU/mL and used to 
inoculate individual universal tubes containing fresh CAMHB containing a range of 
doxycycline, tetracycline and oxytetracycline concentrations based on previously 
defined MIC values (section 3.2.3). Tetracycline exposed cultures were incubated at 
37°C with shaking at 150 rpm. After 6 hours incubation, dilutions were prepared in 
sterile phosphate buffered saline (PBS) and 100 µL dispensed onto MH agar plates 
containing 2 mg/L doxycycline, 2 mg/L tetracycline or 4 mg/L oxytetracycline. 
Solutions were spread over the surface of agar plates using a sterile cotton swab. 
Additionally dilutions of wells were plated onto tetracycline free MH agar to calculate 
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the number of wild type CFU. Agar plates were inverted and incubated for 48 hours at 
37°C. Following incubation, plates were examined and SCVs were recorded as 
presence of non-pigmented microcolonies. The frequency of SCV formation was 
determined as the number of SCVs per total CFU counts on tetracycline free MH 
agar.  
3.2.5 Characterisation of SCV isolates  
S. aureus parent and SCV strains were grown in CAMHB, with SCV cultures being 
supplemented with 1 mg/L tetracycline to prevent reversion to the parent phenotype. 
Overnight parent cultures were prepared by inoculating individual colonies in 
CAMHB followed by incubation at 37°C with shaking at 150 rpm for 18-24 hours. 
SCVs were incubated for additional time (36 – 48 hours) to allow similar cell 
densities to be achieved.  
3.2.5.1 Auxotrophy 
Auxotrophy for haemin, menadione and thymidine in SCV isolates was determined as 
described previously (section 2.2.9.6).  
3.2.5.2 Catalase production  
Addition of 1% w/v hydrogen peroxide (H2O2) (Sigma-Aldrich, Poole, UK) to 
overnight S. aureus parent and SCV cultures was used to detect catalase production. 
Catalase activity was recorded using a 3 point scale. Immediate and rapid bubbling 
following addition of H2O2 was recorded as strong catalase production, bubbling 
observed after longer than 15 seconds was recorded as weak and lack of bubbling was 
recorded as absence of catalase production.  
3.2.5.3 Coagulase production 
Parent and SCV isolates were examined for coagulase activity using the Staphylase 
test kit (Oxoid Ltd, UK) as described previously (section 2.2.5). An absence of 
agglutination was recorded as coagulase negative. Strong agglutination was recorded 
as strong coagulase production and weak agglutination as weak coagulase activity.  
3.2.5.4 DNase production 
DNase agar was prepared by adding 39 g of dehydrate DNase culture media (Oxoid, 
UK) to 1 L of deionised water. Overnight cultures of S. aureus parent and SCV strains 
were adjusted to a density of 1 x 107 CFU/mL and of this suspension 10 µL drops 
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were spotted onto the surface of a DNase agar plate. Following incubation for 24-48 
hours at 37°C, plates were flooded with 1 M hydrochloric acid (HCl) and left for 5 
minutes at room temperature. The addition of HCl causes the hydrolysis of DNA 
resulting in the agar turning opaque. In the presence of DNase enzymes, DNA is 
digested and no DNA is available to be hydrolysed. Therefore clear zones indicated a 
presence of DNase enzymes. Excess hydrochloric acid was removed from the plate 
and zones of clearing were measured digitally using IMAGE J (NIH).  
3.2.5.5 Haemolysis and lipase activity   
MH agar was supplemented with 5% defibrinated sheep blood (Oxoid, UK) to 
examine haemolysis activity. Plates were inoculated with densities stated previously 
and incubated under the same conditions (section 3.2.5.4). Haemolysis activity was 
detected by the production of zones of clearing surrounding bacterial growth. 
Heamolysis activity was quantified on the degree of clearing observed, ranging from 
absent to weak to strong. To examine production of extracellular lipases MH agar was 
supplemented with 10% w/v egg yolk (Sigma Aldrich, UK). Following incubation, 
the diameter of zones of clearing (indicating hydrolysis of lipids) were measured 
digitally using IMAGE J. 
3.2.5.6 Growth rate analysis  
Parent and SCV cultures were adjusted to achieve a starting density of 5 X 105 
CFU/mL in 250 mL conical flasks containing 50 mL MH broth. Flasks were 
incubated at 37°C with shaking at 150 rpm. At set time points 1 mL samples were 
taken and OD630 measured. Following completion of growth rate experiments, flasks 
were aseptically sampled and serial dilutions in PBS made. Final viable counts were 
performed by drop counting on MH agar.    
3.2.5.7 Transmission electron microscopy  
Cells in logarithmic growth phase were fixed by the addition of 1.5% v/v 
glutaraldehyde (TAAB, UK), which was incubated for 12 hours at 37°C. Following 
fixation cells were washed twice in double distilled water (5 minutes each wash) and 
subsequently dehydrated with graded concentrations of ethanol (50%, 70%, 90% and 
100%) with each dehydration step lasting 15 minutes. Following dehydration cells 
were embedded in LR White embedding resin (London Resin Company, UK) and cut 
into sections. Ultrathin sections were stained firstly with 4% w/v aqueous uranyl 
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acetate (5 minutes), water washed and air dried. Cells were then counterstained with 
lead acetate (30 seconds), water washed and air dried. Sections were viewed with a 
CM12 transmission electron microscope (FEI, USA) with images recorded using a 
SIS MegaView III digital camera. 
3.2.5.8 DNA extraction  
DNA extraction from parent and SCV isolates was performed as described previously 
(section 2.2.7) 
3.2.5.9 Random amplified polymorphic DNA PCR (RAPD-PCR) 
All PCR reagents were supplied by Qiagen (UK). RAPD-PCR was carried out as 
described previously by (Mahenthiralingam et al., 1996). Primers 208 (5′-
ACGGCCGACC-3′) 268 (5′-AGGCCGCTTA-3′) 272 (5′-AGCGGGCCAA-3′) 
(MWG Biotech, UK) were used as they have be found to produce good discriminatory 
patterns in S. aureus (Cheeseman et al., 2007). RAPD-PCR was carried out in 25 µL 
reactions consisting of 2 µL template DNA (approximately 50 ng/µL) being added to 
a 23 µL PCR mixture consisting of; sterile polished deionised water, 1 X Coralload 
buffer, 1 X Q solution, 3 mM MgCl2, 1.6 µM each RAPD primer, 200 µM dNTPs, 
and 1 unit Taq DNA polymerase. PCR was conducted in a Flexigene Thermal Cycler 
(Techne Ltd., UK) with the following cycle; 5 min at 94°C, followed by 4 cycles of 
36°C for 5 min, 72°C for 5 min and 94°C for 5 min and a further 30 cycles of 94°C 
for 1 min, 36°C for 1 min and 72°C for 5 min and a final hold at 72°C for 5 minutes. 
PCR products (12 µL) were run on 1.5 % w/v agarose (Sigma Aldrich, UK) gels and 
were visualised with ethidium bromide (0.5 µg/mL final concentration in TAE buffer; 
40 mM Tris-acetate, 1 mM EDTA) for 45 minutes. Molecular standards were run on 
all gels using molecular weight maker Hyperladder I (Invitrogen, UK).  
3.2.5.10 16S rRNA amplification  
Primers rRNS-1 (5’-AGAGTTTGATCCTGGCTCAG-3’) and rRNS-2                                                           
(5’-AAGGAGGTGATCCA(A/G)CCGCA-3’; MWG Biotech, UK) were used to 
amplify the S. aureus 16S rRNA gene of parent and SCV isolates. PCR was carried 
out in 25 µL reactions consisting of: 1 X PCR buffer, 1 X Q Solution, 3 mM MgCl2, 
100 µM dNTPs mixture, 0.4 µM primer, 1 U of Taq DNA polymerase and 2 µL of 
template DNA. PCR was conducted with the following cycle; 5 min at 94°C, followed 
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by 35 cycles of 94 ºC for 30 seconds, 30 seconds at 50ºC, 60 seconds at 72ºC for and 
a final hold at 72ºC for 5 min.  
3.2.5.11 Sequencing 
Prior to sequencing, amplified products were treated and cleaned with Montage PCR 
Centrifugal Filter Devices (Millipore, UK), using various centrifugation steps to 
purify PCR products. PCR products were sequenced with six additional primers listed 
in Table 3.1. Sequencing reactions were performed using the ABI PRISM BigDye 
Terminator v3.1 cycle sequencing kit and run on an ABI 3130×1 Genetic Analyzer.  
Sequences were viewed using Chromas lite v2.01 (Technelysium Pty Ltd). Following 
sequence determination 16S rRNA sequences of SCV and parent strains were 
compared using BioEdit Sequence Alignment Editor (Hall, 1999). 
3.2.6 Statistical analysis  
Analysis of significant differences between characteristics of SCV isolates and parent 
strains were performed as described previously (section 2.2.9.8).  
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Table 3.1 S. aureus 16S rRNA sequence primers (Werner et al., 2008) 
 
Primer Sequence (3’- 5’) 
rRNS-357F CTCCTACGGGAGGCAGCAG 
rRNS-704F GTAGCGGTGAAATGCGTAGA 
rRNS-1114F GCAACGAGCGCAACCC 
rRNS-neu1R CCTACTGCTGCCTCCCGTAG 
rRNS-685R TCTACGCATTTCACCGCTAC 
rRNS-1100R GGGTTGCGCTCGTTG 
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3.3 Results  
3.3.1 Tetracycline selection for SCVs  
Doxycycline, tetracycline and oxytetracycline all selected for S. aureus SCVs (Figure 
3.2). SCVs were recorded as non-pigmented, microcolonies that were approximately 
5-10 times smaller in comparison to parent colonies. SCVs were termed according to 
the antibiotic that selected for them. For example N315 DOX was a SCV derived 
from N315 following exposure to doxycycline. SCVs were detected in control 
experiments (where no antibiotic was added to broth before agar plating) but 
frequencies were significantly lower in comparison to conditions where antibiotics 
were present (P = < 0.01). SCV selection frequencies were highest following exposure 
of cultures to X 0.5 MIC for all 4 strains tested across the panel of tetracyclines 
examined.  
3.3.2 Characterisation of tetracycline selected SCVs 
3.3.2.1 Auxotrophy and SCV characteristics   
SCVs auxotrophic for haemin and menadione were frequently observed in 
tetracycline selected SCVs (Table 3.2). Auxotrophy was for haemin, menadione or 
thymidine was not detected in 25% of the SCVs analysed. All SCVs showed reduced 
catalase, coagulase and haemolysis activity in comparison to their parent counterparts 
with certain SCVs showing a complete absence of catalase, coagulase and/or 
heamolysis activity. To confirm auxotrophy requirements SCV cultures were 
supplemented with either haemin or menadione and examined for restoration of parent 
characteristics. In all cases SCVs reverted to the parent phenotype and produced 
catalase, coagulase, and haemolysis activity comparable with that activity recorded in 
parent strains.  
3.3.2.2 Cellular morphology  
Differences in cellular morphology were observed between parent and SCV strains 
(Figure 3.3). Transmission electron micrographs showed SCV cell walls to be 
significantly thicker in comparison to parent cell walls (P = < 0.01). Individual parent 
cells showed regular patterns of division with a clear regularly shaped septum. SCVs 
frequently displayed an irregular shaped septum, with a curved appearance in contrast 
to the straight septum shown in parent cells. 
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Figure 3.2 SCV formation frequencies after exposure to various concentrations 
of tetracycline antibiotics A) - Doxycycline; B) - Tetracycline; C) - Oxytetracycline. 
Control conditions had no prior exposure to tetracycline. SCV formation frequencies 
were determined as the number of SCVs per total CFU counts on antibiotic free 
MHA. Results are the means of three independent replicates and three biological 
replicates. Error bars represent standard error. 
Control 
X 0.25 MIC
X 0.5 MIC
MIC
B) 
A) 
C) 
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Table 3.2 Characteristics of SCVs isolated after exposure to various tetracyclines 
 
 
Strain Auxotrophy  Catalase Coagulase Haemolysis 
ATCC 25923 NT + + + +  + 
 ATCC 25923 SCV DOX Haemin - - - 
ATCC 25923 SCV TET ND + + - 
ATCC 25923 SCV OXY Haemin + + - 
NCTC 6571 NT + +  + + ++ 
NCTC 6571 SCV DOX Haemin + + + 
NCTC 6571 SCV TET Menadione  - - - 
NCTC 6571 SCV OXY Menadione - - - 
N315 NT + + + + ++ 
N315 SCV DOX ND + + + 
N315 SCV TET Haemin - - + 
N315 SCV OXY ND - + - 
EMRSA 15 NT + + + + ++ 
EMRSA 15 SCV DOX Menadione  + - - 
EMRSA 15 SCV TET Haemin - - + 
EMRSA 15 SCV OXY Haemin + + - 
 
 
++ - Strong catalase/coagulase/haemolysis activity; + - Weak catalase/coagulase/ haemolysis activity; - = Absence of catalase/coagulase/ 
haemolysis activity; DOX - doxycycline; TET - tetracycline; OXY - oxytetracycline; ND - not detected; NT =- not tested 
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Figure 3.3 Transmission electron micrographs of SCV selected in the presence of tetracycline and parent cells A) - Parent individual cocci 
showing regular cell wall and septum, B) - Individual SCV showing increased cell wall thickness, C) - SCVs showing irregular septum 
formation. All images magnification X 31,000. 
A) B) C) 
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3.3.2.3 DNase and lipase activity  
A measurement of extracellular DNase activity was obtained by measuring zones of 
DNA hydrolysis (Figure 3.4). All SCV isolates from all three tetracycline antibiotic 
produced significantly less DNase in comparison to parent strains (P = < 0.01). The 
average zone of DNA hydrolysis in parent strains was 18.75 mm where as the SCV 
average was over 4 times smaller at 4.24 mm (Figure 3.4). SCVs also produced 
significantly less extracellular lipase activity than parent strains (P = < 0.01). Zones of 
clearing on MH agar containing egg yolk were an average of 11.7 mm in diameter for 
parent strains were as SCV isolates produced average diameter zones of lipase activity 
of 1.04 mm (Figure 3.4). A complete absence of lipase activity was observed in 3 out 
of the 12 SCV isolates examined. 
3.3.2.4 Growth rate analysis  
Growth rate analysis revealed changes in parent and tetracycline selected SCV growth 
profiles. As shown in Figure 3.5 the SCVs of ATCC 25923 and EMRSA 15 in the 
presence of doxycycline, tetracycline and oxytetracycline all exhibited increases in the 
duration of the lag phase of growth. The duration of lag phase in parent strains was 
approximately 1.5 hours in comparison to an average of 14 hours for the 6 
representative SCVs shown in Figure 3.5. Furthermore SCVs also reached lower 
maximum cell densities reflected by the lower optical density values (Figure 3.5). 
Viable counts revealed that on average SCVs reached a maximum cell density of 2.7 
X 108 CFU/mL. In comparison both parent strains reached higher average cell 
densities of 5 X 109 CFU/mL.  
3.3.2.5 Susceptibility profiles 
MICs of parent and SCV isolates were obtained for all tetracycline antibiotics 
examined as well as for a fluroquinolone (ciprofloxacin), an aminoglycoside 
(gentamicin) and a ß lactam (oxacillin) according to CLSI guidelines (Table 3.3). 
SCV isolates exhibited an increase in MIC for all 3 members of the tetracycline class 
of antibiotics regardless of the tetracycline antibiotic used for selection. For example 
ATCC 25323 DOX (selected for in the presence of doxycycline) exhibited an 8 fold 
increase in doxycycline susceptibility, as well as a 4 fold increase in tetracycline and 
oxytetracycline susceptibility (Table 3.3). SCVs also showed reduced susceptibility to 
gentamicin and oxacillin. Gentamicin MICs for SCV isolates were 2-8 fold higher 
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Figure 3.4 DNase and lipase activity in SCVs and corresponding parent strains  
A) - DNase zones represent hydrolysis of DNA and extracellular DNase activity;            
B) - Lipase activity zones representing breakdown of lipids. Results are the means of 
three independent replicates and three biological replicates. Error bars represent 
standard error. 
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Figure 3.5 Tetracycline selected SCVs and parent growth dynamics A) - ATCC 
25923 and SCV derivatives B) - EMRSA 15 and SCV derivatives. SCVs exhibited 
extended lag phases and reached lower maximum cell densities in comparison to 
parent strains. Results are the means of three independent replicates and three 
biological replicates. Error bars represent standard error. 
A) 
B) 
Wildtype 
DOX SCV 
TET SCV 
OXY SCV 
 91 
Table 3.3 MIC (mg/L) for SCV isolated in the presence of various tetracycline antibiotics and their corresponding parent strains  
 
 
 
 
 
 
CIP - Ciprofloxacin; DOX - Doxycycline; GEN - Gentamicin; OXA - Oxacillin; OXY - Oxytetracycline; TET - Tetracycline; NT - not tested. 
Modal MIC values are presented. Modal values were obtained from three independent replicates and three independent biological replicates. 
Strain DOX TET OXA CIP GEN OXA 
ATCC 25923 0.25 0.5 1 0.75 0.25 0.5 
 ATCC 25923 SCV DOX 2 2 4 0.5 1 2 
ATCC 25923 SCV TET 1.5 2 3 0.75 1.5 1 
ATCC 25923 SCV OXY 2 2 4 0.75 1 1 
NCTC 6571 0.5 0.5 2 0.5 0.125 0.5 
NCTC 6571 SCV DOX 2 1.5 5 0.5 1 1.5 
NCTC 6571 SCV TET 2 2 4 0.75 0.75 1 
NCTC 6571 SCV OXY 2 2 4 0.5 1 1 
N315 0.5 1 2 0.75 0.5 NT 
N315 SCV DOX 2 2 5 0.75 1.5 NT 
N315 SCV TET 2 2.5 5 0.75 2 NT 
N315 SCV OXY 2 2 4 0.5 2 NT 
EMRSA 15 0.25 0.5 1 0.75 1 NT 
EMRSA 15 SCV DOX 2 2 3 0.5 2 NT 
EMRSA 15 SCV TET 1.5 1.5 4 0.75 2 NT 
EMRSA 15 SCV OXY 2 2 4 0.75 3 NT 
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Figure 3.6 Typical SCV and parent RAPD profiles L - Hyperladder 1; 1 – ATCC 
25923; 2 – ATCC 25923 SCV DOX; 3 – ATCC 25923 SCV OXY; 4 – ATCC 25923 
SCV TET. RAPD analysis of SCVs selected in the presence of various tetracyclines 
showed SCVs displayed identical profiles in comparison to parent strains with three 
different primer sets.  
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than parent MICs and 2-4 fold increase in SCV susceptibility to oxacillin 
susceptibility was also recorded. MICs for the DNA replication inhibitor 
ciprofloxacin showed no consistent variation in comparison of parent and SCV 
isolates. Although though increases in MIC for all SCV isolates were detected in 5 out 
of the 6 antibiotics tested none of the increases were large enough to classify them as 
resistant according to CLSI guidelines.  
3.3.2.6 RAPD profiles  
RAPD fingerprints for SCVs isolated from different tetracycline antibiotics were 
identical to parent fingerprints generated from all three primer sets (Figure 3.6). The 
same banding patterns were also observed between SCV isolates (from the same 
parent strain) recovered from different selection backgrounds.    
3.3.2.7 16S rRNA sequence analysis 
Sequence analysis of the 16S rRNA showed a 99.9 % sequence similarity between                      
S. aureus parent strains. Sequence compassion of S. aureus parents and SCVs selected 
in the presence of tetracycline however revealed no difference in 16S rRNA sequence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 94 
3.4 Discussion  
 
Exposure of wildtype cultures to doxycycline, tetracycline and oxytetracycline 
resulted in the selection of SCVs in both MSSA and MRSA strains. SCVs isolated 
displayed morphological characteristics that correlate with other studies that report 
SCV as non-pigmented microcolonies that take 24-48 hours to appear on solid agar 
(Pan et al., 2002; Seaman et al., 2007). The appearance of these atypical phenotypes 
(in comparison to wildtype strains) was attributed to defects in the S. aureus electron 
transport chain (ETC).  
 
Auxotrophy for haemin and menadione was regularly detected (75 % of total isolates) 
in the tetracycline selected SCVs isolated this study. Auxotrophy for haemin and 
menadione has been widely reported in S. aureus SCVs as well as SCVs isolated from 
several other bacterial species (Colwell, 1946; Sasarman et al., 1970). Haemin and 
menadione are both crucial components of the bacterial ETC. Haemin is required for 
the synthesis of cytochromes and menadione is isoprenylated to form menaquinone 
and is the acceptor of electrons from nicotinamide adenine dinucelotide (NADH) and 
flavin adenine dinucelotide (FADH2) (von Eiff et al., 2001b; Bates et al., 2003). The 
inability to produce menaquinone and haemin in the SCVs selected for by 
tetracyclines results in a disrupted ETC resulting in reduced ATP levels. The 
reduction in cellular ATP levels results in the characteristic non-pigmented 
microcolonies observed. The production of pigment in S. aureus requires energy to 
drive carotenoid biosynthesis, whilst ATP is essential to driver cellular process such 
as protein and cell wall synthesis (Proctor et al., 2006). The attenuated production of 
catalase, coagulase, DNase and lipase production agrees with previous research which 
shows that SCVs produce lower amounts of extracellular accessory proteins (Proctor 
et al., 2006; Seaman et al., 2007). Many of these proteins are under the control of the 
accessory gene regulator (agr) and staphylococcal accessory regulator (sarA) which 
has been shown to be downregulated in SCVs (Kahl et al., 2005). The reduction in 
various extracellular accessory proteins suggests the expression of global regulators is 
also altered in tetracycline selected SCVs. The selection of SCVs following exposure 
to tetracyclines may act as a survival mechanism in which the switching to the SCV 
phenotype renders the loss of certain functions but most importantly permits survival 
and persistence.   
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All SCVs were also examined for the presence of thymidine auxotrophy. Thymidine 
auxotrophy has been reported in S. aureus SCVs and has been associated with SCVs 
recovered from cystic fibrosis patients (CF) (Kahl et al., 1998). Thymidine 
auxotrophic SCVs share characteristics with haemin and menadione auxotrophs but a 
link between thymidine auxotrophy and exposure to trimethoprim sulphamethoxazole 
(SXT) is apparent (Gilligan et al., 1987). SXT is commonly used to treat CF and 
thymidine auxotrophic SCVs are commonly recovered from CF patients. Exposure to 
SXT results in mutations in thyA which encodes thymidylate synthase in S. aureus 
(Besier et al., 2007). The failure to detect thymidine auxotrophs in this and previous 
studies (Chapter 2) suggests that thymidine auxotrophy is not accountable for the 
SCV phenotype following exposure to aminoglycosides and tetracycline. However 
analysis of isolates from different sources (such as clinical derived specimens) may 
yield thymidine auxotrophs. In several of the SCVs isolated, no auxotrophy profile 
was detected. Various studies have reported the isolation of SCVs where no 
auxotrophy profile can be detected including SCVs selected in the presence of 
linezolid, sparfloxacin and triclosan (Gao et al., 2010; Pan et al., 2002; Seaman et al., 
2007). Possible candidates for the site of auxotrophy are unsaturated fatty acid 
biosynthesis or in the F0F1-ATPase as discussed previously (section 2.4).  
 
SCVs commonly display reduced susceptibility to a variety of antimicrobial 
compounds as a direct result of the SCV phenotype. The SCVs isolated in this study 
showed reduced susceptibility to tetracyclines as well as gentamicin and oxacillin in 
comparison to parent strains. It is well documented that SCVs are less susceptible to 
aminoglycosides antibiotics such as gentamicin (Proctor et al., 1998). The presence of 
an electrochemical gradient across the bacterial membrane is essential for the uptake 
of positively charged molecules such as aminoglycosides (Balwit et al., 1994). As 
SCVs have a reduced electrochemical gradient, less uptake of these positively charged 
molecules occurs, resulting in reduced susceptibility. The reduced susceptibility to ß-
lactam antibiotics observed is has been related to the slow growth rate of SCVs 
reducing the effectiveness of these cell wall active antibiotics (Schnitzer et al., 1943; 
Youmans et al., 1945). Although tetracycline selected SCVs produced atypical 
growth profiles, following the extension of lag phase only subtle differences were 
observed in growth rate, which suggests others mechanisms are responsible for 
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reduced oxacillin susceptibility. The thickening of the SCV cell wall observed in 
electron micrographs may be responsible for reduced susceptibility to oxacillin. Cell 
wall thickening has been observed in S. aureus strains displayed reduced 
susceptibility to vancomycin (Cui et al., 2003) and has also been shown to be 
responsible for reducing susceptibility to ß-lactam antibiotics (Morikawa et al., 2001). 
Thickening of the cell wall may impact on the penetration of cell wall specific 
antibiotics (such as oxacillin), which must cross the cell wall in order to reach their 
cellular target (Lambert, 2002). No difference in susceptibility between SCV and 
parent strains to the DNA gyrase/topoisomerase inhibitor ciprofloxacin was observed. 
Similarly to the reduced susceptibility to ß-lactam antibiotics, it would be 
hypothesised that a slower growth rate would result in reduced susceptibility to 
ciprofloxacin due to lower rates of DNA synthesis. The similarities in growth rate and 
ciprofloxacin susceptibility suggest that DNA synthesis in the exponential phase is 
proceeding at similar levels in parent and SCV strains.   
 
RAPD has been applied to study and track the epidemiology of S. aureus in both 
clinical and environmental settings (Lee, 2003; VandenBergh et al., 1999). RAPD 
was successfully applied to SCV isolates which had been selected for in the presence 
of various tetracyclines. SCV isolates displayed fingerprint patterns that were 
identical to their parent counter parts and identical fingerprints of SCV isolated from 
different tetracyclines were also observed confirming the clonality of the tetracycline 
selected SCV isolates. Although RAPD is not as powerful as other molecular 
techniques for studying epidemiology (such as pulse field gel electrophoresis; PFGE) 
the homology observed between SCV isolates and parent strains confirms clonality is 
associated with tetracycline selected SCVs. 
 
In order to identify the genetic basis for the mutations that give rise to the SCV 
phenotype investigators have sequenced genes that may be potential targets for 
mutations. Norstrom et al., (2007) have shown that fusidic acid can select for SCVs 
via mutations in fusA and rplF (ribosomal protection protein). Fusidic acid targets 
protein synthesis through preventing the release of translation elongation factor EF-G 
(Bodley et al., 1969). Mutations in fusA reduce the affinity of fusidic acid for its target 
where as mutations in rplF results in alteration (directly or indirectly) of the structural 
conformations of EF-G on the ribosome (Norstrom et al., 2007). These mutations 
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represent novel mechanism for fusidic acid that give rise to the SCV phenotype. In 
this study we sequenced the 16S rRNA sequence of parent and SCV S. aureus isolates 
in order to identify mutations that may be responsible for the tetracycline selected 
SCV phenotype. However no alterations in the DNA sequences were detected. 
Studies have reported an absence of mutation(s) in the gene(s) targeted by the 
selecting antibiotic that results in SCVs. An outcome of this is no known genetic basis 
for the SCV phenotype. For example Mitsuyama et al., (1997) demonstrated that 
pazufloxacin (a broad spectrum fluoroquinolone) selected for S. aureus SCVs but no 
mutations were detecting in the quinolone resistance determining regions of either 
DNA gyrase of topoisomerase IV. Therefore the authors suggest that the 
fluoroquinolone resistance may follow a similar mechanism of resistance to 
aminoglycosides in SCVs i.e. reduced uptake due to reduced electrochemical gradient 
across the bacterial membrane. The mechanisms of reduced tetracycline susceptibility 
in SCVs may follow the similar mechanism. Uptake of tetracycline in susceptibile E. 
coli involves both energy dependent and energy independent systems (McMurry & 
Levy, 1978). Furthermore the uptake of tetracycline in E. coli has been partially 
attributed to the presence of a proton motive force (Smith & Chopra, 1984). As SCVs 
are deficient in the generation of a proton motive force (due to electron transport 
chain interruption), this may be responsible for a reduction in tetracycline uptake in 
tetracycline selected SCVs, reducing their susceptibility in comparison to parent 
strains.  
 
The findings in this chapter illustrate the ability of several members of the tetracycline 
class of antibiotics to select for SCVs in vivo. Although several other antibacterial 
compounds have been shown to select for SCVs this is the first case to our knowledge 
where tetracyclines have been demonstrated to select for the SCV phenotype. The 
SCVs isolated shared similar characteristics with those that have been reported in 
various other studies. The ability of tetracycline to select for SCVs raises concerns 
regarding the clinical use(s) of tetracycline. Although large reductions in 
antimicrobial susceptibility were not observed, the selection of SCVs is unfavourable 
due to their ability to hide inside host cells, which can serve a reservoir for chronic 
and therapy-refractive infections (Tuchscherr et al., 2011b).  
 
 
 98 
 
 
 
3.5 Conclusions 
• Doxycycline, tetracycline and oxytetracycline can select for S. aureus SCVs at a 
range of concentrations. 
• Exposure to X 0.5 MIC results in the highest SCV formation frequencies in the 
three tetracyclines analysed.  
• Tetracycline selected SCVs display increased cell wall thickness and irregular 
septum formation.  
• Auxotrophy for haemin and menadione was widely observed in SCV isolates 
correlating to defects in electron transport. 
• Tetracycline selected SCVs show attenuated catalase, coagulase and heamolysis 
activity and reduced production of extracellular enzymes.   
• Tetracycline selected SCVs showed reduced susceptibility to a range of 
tetracycline, gentamicin and oxacillin. 
• Reduced tetracycline susceptibility in SCVs is not related to mutations in 16S 
rRNA. 
• Tetracycline selected SCVs and parents produced identical RAPD profiles 
indicating clonality. 
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4 CHAPTER 4: BIOFILM FORMATION IN STAPHYLOCOCCUS 
AUREUS SMALL COLONY VARIANTS  
4.1 Introduction  
4.1.1 Biofilms 
Bacteria have the ability to produce a protective hydrated matrix of polysaccharide 
and protein, forming a slimy layer known as a biofilm (Stewart et al., 2001). A 
biofilm can be further defined as an ‘assemblage of microbial cells that is irreversibly 
associated (not removed by gentle rinsing) with a surface and enclosed in a matrix of 
primarily polysaccharide material’ (Donlan, 2002). This polysaccharide is composed 
of extracellular polymeric substances (EPS) and consists of a variety of different 
biopolymers which immobilise biofilm cells, keeping them within close proximity of 
one another (Flemming & Wingender, 2010). Various bacterial infections in the 
modern world are thought to involve biofilm formation (Costerton et al., 1999), 
underlying the importance of this area in the clinical setting. Biofilms constitute a 
protected mode of growth that allows survival in a hostile environment and therefore 
treatment of biofilm related infections depends on long term, high-dose antibiotic 
therapies and may require the removal of indwelling devices (Fux et al., 2005).  
4.1.2 Staphylococcal biofilms 
Staphylococcus aureus and S. epidermidis biofilms are among the most commonly 
encountered organisms in the clinical setting and are responsible for a large 
proportion of biofilm-mediated device-related infections (O'Gara & Humphreys, 
2001). Staphylococci can form biofilms on frequently used medical devices such as 
catheters (Marrie & Costerton, 1984b), pacemakers (Marrie & Costerton, 1984a) and 
prosthetic knee and hip joints (Rohde et al., 2007). Staphylococcal biofilms represent 
a focus of infection which may allow clusters of cells to detach from the biofilm, 
resulting in bloodstream infection and metastatic spread (Fitzpatrick et al., 2005).  
4.1.2.1 Staphylococcal biofilm formation 
Staphylococcal biofilm formation is a two step process, attachment of cells to a 
surface, followed by accumulation of cells to form a multilayered cell cluster (Gotz, 
2002). Figure 4.1 shows that adhesion to a surface is the crucial transition stage from 
free-floating planktonic cells to a biofilm and involves the interplay of several 
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adhesion molecules enabling the physico-chemical interactions between the cells and 
the surface (Kong et al., 2006). The transition from planktonic to multicellular 
lifestyle requires the co-ordinated expression of a variety of specialised extracellular 
and cellular components (Valle et al., 2003). 
4.1.2.2 Molecules contribution to adhesion  
Adhesion to a surface in staphylococci is mulifactoral. Interactions between the 
bacterial surface, substrate surface and the surrounding environment all play a role 
(Wang et al., 1995). Nutrient flow, pH and hydrodynamic flow are all examples of 
environmental factors that contribute to the adhesion process, although the 
physiochemical properties of the bacterial and substrate surface determine the non 
specific interactions that determine attraction or repulsion (Higashi & Sullam, 2006).  
 
Although various environmental factors are play a role, bacterial surface proteins are 
crucial for initial adhesion. Many surface proteins are produced in staphylococci and a 
large proportion belong to the microbial surface components recognising adhesive 
matrix molecules (MSCRAMM) family (Higashi & Sullam, 2006), the majority of 
which are anchored to cell wall peptidoglycan (Patti et al., 1994). Fibronectin-binding 
proteins (FnBPs), a collagen-binding protein, Cna, and clumping factor (Clf) are all 
adhesins belonging to MSCRAMM family (Foster & Hook, 1998). These components 
bind to the extracellular matrix of host tissues and mediate initial attachment.                   
S. aureus also produces secreted proteins to facilitate adhesion. One such example is 
extracellular adherence protein (EAP; Palma et al., 1999) which is required for the 
adherence of S. aureus to eukaryotic cells and also facilitates internalisation (Haggar 
et al., 2003). Although a variety of different surface proteins exist they all share the 
same principal role; bacterial adhesion. This adhesion is crucial for the first step in 
biofilm biogenesis to allow the subsequent steps of biofilm formation to proceed.  
4.1.2.3 Molecules responsible for exopolysaccharide production  
Following adhesion the next stage in staphylococcal biofilm formation is the synthesis 
of exopolysaccharide, which aids aggregation and cellular adhesion. The principle 
exopolysaccharide produced by staphylococci is polysaccharide intracellular adhesin 
(PIA) (Mack et al., 1996) which is considered essential in mediating cellular 
accumulation (Figure 4.1) and biofilm development (Gotz, 2002). PIA, also termed 
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polymeric N-acetyl glucosamine (PNAG), is composed of 2 polysaccharide fractions, 
polysaccharide I (~ 80%) and polysaccharide II (~20%; Mack et al., 1996). 
Polysaccharide I is composed of linear ß 1, 6-linked N-acetylglucosamine residues 
containing up to 15% de-N-acetylated amino groups and substitution with succinate 
and phosphate residues introducing simultaneously positive and negative charges into 
the polysaccharide (Cramton et al., 2001a; Cucarella et al., 2001; Mack et al., 1996). 
Polysaccharide II is structurally related to polysaccharide I but has a lower content of 
non N-acetylated D-glucosminyl residues (Gotz, 2002).  
4.1.2.4 PIA production and the intracellular adhesin locus  
PIA production is under the control of the intracellular adhesin (ica) operon (Figure 
4.2), which was first identified in S. epidermidis (Heilmann et al., 1996). Using 
transposon mutagenesis Heilmann et al., (1996) isolated a biofilm-negative mutant 
with an insertional inactivation of the icaABC gene cluster which had lost the ability 
to form biofilms on a polystyrene surface. Complementation with an                       
icaABC-carrying plasmid restored the mutant’s biofilm forming capacity and the 
expression of PIA. The ica operon was later identified in S. aureus and sequence 
comparison with the S. epidermidis ica genes revealed 59 to 78% amino acid identity 
(Cramton et al., 1999). The ica operon consists of PIA biosynthesis genes (icaADBC) 
and a regulator (icaR) (Higashi & Sullam, 2006). icaR is located upstream of 
icaADBC (Figure 4.2) and is a member of the tetR family of transcriptional regulators 
that is divergently transcribed and functions as a negative regulatory protein (Conlon 
et al., 2002). IcaR binds the ica operon promoter region close to the IcaA start codon 
and exerts its repressor activity by obscuring the binding site of the ica promoter 
(Jefferson et al., 2003; Jefferson et al., 2004). IcaADBC encode the biosynthetic 
genes that are responsible for PIA biosynthesis; icaA encodes a transmembrane 
protein that synthesises N-acetyl-glucosamine oligomers (Gerke et al., 1998). The 
surface-attached protein icaB is then responsible for deacetylation of the N-
acetylglucosamine polymer (Vuong et al., 2004b). IcaC is involved in translocation 
and externalisation of the growing polysaccharide to the cell surface (O'Gara, 2007) 
and icaD is thought to function as a chaperone, directing the correct folding and 
membrane of insertion of IcaA (Gotz, 2002).  
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Figure 4.1 Formation of S. aureus biofilms Planktonic cells firstly attach to a 
surface substrate, followed by cell proliferation. As cell numbers increase, PIA is 
produced in increasing amounts encapsulating the bacteria in slime like matrix. With 
time a large community of cells forms a mature biofilm from which individual cells 
may detach to initiate formation of other biofilms. Adapted from Vuong & Otto 
(2002).   
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Figure 4.2 Organisation of ica locus in S. aureus Oligomers derived from UDP N-
acetylglucosamine are synthesised by icaA, which are then modified with longer 
oligomers produced by icaD. Deacetylation of the poly-N-acetylglucosamine 
molecule is carried out by icaB and icaC is finally responsible for translocation of the 
completed PIA to the cell surface. Adapted from Gerke et al.,(1998) and Gotz (2002). 
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4.1.2.5 Other molecules involved in biofilm formation 
As well as PIA, other ica-independent molecules are known to impact on 
staphylococcal biofilm formation. The biofilm associated protein (Bap) was first 
identified by Cucarella et al., (2001) using transposon mutagenesis. The mutant strain 
displayed a significant decrease in attachment to inert surfaces, intercellular adhesion, 
and biofilm formation. Bap is a multidomain surface-associated protein that promotes 
both primary attachment to surfaces and intracellular adhesion (Lasa & Penades, 
2006). Bap negative strains produce lower levels of PIA; however a PIA producing S. 
aureus strain complemented with Bap produced PIA in significantly greater quantities 
(Cucarella et al., 2001). Staphylococcal isolates that contain Bap are strong biofilm 
producers (despite not containing the ica operon) indicating Bap mediates a 
alternative mechanism of biofilm development, to the regular PIA-dependent 
mechanism (Tormo et al., 2005a).  
4.1.2.6 Influence of environmental stimuli and global regulators on 
staphylococcal biofilm formation 
The role of environmental stimuli and their impact on biofilm formation has been the 
subject of much research. Certain environmental stimuli can induce changes in global 
gene expression which can promote biofilm formation. The diverse environmental 
conditions encountered by staphylococci therefore have a direct impact on the extent 
to which strains can form biofilms (Table 4.1). The accessory gene regulator (agr) 
effects the regulation of various virulence genes in S. aureus and plays a role in 
quorum sensing. Agr is an example of a two component system consisting of a sensor 
protein that subsequently activates a response regulator protein (Higashi & Sullam, 
2006). Agr mutants display increased capacity to form biofilms, which appears to be 
independent of PIA production (Vuong et al., 2000). Increased biofilm formation is 
attributed to the inability of cells to detach from the mature biofilm, as agr plays a 
role in the detachment process (Kong et al., 2006; Vuong et al., 2004a). Other global 
regulators also affect biofilm formation in staphylococci, most notably the 
staphylococcal accessory regulator (sarA; Tormo et al., 2005b; Valle et al., 2003)  
and the alternative sigma factor, σB (Knobloch et al., 2004). sarA mutants showed 
down-regulation of the ica operon transcription and subsequent decrease in PIA 
production (Valle et al., 2003). Valle et al. (2003) suggesting that sarA enhances ica 
operon transcription and suppresses transcription of a protein involved in the turnover 
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of PIA. S. epidermidis mutants with mutations in σB show an upregulation of icaR (the 
repressor of the ica locus), resulting in reduced PIA synthesis (Knobloch et al., 2004).   
4.1.2.7 Antimicrobial resistance in staphylococcal biofilms 
Formation of biofilms leads to a reduction in antimicrobial susceptibility in 
staphylococci (Amorena et al., 1999). Even antimicrobial-sensitive bacteria that do 
not have a known genetic basis for resistance demonstrate reduced susceptibility 
when they form a biofilm (Stewart & Costerton, 2001), a trait that which appears to 
be multi-factorial. One mechanism is the failure of an agent to penetrate the full depth 
of the biofilm. Components of the biofilm (such as the exopolysaccharide matrix) can 
limit the transport of antimicrobial agents to the cells within the biofilm (Mah & 
O'Toole, 2001). Farber et al., (1990) for example has demonstrated that addition of S. 
epidermidis PIA to microdilution susceptibility plates increased the MIC of 
glycopeptide antimicrobials, as these large molecules are poorly absorbed. The 
presence of an exopolysaccharide matrix can create a permeability barrier, meaning 
the antimicrobial cannot penetrate the biofilm (Stewart, 1996).  
 
Secondly, the growth rate of cells within a biofilm is substantially reduced in 
comparison with planktonic cells as cells growing in biofilms are commonly nutrient-
depleted (Mah & O'Toole, 2001). Reduced growth rates lead to reduced susceptibility 
to antimicrobials designed to target fast growing bacteria (Tuomanen et al., 1986). 
Eng et al., (1991) demonstrated that bacteria exposed to nutrient limitation showed 
reduced antimicrobial susceptibility to a range of antimicrobial classes. The reduced 
metabolic activity of cells embedded in the biofilms mimic this nutrient depleted state 
correlating with reduced antimicrobial susceptibility in biofilms (Dunne, 2002) 
Finally, it has been hypothesised that cells present in a biofilm may induce a specific 
‘biofilm phenotype’. This ‘biofilm phenotype’ has been likened to a spore-like state 
entered into by some of the bacteria resulting in reduced susceptibility to antibiotics 
and disinfectants (Stewart & Costerton, 2001). Reduced antimicrobial susceptibility to 
ß-lactams, quinolones and glycopeptides has been observed in biofilms formed by S. 
aureus (Chuard et al., 1997). Specifically a recent study by Singh et al. (2010a) has 
highlighted the poor penetration of certain antimicrobial agents through 
staphylococcal biofilms. ß-lactam antibiotics (oxacillin and cefotaxime) and a  
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Table 4.1 Effect of environmental stimuli on biofilm formation in staphylococci 
  
Factor  Effect Reference  
Anaerobic conditions Stimulate ica transcription, 
increasing PIA production 
 
(Cramton et al., 2001b) 
Ethanol  Reduced transcription of the 
icaR repressor 
 
(Conlon et al., 2002) 
Supplementation with 
carbohydrates 
Increased adherence to surfaces 
 
 
(Mack et al., 1992) 
Iron limitation Increased PIA production  (Deighton & Borland, 
1993) 
Sodium chloride  Increased biofilm formation, ica 
independent mechanism 
 
(Lim et al., 2004) 
Subinhibitory 
antibiotic 
concentrations  
 
Increased ica expression and 
PIA production 
(Rachid et al., 2000) 
High temperature  Increased ica expression and 
PIA production 
(Rachid et al., 2000) 
 
 
 
 
 
 
 
 
 107 
glycopeptide (vancomycin) show a significantly reduced penetration through S. 
aureus and S. epidermidis biofilms. Biofilms produced by S. aureus may also protect 
against clearance by host immune systems. Presence of PIA and biofilm formation 
has been shown to protect cells from phagocytosis and killing by polymorphonuclear 
leukocytes (Vuong et al., 2004c). Other studies have shown that although leukocytes 
can penetrate the biofilm matrix they are unable to penetrate bacterial cells and 
promote phagocytosis due to unfavourable conditions (Leid et al., 2002).  
4.1.3 Biofilm formation in small colony variants  
As S. aureus SCVs are frequently recovered from patients with infections typically 
associated with biofilm formation (endocarditis, soft tissue infections and 
osteomyelitis) there is a suggestion that SCVs and biofilms may have a similar 
underlying physiology (Higashi & Sullam, 2006). Several studies have shown that 
SCVs from different bacterial species are capable of forming biofilms (Al Laham et 
al., 2007; Haussler et al., 2003b; Sendi et al., 2006; Singh et al., 2010b). For example 
P. aeruginosa SCVs isolated from cystic fibrosis (CF) patients have been shown to 
display a marked increase in biofilm forming capacity (Haussler et al., 2003b). SCVs 
also displayed increased binding to an eukaryotic cell line and increased pilli 
mediated twitching motility which may play a role in adaptation the CF environment. 
In staphylococci SCVs biofilm formation has been attributed to various mechanisms.  
 
Vaudaux et al. (2002) demonstrated that S. aureus SCVs increase surface display of 
the MSCRAMMs, in particular, fibronectin binding proteins FnBPs. Increased 
transcript levels of clumping factor A (clfA) and fibronectin protein (fbn) were 
responsible for the increased production of these adhesins, and increased adhesion to 
fibronectin coated surfaces. Mitchell et al., (2008) also demonstrated increased 
expression of FnBPs in SCVs and an increased capacity to bind fibronectin. 
Furthermore the authors showed the importance of the alternative sigma factor σB, on 
the expression of FnBPs, suggesting that sustained σB activity in S. aureus SCVs 
locks SCVs into a constant state of colonisation.  
 
Increased capacity to form biofilms has also been attributed to PIA dependent 
mechanisms in S. epidermidis SCVs (Al Laham et al., 2007). The study demonstrated 
that increased production of PIA (and augmented expression of the ica operon) is 
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responsible for increased adhesion to surfaces and increased biofilm forming capacity 
in SCVs. Reduced antimicrobial susceptibility has also been investigated in SCVs. S. 
aureus SCVs exhibit more pronounced reductions in antimicrobial susceptibility than 
parent strains when adhering to a fibronectin surface (Chuard et al., 1997). SCVs 
were highly resistant to the bactericidal action of vancomycin and oxacillin whereas 
the parent strain showed a reduction in viable cell numbers.  
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4.1.4 Aims  
Several studies have examined the ability of SCVs to form biofilms however a limited 
number of studies are available regarding biofilm formation in S. aureus SCVs as well 
as the susceptibility of SCV biofilms to antimicrobial agents. The aims of this study 
were to: 
 
• Assess the ability of S. aureus parent and SCV isolates to produce polysaccharide 
using a simple agar screen. 
• Quantify biofilm formation to provide a comparison of biofilm formation in 
parent and SCV isolates.  
• Examine antimicrobial susceptibility of parent and SCV biofilms to a range of 
antimicrobial agents.  
• Examine the mechanism for any difference in antibiotic susceptibility between 
parent and SCV biofilms.  
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4.2 Materials and methods 
4.2.1 Bacterial strains  
Methicillin-sensitive S. aureus (MSSA) strains ATCC 25923 and NCTC 6571 and 
methicillin-resistant S. aureus (MRSA) strains COL, EMRSA 15, EMRSA 16 and 
N315 and their SCVs were all examined for their ability to form biofilms. 
Additionally S. aureus strains Sa 6538 (biofilm positive) and Sa 5374 (biofilm 
negative; Tote et al., 2008) were used as positive and negative controls respectively. 
SCVs previously selected for in the presence of gentamicin (SCVGEN) and tetracycline 
(SCVTET) were subject to multiplex PCR (as described previously) to confirm SCVs 
were S. aureus. Strains were maintained at -80°C in Mueller Hinton (MH) broth 
supplemented with 8% dimethyl sulfoxide (DMSO) and re-isolated on MH agar plates 
when required. 
4.2.2 Congo red agar screen 
Before biofilm quantification was assessed a simple morphological screen was 
performed using Congo red agar to detect polysaccharide production in S. aureus 
(Freeman et al., 1989). Congo red agar was prepared by adding 50 g sucrose and 10 g 
of purified agar to 1 L of brain heart infusion broth (Oxoid, UK). After autoclaving 
the agar was cooled to 55°C and a filter sterilised solution of Congo red (Sigma, UK; 
0.8 g in 10 mL) added. Several individual S. aureus colonies were used to inoculate 
Congo red agar plates which were incubated at 37°C. After 48 hours incubation plates 
were examined for the presence of black crystalline colonies indicative of 
polysaccharide production. Absence of polysaccharide production was recorded 
following the appearance of pink colonies with occasional darkening at the centre of 
the colony.   
4.2.3 Quantification of biofilms  
Biofilms formed by S. aureus strains were quantified using the method of Tote et al., 
(2008). This assays uses the cationic dye dimethyl methylene blue (DMMB) to 
quantify biofilms as it binds specifically to S. aureus PIA. 
4.2.3.1 Preparation of dimethyl methylene blue working solution  
DMMB (32mg) powder (Sigma, UK) was dissolved in 25 mL of ethanol and filter 
sterilised. Two formic acid buffer (FAB) were prepare; FAB1 was prepared by adding 
4.77 g guanidine hydrochloride (Sigma, UK) and 0.5 g sodium formate (Sigma, UK) 
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to 237 mL of ultrapure water, followed by the addition of 0.5 mL formic acid (Sigma, 
UK) and 12.5 mL ethanol to create a final working volume of 250 mL. FAB 2 was 
prepared by adding 4.77 g guanidine hydrochloride and 0.5 g sodium formate to 49.5 
mL of ultrapure water followed by the addition of 0.5 mL formic acid. The final 
DMMB working solution was prepared by adding FAB 1 and FAB 2 to 12.5 mL of 
the filtered DMMB solution which was stored at room temperature and protected 
from light.  
4.2.3.2 Preparation of decomplexation solution  
Decomplexation solution (DECO) was prepared by adding 50 mL of 1- propanol 
(Sigma, UK) to 500 mL of 50 mM sodium acetate buffer. This was used to dissolve 
380 g of guanidine hydrochloride to achieve a final concentration of 4 M.  
4.2.3.3 Biofilm growth  
Several individual S. aureus colonies were inoculated into MH broth supplemented 
with 0.5% glucose and incubated at 37°C with shaking at 150 rpm, until reaching a 
start inoculum of 1 x 106 CFU/mL. Bacterial suspensions (100 µL) were added to 
individual wells of 96 well flat bottom microtitre plates (Fisher, UK) with replicates 
for each strain. Plates were incubated on a horizontal shaking platform for 72 hours at 
37°C. Growth medium was discarded every 24 hours and fresh medium added to 
avoid the build up of toxic metabolites.  
4.2.3.4 Quantification of biofilms  
Following 72 hours incubation, growth medium was discarded and adhering biofilms 
were washed twice with phosphate buffered saline (PBS). DMMB working solution 
(200 µL) was added to each individual well and incubated at room temperature for 30 
minutes whilst protected from light. DMMB was then discarded by centrifuging well 
plates for 20 minutes at 6000 rpm. Wells were then washed with 200 µL of ultrapure 
water to remove any unbound DMMB, before adding 250 µL of DECO solution. 
Plates were incubated at room temperature for 30 minutes and optical density was 
measured at OD630 using a DYNEX Technologies MRX® Microplate Absorbance 
Reader with RevelationTM application programme.  
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4.2.4 Adhesion to silicone  
Adhesion of S. aureus to silicone was assessed using the method of Williams et al., 
(1997). Silicone catheter discs were prepared by cutting silicone sheets to equal 
dimensions (0.5 cm2). Discs were sterilised by overnight submersion in 90% ethanol, 
followed by 2 hour incubation at room temperature to allow the evaporation of excess 
ethanol. Overnight S. aureus cultures grown in MH broth were adjusted to 1 X 105 
CFU/mL and catheter discs were placed in the suspension. Discs were incubated 
statically at 37°C for 7 days hours to allow attachment of the bacteria. The discs were 
aseptically transferred (ensuring adhering cells were not disrupted) to fresh MH broth 
every 48 hours to prevent build-up of toxic metabolites. After 7 days incubation discs 
were washed gently in PBS and transferred to fresh MH broth. In order to enumerate 
bacteria, discs were sonicated for 5 minutes and vortexed for a further 1 minute to 
remove adherent bacteria. Serial dilutions were performed in PBS and viable counts 
performed on the resulting suspensions, using drop counts.  
4.2.5 Cell-surface hydrophobicity  
Cell-surface hydrophobicity has been implicating in enhancing the ability of the SCVs 
of P. aeruginosa to form biofilms and to influence cell clumping. This was 
investigated in S. aureus using a microbial adhesion to hydrocarbons assay (Perez et 
al., 1998). Overnight cultures of S. aureus strains grown in MH broth, were pelleted 
by centrifugation at 10,000 rpm for 5 min and subsequently washed twice with PBS. 
Cells were adjusted to an optical density of 0.5 at OD600 and 2 mL mixed with 400 µl 
xylene and vortexed for 2 min. After 30 min incubation at room temperature, the 
aqueous phase was collected carefully and its OD600 was determined. The OD600 of the 
aqueous phase relative to the initial suspension was taken as a measure of cell-surface 
hydrophobicity (H%), which was calculated with the formula: 
 
H% = [(OD0  OD)/OD0] × 100 
 
Where OD0 and OD are the optical density before and after extraction with xylene. 
4.2.6 Scanning electron microscopy  
Biofilms were prepared on Thermanox glass coverslips (Fisher Scientific, UK). 
Coverslips were aseptically transferred to S. aureus strains growing in MH broth. 
Coverslips were incubated statically at 37°C for 7 days, with growth medium being 
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changed every 48 hours. Biofilms formed on coverslips were fixed by the addition of 
1.5% v/v glutaraldehyde (TAAB, UK), which was incubated for 12 hours at 37°C. 
Following fixation biofilms were washed twice in double distilled water (5 minutes 
each wash) and subsequently  dehydrated with graded concentrations of ethanol (50%, 
70%, 90% and 100%) with each dehydration step lasting 5 minutes. Samples were 
then treated with three 5 mins applications of hexamethyldisilazane and sputter coated 
with gold. Samples were then viewed with JEOL 840A scanning electron microscope 
(JEOL Ltd, UK) with images recorded on SIS Imaging Software.  
4.2.7 Activity of antimicrobial agents against S. aureus biofilms  
S. aureus strains ATCC 25923 and EMRSA 15 and corresponding SCVs were chosen 
to investigate the effect of antimicrobial agents on biofilms. A modification of the 
DMMB assay was applied to determine the effect if antimicrobials on biofilms (Tote 
et al., 2009). Biofilms were grown as described previously (section 4.2.3.3) and 
culture medium carefully removed with a pipette, ensuring biofilms were not 
disrupted. Ciprofloxacin, chloramphenicol, gentamicin, tetracycline, rifampicin 
(Sigma, UK) and triclosan (Ciba, Germany) were prepared at the following 
concentrations – X 16 MBC; X 8 MBC; X 4 MBC; X 2 MBC; MBC, and MIC. 50 µL 
of the antimicrobial and 50 µL of MH broth were added to individual wells with 
established biofilms. Due to the dilution with MH broth double the required 
antimicrobial concentrations were prepared initially. Ultrapure water was used to 
replace antimicrobials for the formation of untreated control biofilms. Plates were 
subsequently incubated on a horizontal shaking platform for 48 hours at 37°C and 
biofilms quantified as described previously (section 4.2.3.4). Differences in 
absorbance were used to quantify the % reduction in antimicrobial treated biofilms in 
comparison with untreated controls.   
4.2.8 Preparation of colony biofilms and susceptibility to antimicrobial agents 
The method of Anderl et al., (2000) was used to form colony biofilms which were 
assessed for susceptibility to various antimicrobial agents. S. aureus strains were 
grown in MH broth and adjusted to ~ 1 x 107 CFU/mL and 10 µl of this suspension 
was used to seed black polycarbonate membrane filters (Fisher, UK; 13 mm diameter, 
pore size 0.4 µm). Filters were inverted and placed onto MH agar and incubated at 
37 °C for 4 days. Membrane-supported biofilms were transferred to fresh culture 
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medium every 48 hours. Following incubation, biofilms were washed with PBS to 
remove non-adherent cells. Adherent bacteria were enumerated by suspending 
membranes in 1 mL PBS and vortexing at high speed for 2 min. PBS was used to 
perform serial dilutions on the resulting suspension and dilutions were plated onto 
MH agar and incubated for 48 hours at 37°C. To examine the effect of the 
antimicrobial agents on biofilms formed. Colony biofilms were prepared as stated 
previously and following incubation transferred to MH agar containing ciprofloxacin, 
chloramphenicol, gentamicin, tetracycline, triclosan and rifampicin at concentrations 
ranging from 0 – 256 mg/L. Plates were incubated at 37 °C for 48 hours and 
antibiotic-treated biofilms were enumerated as stated above for control biofilms.  
4.2.9 Antimicrobial penetration through biofilms 
The method of Singh et al., (2010a) was used to measure the penetration of the six 
antimicrobial agents examined previously through S. aureus ATCC 25923 and 
EMRSA 15 and corresponding SCVs biofilms. This method uses zones of inhibition 
to measure the penetration of antimicrobial agents through biofilms (Figure 4.3). 
Colony biofilms were prepared as described previously (section 4.2.8) and transferred 
to MH agar plates inoculated with S. aureus ATCC 25923 in order to provide 
confluent lawn growth. A 6 mm diameter nitrocellulose membrane (Fisher, UK; pore 
size 0.4 µm) was placed  on the surface of each biofilm along with an antibiotic disc 
(ciprofloxacin 5 µg, chloramphenicol 30 µg, gentamicin 10 µg, rifampicin 5 µg, 
tetracycline 30 µg, (Oxoid, UK) and triclosan 10 µg). Each disc was moistened with 
24 µL of sterile polished water to prevent antibiotic movement through biofilms via 
capillary action. Control conditions were prepared replicating previous conditions 
with sterile membrane filters being excluded so no biofilms were present. Plates were 
incubated at 37 °C for 48 hours and the zone of inhibition measured digitally using 
IMAGE J (NIH). Inhibition zones produced by control conditions were taken to 
represent 100% penetration through S. aureus biofilms. 
4.2.10 Statistical analysis  
Analysis of significant differences between biofilm formation and antimicrobial 
susceptibility of SCV and parent biofilms was performed using the statistical analysis 
described previously (section 2.2.9.8).  
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Figure 4.3 Schematic displaying experimental setup to examine antibiotic 
penetration through S. aureus biofilms Adapted from Singh et al., (2010a). 
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4.3 Results  
4.3.1 Congo red agar screen 
Eight S. aureus strains and their SCV derivatives (selected for in the presence of 
gentamicin or tetracycline) were investigated for their ability to form biofilms using 
an agar screen. All parent strains grown on Congo red agar produced a black 
crystalline morphology, except the biofilm negative Sa 5374 strain which produced 
pink colonies. Black crystalline colonies indicated the ability to produce 
polysaccharide and were recorded as biofilm positive. All SCV strains (including 
SCVs isolated from Sa 5374) produced a black crystalline morphology. The positivity 
of Sa 5374 SCVs was surprising, although subsequent repeats confirmed Sa5374 
SCVs produce polysaccharide. SCV colonies were distinctly smaller than parental 
colonies but produced the black crystalline morphology associated with 
polysaccharide production.    
4.3.2 DMMB biofilm quantification and adhesion to silicone 
A DMMB microtitre well plate assay was applied to the same panel of strains using 
optical density measurements to correspond to biofilm production. Biofilm formation 
was observed in all parent strains (except the negative control; Sa 5374) and all SCVs 
including Sa 5374 (Figure 4.4). Excluding the negative control no significant 
difference was observed in biofilm formation between MRSA and MSSA strains (P = 
> 0.05). Across all strains tested biofilm formation was significantly increased in 
SCVs compared to parents (P < 0.01; Figure 4.4). As the DMMB assay used directly 
quantifies PIA production these results confirms the presences of increased PIA in 
SCV biofilms. Similar results were also observed using silicon catheter disc biofilm 
quantification assay (Figure 4.4). Significantly greater numbers of SCV viable cells 
were recovered from silicone discs in comparison to parent strains (P = < 0.01). 
Consistently lower numbers of Sa 5374 parent viable cells (~ 1 x 102 CFU/mL) were 
recovered from silicone discs compared to corresponding SCVs (~106 CFU/mL). 
4.3.3 Cell-surface hydrophobicity  
In order to confirm that the difference in biofilm formation between SCV and parent 
strains was related to differences in PIA production rather than cell surface 
hydrophobicity, their ability to adhere to hydrocarbons was observed. No significant 
difference in cell-surface hydrophobicity values were observed for SCV and parent  
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Figure 4.4 Biofilm formation in S. aureus SCV and parent strains A) - Biofilm formation assessed by DMMB assay; B) – Bacterial counts 
recovered from silicone catheter discs assessed by viable count. SCVs formed greater biofilms and consistently higher numbers of SCVs were 
recovered from silicone catheter discs in comparison to parent strains. Results are means values of three independent replicates and three 
independent biological replicates. Error bars represent standard error.  
A) B) 
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strains (P = > 0.05); mean H% = 65.2 (±3.2) in SCV strains and 67.7 (±4.8) in parent 
strains.  
4.3.4 Scanning electron micrograph analysis of biofilms   
Dense multilayered biofilms were observed in SCVs adhered to Thermanox 
coverslips (Figure 4.5 C). Although clustering and aggregation of cells was observed 
in parent biofilms, an absence of multilayer clusters of cells is apparent (Figure 4.5 
A). SEM images at increased magnification (Figure 4.5 B and D) demonstrate the 
presence of extracellular polysaccharide in SCV biofilms which appears absent in 
biofilms formed by parent strains. The SCV cellular cluster (Figure 4.5 D) is clearly 
covered in a ‘slimy’ extracellular polysaccharide substance whereas parent biofilms 
lack this substance (Figure 4.5 B).  
4.3.5 Susceptibility of biofilms to antimicrobial agents 
The effect of antimicrobial treatment on established biofilms was evaluated using the   
DMMB method. Six different antimicrobial agents were applied at various 
concentrations to S. aureus parent ATCC 25923 and EMRSA 15 biofilms, and 
biofilms formed by their corresponding SCVs. Both parent and SCV biofilms showed 
reduced susceptibility to concentrations of antimicrobial agents that normally 
inhibited planktonic cells (Tables 4.2 and 4.3). Application of MIC and MBC 
concentrations to both parent and SCV biofilms resulted in no reduction of established 
biofilms in both strains. Furthermore treatment with X 2 MBC concentrations of all 
six antimicrobials tested resulted in no reduction of EMRSA 15 parent and SCV 
biofilms.  
 
Comparison of the effects of antimicrobial agents on SCV and parent biofilms SCV 
biofilms revealed SCV biofilms were significantly less susceptible to all six 
antimicrobial compounds tested (P = < 0.01). Application of X 2 MBC of 
ciprofloxacin, triclosan and rifampicin to ATCC 25923 parent biofilms resulted in 
reduction in biofilms in comparison to control; however the same concentrations 
produced no reduction in ATCC 25923 SCV biofilms (Table 4.2). Similar results 
were observed in EMRSA 15 biofilms. Application of X 4 MBC ciprofloxacin, 
tetracycline and rifampicin resulted in a reduction of EMRSA 15 parent biofilms, but 
the same concentrations produced no effect on SCV biofilms (Table 4.3).  
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B) D)
 
 
Figure 4.5 Scanning electron micrographs of S. aureus SCV and parent biofilms 
formed on Thermanox coverslips Images A and B show wildtype biofilms, and 
SCV biofilms are displayed in images C and D. Images A and C x 2000 
magnification, scale bar represents 10 microns. Images B and D x 4000 magnification, 
scale bar represents 1 micron.  
 
.    
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Table 4.2 Effect of antimicrobial agents on biofilm formation in S. aureus ATCC 25923 SCVs and corresponding parent strain  
 
 X 2 MBC X 4 MBC X 8 MBC X 16 MBC 
 P SCVGEN SCVTET P SCVGEN SCVTET P SCVGEN SCVTET P SCVGEN SCVTET 
Ciprofloxacin 
 
11 ± 1 0 0 11 ± 1 0 8 ± 1 27 ± 2 18 ± 2 24 ± 3 79 ± 5 47 ± 4 55 ± 3 
Chloramphenicol 
 
0 0 0 0 0 0 18 ± 3 0 0 29 ± 2 0 0 
Gentamicin 
 
0 0 0 4  ± 1 0 0 14 ± 3 0 0 32 ± 4 0 0 
Tetracycline 
 
0 0 0 17 ± 3 7 ± 1 11 ± 2 38 ± 5 0 0 68 ± 2 39 ± 4 41 ± 3 
Triclosan 
 
15 ± 2 0 0 24 ± 2 0 0 49 ± 4 6 ± 1 8 ± 1 79 ± 6 21 ± 2 19 ± 2 
Rifampicin 
 
17 ± 3 0 0 28 ± 3 14 ± 4 18 ± 2 41 ± 2 25 ± 4 32 ± 2 87 ± 4 69 ± 3 74 ± 2 
 
 
MIC and MBC concentrations showed no activity against S. aureus SCV 25923 and parent biofilms. Data shown is % reduction from control 
conditions (untreated biofilms) and is the mean of eight replicates and two independent biological replicates.  
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Table 4.3 Effect of antimicrobial agents on biofilm formation in S. aureus EMRSA 15 SCVs and corresponding parent strain  
 
 X 4 MBC X 8 MBC X 16 MBC 
 P SCVGEN SCVTET P SCVGEN SCVTET P SCVGEN SCVTET 
Ciprofloxacin 
 
9 ± 2 0 0 33 ± 4 15 ± 2 9 ± 1 67 ± 3 41 ± 2 37 ± 4 
Chloramphenicol 
 
0 0 0 19 ± 2 0 0 39 ± 4 0 0 
Gentamicin 
 
0 0 0 17 ± 1 0 0 31 ± 2 0 0 
Tetracycline 
 
11 ± 1 0 0 35 ± 2 0 0 59 ± 4 38 ± 3 27 ± 2 
Triclosan 
 
0 0 0 29 ± 2 14 ± 1 0 66 ± 2 31 ± 4 21 ± 1 
Rifampicin 
 
15 ± 2 0 0 41 ± 5 31 ± 3 24 ± 3 85 ± 3 67 ± 6 57 ± 2 
 
MIC, MBC and X 2 MBC concentrations showed no activity against S. aureus EMRSA 15 SCV and parent biofilms. Data shown is % reduction 
from control conditions (untreated biofilms) and is the mean of eight replicates and two independent biological replicates.  
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Concentrations of X 16 MBC ciprofloxacin, tetracycline, triclosan and rifampicin and 
triclosan produced the greatest reduction (73 ± 3.625 %) in biofilm formed by parent 
strains. Application of the same antimicrobial concentrations to SCV biofilms resulted in 
a reduction, however the reduction (43 ± 3 %) was significantly lower in comparison to 
parent biofilms (P = < 0.01). The highest concentrations of chloramphenicol and 
gentamicin examined produced a 33 ± 3 % reduction in parent biofilms. The same 
concentrations however resulted in no reduction of SCV biofilms. No single antimicrobial 
agent completely eradicated parent and SCV biofilms at all concentrations examined. 
Rifampicin was the most active antimicrobial in reduction of both SCV (67 ± 3.25 %) and 
parent (86 ± 3.5 %) biofilms in both strains examined (Tables 4.2 and 4.3).  
4.3.6 Effect of antimicrobial agents on colony biofilms  
A colony biofilm assay was implemented to determine the total viable bacterial burden 
within a biofilm and to allow the detection of any SCV disseminating from parent 
biofilms. The six antimicrobial agents tested previously were tested against parent and 
SCV isolates. Initial observations showed that significantly higher numbers of SCVs (~ 1 
x 107 CFU/mL) were recovered from colony biofilms formed by both strains in 
comparison to parent colony biofilms (~ 1 x 105 CFU/mL; P = < 0.01). Ciprofloxacin, 
rifampicin, tetracycline and triclosan all reduced viable cell counts in ATCC 25923 and 
EMRSA 15 parent biofilms, although no antimicrobial concentration tested completely 
eliminated viable cells (Figure 4.6 and Figure 4.7). Viable cell counts showed that the 
highest concentrations of the four antimicrobials tested achieved an average 3.8 log10 
reduction in CFU/mL in comparison to controls.  
 
Chloramphenicol and gentamicin were less active against parent biofilm with the highest 
concentrations examined achieving a mean 1.35 log10 reduction in viable cell counts. 
Similarly to parent strains, chloramphenicol and gentamicin showed the lowest reduction 
in SCV viable cell counts (1.175 log10 reduction). Ciprofloxacin and rifampicin showed 
the greatest reduction in viable counts of SCVs in both strains. The highest concentration 
of ciprofloxacin produced an average 2.75 log10 reduction, where as treatment with the 
highest rifampicin concentration resulted in average 4.15 log10 reduction in SCV viable 
cell counts (Figures 4.6 and 4.7). Although higher numbers of SCVs were recovered from  
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Figure 4.6 Effect of exposure to six antimicrobials on colony biofilms formed by S. aureus ATCC 25923 SCVs and corresponding parent 
strain Exposure to various concentrations of ciprofloxacin, gentamicin, tetracycline and triclosan yielded SCVs in 25923 colony biofilms 
represented by #. Results are means values of eight independent replicates and two independent biological replicates. Error bars represent 
standard error. 
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Figure 4.7 Effect of exposure to six antimicrobials on colony biofilms formed by S. aureus EMRSA 15 SCVs and corresponding parent 
strain Exposure to various concentrations of ciprofloxacin, gentamicin, tetracycline and triclosan yielded SCVs in EMRSA 15 colony biofilms 
represented by #. Results are means values of eight independent replicates and two independent biological replicates. Error bars represent 
standard error. 
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Table 4.4 Penetration of antimicrobial agents through S. aureus ATCC 25923 and EMRSA 15 SCV and parent biofilms 
 
Antimicrobial Concentration (µg) Control inhibition 
zone (mm) 
25923 parent biofilm 
zone diameter 
25923 SCVGEN biofilm 
zone diameter 
253923 SCVTET biofilm 
zone diameter 
Ciprofloxacin  5 27 ± 1.05 25 ± 0.45 24 ± 0.64 24 ± 1.46 
Chloramphenicol 30 24 ± 0.55 <13  <13 <13 
Gentamicin 10 22 ± 0.71 <13 <13 <13 
Rifampicin  5 32 ± 1.22 29 ± 1.02    28 ± 1.27  27 ± 1.15 
Tetracycline  30 28 ± 0.64 25 ± 0.74   12 ± 0.76  15 ± 0.52 
Triclosan 10 32 ± 1.88 28 ± 1.09   19 ± 1.51  22 ± 1.01 
 
Antimicrobial Concentration (µg) Control inhibition 
zone (mm) 
EMRSA 15 Parent EMRA 15 SCVGEN EMRSA 15 SCVTET 
Ciprofloxacin  5 27 ± 1.05 24 ± 1.63 22 ± 1.38 23 ± 0.67 
Chloramphenicol 30 24 ± 0.55 <13  <13 <13 
Gentamicin 10 22 ± 0.71 <13 <13 <13 
Rifampicin  5 32 ± 1.22 27 ± 1.25 28 ± 0.87 26 ± 0.74 
Tetracycline  30 28 ± 0.64 25 ± 1.17 19 ± 0.87 17 ± 0.83 
Triclosan 10 32 ± 1.88 26 21 ± 1.59 18 ± 1.12 
 
Limit of detection was 13 mm due to the presence of the membrane filter that biofilms were grown on.  Results are means values of three 
independent replicates. 
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biofilms, the reductions achieved by ciprofloxacin, rifampicin, tetracycline and 
triclosan were significantly lower in SCV biofilms in comparison to parents (P = < 
0.05). SCVs were not detected in any of the control biofilms and were only detected 
in the presence of higher antimicrobial concentrations of ciprofloxacin, gentamicin, 
tetracycline and triclosan (Figures 4.6 and 4.7).  For example in parent biofilms 
treated with gentamicin no SCVs were observed upon treatment with concentrations 
of 0-16 mg/L, but SCVs were subsequently detected at 32, 64 and 128 mg/L 
concentrations in ATCC 25923 biofilms. No SCVs were detected in biofilms treated 
with chloramphenicol and rifampicin.  
4.3.7 Antimicrobial penetration of biofilms 
As differences in the efficiency of antimicrobials at reducing biofilms and viable cell 
counts were observed the penetration of antibiotics through biofilms was examined 
using the method of Singh et al., (2010a). The penetration of chloramphenicol and 
gentamicin through SCV and parent biofilms of both strains was significantly reduced 
in comparison to control conditions (Table 4.4; P < 0.05). No significant difference 
was observed in the penetration of ciprofloxacin, rifampicin, tetracycline and triclosan 
through parent biofilms formed by ATCC 25923 and EMRSA 15 (P = > 0.05). 
Ciprofloxacin and rifampicin also showed no significant reduction in the penetration 
of SCV biofilms formed by both strains (P = > 0.05; Table 4.4). In contrast to parents 
the penetration of tetracycline and triclosan through SCV biofilms was significantly 
reduced (P = < 0.01).   
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4.4  Discussion 
S. aureus is well known for its ability to form biofilms on a range of materials 
including indwelling catheters (Marrie & Costerton, 1984b) and prosthetic devices 
(Litzler et al., 2007; Rohde et al., 2007). This study has identified the ability of 
several S. aureus parent and SCV strains to form biofilms using a simple agar screen. 
In addition quantification of biofilms was achieved using DMMB biofilm assay 
developed by Tote et al., (2008). Although biofilm formation in staphylococci 
involves various steps and stages the accumulation of cellular aggregates and the 
ability to form biofilms is dependent on the production of exopolysaccharide 
(Heilmann et al., 1996). In staphylococci this is dependent on the production of PIA 
which is regulated by the icaADBC genes (making up the ica operon). This study 
demonstrates that SCVs produced significantly greater biofilms in comparison to 
parent strains. As the DMMB assay directly quantifies PIA and SCVs showed no 
difference in cell surface hydrophobicity these results suggest that PIA production in 
increased is SCVs and hence they exhibit an increased capacity to form biofilms.  
 
Anaerobic conditions are known to increase the expression of PIA in S. aureus, which 
has been attributed to increased ica gene transcription (Cramton et al., 2001b). As the 
SCV phenotype draws parallels with S. aureus when it is grown anaerobically (Balwit 
et al., 1994), increased ica transcription may be responsible for the increased PIA 
production in SCVs observed in this study. Inhibition of the TCA cycle has been 
shown to impact on PIA production in S. epidermidis (Vuong et al., 2005). 
Subsequently this has been suggested as the mechanism for increased PIA production 
in a S. epidermidis SCV constructed mutant (Al Laham et al., 2007) and menadione 
auxotrophic S aureus SCV (Singh et al., 2010a). As part of this study a lack of 
utilisation of carbohydrates was observed (Chapter 2). This suggests inhibition of the 
TCA cycle may also play a role in increased PIA production in the SCVs studied for 
biofilm formation.  
 
SCVs display important differences in their expression profile in comparison to parent 
strains (Seggewiss et al., 2006) and therefore it is feasible that variation in gene 
expression may relate to differences in biofilm production. Perhaps the most attractive 
candidate to explain the difference between biofilm formation in parent and SCV 
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strains is the staphylococcal accessory regulator (sarA). Studies have shown that sarA 
can influence the expression of the ica operon (Beenken et al., 2004; Valle et al., 
2003). In S. aureus sarA mutants ica transcription is decreased, decreasing PIA 
production. S. aureus SCVs (recovered following aminoglycoside exposure) however, 
show increased expression levels of sarA (Mitchell et al., 2010a). Alterations in the 
expression of sarA may be therefore responsible for increased ica transcript and 
subsequent increased PIA production.   
 
Antimicrobial susceptibility of S. aureus biofilms is notably reduced in comparison 
with planktonic cells (Amorena et al., 1999). This has been attributed to several 
factors including the presence of exopolysaccharide matrix and a reduced growth rate 
(Mah & O'Toole, 2001). Coupled with resistance mechanisms such as biofilm 
exopolysaccharide and slow growth rate of cells growing within biofilms, S. aureus 
biofilms provide a unique mechanism for colonisation and reduced antimicrobial 
susceptibility. In this study, SCV and parent biofilms displayed reduced susceptibility 
to ciprofloxacin, chloramphenicol, gentamicin, tetracycline, triclosan and rifampicin 
at concentrations normally bactericidal to planktonic cells. Antimicrobial 
susceptibility testing showed antimicrobial agents to have significantly smaller 
inhibitory effect on SCV biofilms in comparison to biofilms formed by parent strains. 
These results agree with previous studies that have shown SCV biofilms to exhibit 
reduced susceptibility to antimicrobials in comparison with parents (Chuard et al., 
1997; Williams et al., 1997).  
 
Antibiotic penetration was shown to be an important factor in the reduction of biofilm 
mass and cell quantity by antimicrobial agents. Chloramphenicol and gentamicin 
showed a significant reduction in penetration of parent and SCV biofilms correlating 
with the lowest overall reduction in biofilm mass and viable cell count. A difference 
in the penetration of antimicrobial agents was observed between parent and SCV 
strains; no significant reduction in penetration of tetracycline and triclosan penetration 
was observed in parent biofilms however the opposite was apparent in SCV biofilms. 
The differences in responses between SCV and parents may be explained by the 
difference in PIA production observed, which is known to reduce the activity of 
various antimicrobials (Souli & Giamarellou, 1998). Increased PIA production in 
SCVs may limit the diffusion and/or inactivate the antibiotics examined, accounting 
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for the differences observed between SCV and parent strains. Furthermore SEMs in 
this study show a difference in biofilm structure formed by SCV and parent strains. 
The multilayered complexity of SCV biofilms may contribute to reduced antibiotic 
penetration and the observed reduction in antimicrobial susceptibility observed. 
Rifampicin proved to be the best agent in reducing biofilm mass and also reducing 
viable counts in both SCV and parent biofilms. Previous studies have shown that 
rifampicin can penetrate biofilms formed by S. epidermidis (Zheng & Stewart, 2002) 
and that PIA does not inhibit rifampicin activity (Souli & Giamarellou, 1998). 
Biofilms formed by both parent and SCV strains showed no significant effect on the 
penetration of rifampicin which may account for the activity of rifampicin against 
parent and SCV biofilms observed in this study.  
 
Although differences in the susceptibility of SCV and parent biofilms to antimicrobial 
agents was observed, no single antimicrobial agent eradicated biofilms or completely 
eliminated viable cells. The remaining cells encountered may represent the formation 
of biofilm-specific, drug-resistant or drug-tolerant physiologies, including the 
presence of persister cells (Stewart & Costerton, 2001). Persisters represent a 
subpopulation of bacteria that exhibit the ability to survive at lethal concentrations of 
antimicrobials without any clear resistance mechanism (Lewis, 2005). A recent study 
has shown large numbers of persisters to be present in S. aureus biofilms that confer 
resistance to various antimicrobials (Singh et al., 2009). Persisters may explain the 
ability of parent biofilms to withstand elevated concentrations of antimicrobials tested 
in this study. 
 
Although this study did not actively assay for persisters, SCVs were isolated from 
parent biofilms. The presence of SCVs in biofilms has been observed in P. aeruginosa 
(Haussler et al., 2003b) and S. pneumonia (Allegrucci & Sauer, 2007) which as well 
as persisters may contribute to the reduced antimicrobial susceptibility of biofilms. 
Singh et al., (2009) have suggested that SCVs contribute significantly to reduced 
susceptibility in S. aureus biofilms. Although we did not observe the presence of 
SCVs in biofilms that were not treated with antimicrobial agents their presence would 
clearly result in further reduced antimicrobial susceptibility. S. aureus SCVs display 
reduced susceptibility to cell wall specific antibiotics and aminoglycosides as a direct 
result of interruption of the electron transport chain and slow growth characteristics 
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(McNamara & Proctor, 2000). As SCVs already exhibit reduced susceptibility in their 
planktonic state this would suggest that in a biofilm, this reduced susceptibility would 
be further amplified. A biofilm formed completely of SCVs would exhibit further 
reduced susceptibility in comparison to a biofilm composed solely of parent/wildtype 
cells. This may also contribute to the reduced susceptibility of SCV biofilms to 
antimicrobial agents observed in this study.  
 
The enhanced biofilm forming capacity of SCVs may correlate to their ability to cause 
persistent and recurrent infections. The ability of SCVs to form biofilms on materials 
such as silicone (frequently used in catheter; Jones et al., 2006) may provide an 
increased opportunity to cause disease and persist in the hospital setting. SCVs have 
been isolated from CF pulmonary infections, osteomyelitis, and prosthetic device 
related infections (Proctor et al., 2006) all of which have been linked to the presence 
of biofilms (Costerton et al., 1999). This suggests that SCVs may play a significant 
role in biofilm related infections. Currently no antimicrobial drug has been found that 
completely eradicates adherent microbial populations, meaning biofilm infections are 
rarely resolved and usually persist until the removal of the effected medical device 
(Cos et al., 2010). Novel approaches to combat biofilm associated infections 
including antibiotic lock therapy, inhibition of quorum sensing, and degradation of 
biofilms by genetically engineered phage are prospective treatment options (Agarwal 
et al., 2010). The enhanced resistance of SCVs may in turn contribute to the adverse 
therapeutic outcome in these infections (Singh et al., 2009). 
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4.5  Conclusions  
 
• The Congo red agar screen is a useful method to screen polysaccharide production 
in S. aureus SCVs. 
• S. aureus SCVs have an increased capacity to form biofilms in comparison to 
parent strains 
• No difference in cell surface hydrophobicity between SCV and parent strains 
suggest increased PIA production is the mechanism for increased biofilm 
formation in SCVs.  
• S. aureus biofilms are less susceptible to ciprofloxacin, chloramphenicol, 
gentamicin, tetracycline, triclosan and rifampicin than planktonic forms.  
• SCVs are present in S. aureus biofilms following treatment with antimicrobial 
agents.  
• SCV biofilms display further reductions in antimicrobial susceptibility which can 
be attributed to reduced antibiotic penetration through biofilms. 
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5 CHAPTER 5: SUSCEPTIBILITY, RESISTANCE INDUCTION 
AND SYNERGISTIC EFFECTS OF VARIOUS PLANT 
ANTIMICROBIALS AGAINST STAPHYLOCOCCUS AUREUS 
SMALL COLONY VARIANTS 
5.1 Introduction 
5.1.1 Issues surrounding antibiotic discovery 
Following the development of the sulphonamides in the 1930s and penicillin in the 
1940s many new classes of antibiotics have been developed, however in the past 30 
years only two new classes of antibiotics (the oxazolidinones and lipopeptides) have 
been developed (Norrby et al., 2005; Silver, 2011). Various challenges to antibacterial 
drug discovery have kept the output of new classes of antibacterial agents extremely 
low. These difficulties have further exacerbated the current crisis of increasing 
antibiotic resistance in clinically-relevant bacteria. One of the key problems regarding 
the discovery of novel antibacterial agents is that the majority of targets which allow 
selective toxicity have already been exploited (Moellering, 2011). Furthermore, the 
difficulty and the time taken to develop novel agents mean a huge financial 
investment by the pharmaceutical industry. Payne et al., (2007) estimate that for each 
individual agent, from the initial target identification to the file to launch procedure 
takes an average of 14 years. In addition the expenses associated with the 
pharmaceutical research and development of each individual agent is $400 - $800 
million (DiMasi et al., 2003). This has resulted in several large global pharmaceutical 
companies (GlaxoSmithKline, Eli Lilly and Proctor and Gamble,) reducing their 
investment in or completely deserting antibiotic discovery (Overbye & Barrett, 2005).  
 
Further issues have arisen regarding the regulations which govern antibiotic 
development, and the bodies that control the approval of new antibiotics agents have 
received criticism. The Food and Drugs Administration (FDA) in the US has been 
accused of ‘shifting the goalposts’ in antibiotic approval after changing the approval 
criteria for antibiotics (Lancet, 2006). In addition, the lack of clinical trial guidelines, 
difficulties in recruiting sufficient subjects for clinical trials and the ambiguity 
surrounding the acceptability of model based evidence provide further hindrances 
(Spellberg et al., 2008). Consequently it is not surprising that the number of novel 
agents in the antibiotic pipeline are far and few between.  
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5.1.2 Plant products as antimicrobials  
The rapid decline in the development of novel antimicrobial has resulted in alternative 
approaches to antimicrobial development being sought. Natural products offer 
potential for the development of new antibacterial drugs and a new avenue to 
overcome the productivity crisis facing those engaged in drug discovery and 
development (Newman et al., 2003). Plants are rich in a wide variety of secondary 
metabolites, such as tannins, terpenoids, alkaloids, and flavonoids, many of which 
display antimicrobial properties in vivo (Cowan, 1999). Approximately 420,000 plant 
species are present on earth (Vuorela et al., 2004), with only 5% of known plants 
being systematically investigated for the presence of bioactive compounds (Verpoorte 
et al., 2000). Therefore plants may represent a huge reservoir of potential new 
compounds, which remains untapped. 
5.1.3 Essential oils  
Essential oils (EOs) are aromatic oily liquids obtained from a variety of different plant 
materials including bark, flowers, leaves and roots (Burt, 2004). The main 
constituents of EOs are mono- and sesquiterpenes (including carbohydrates, alcohols 
and ethers) which are responsible for the fragrant and biological properties of 
aromatic plants (Kalemba & Kunicka, 2003). They are frequently liquid, volatile, 
rarely coloured, and soluble in organic solvents (Bakkali et al., 2008). EOs are used in 
the food industry as flavour additives and for the preservation of foodstuffs (Bouhdid 
et al., 2010) and EOs and their components have been deemed safe for use in food 
and beverages by the FDA (USFDA, 2009). Previous years have seen a revival in the 
use of EOs in protecting livestock and food from disease, due to their spectrum of 
antibacterial activity (Dorman & Deans, 2000). It is well documented that EOs posses 
antibacterial, (Deans & Ritchie, 1987; Holley & Patel, 2005), antimycotic (Azzouz & 
Bullerman, 1982) and antiparasitic activity (Pandey et al., 2000).  
 
Although the exact antimicrobial effects of EOs have not been determined, it is 
accepted that the action is dependent on the lipophilic character of their hydrocarbon 
skeleton and the hydrophobic character of their functional groups (Kalemba & 
Kunicka, 2003). As EOs are composed of several different chemical compounds, their 
antibacterial activity is not attributed to one specific mechanism and there are several 
known targets in the bacterial cell. EOs are known to cause degradation of the 
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bacterial cell wall (Helander et al., 1998), damage the cytoplasmic membrane 
(Sikkema et al., 1994) and damage membrane proteins (Ultee et al., 1999).  
 
Gram positive and Gram negative bacteria display differences in susceptibility to EOs 
due to differences in there cellular composition. The outer membrane (OM) of Gram 
negative bacteria contains lipopolysaccharide (LPS) molecules, providing the bacteria 
with a hydrophilic surface (Nikaido, 1994), which in turn serves as a penetration 
barrier to hydrophobic EOs. Pseudomonas aeruginosa for example displays intrinsic 
resistance to a variety of EOs due to the hydrophilic nature of it’s OM.  
5.1.3.1 Oregano – Origanum vulgare  
Oregano EO is composed of two main antibacterial components; thymol and 
carvacrol, the precursors of which are the monoterpene hydrocarbon molecules, γ-
terpinene and p-cymene (Nostro et al., 2004). Thymol and carvacrol are phenolic 
compounds known to posses bacteriostatic or bactericidal activity depending on the 
concentration (Dorman & Deans, 2000). Thymol is structurally very similar to 
carvacrol, the major difference being a different location of the hydroxyl group on the 
phenolic ring (Burt, 2004). Carvacrol is the major component of oregano EO fraction 
(60 – 74%) (Ultee et al., 1999) with thymol concentrations ranging from 0 - 33% 
(Faleiro et al., 2005). The compositions can vary greatly depending upon the 
geographical region, variety and age of the plant, the method of drying and the 
method of extraction of the oil (Jerković et al., 2001).  
  
Several studies have shown a wide range of human pathogens to be susceptible to 
oregano oil, including Candida albicans, Escherichia coli Staphylococcus aureus, and 
Salmonella typhimurium (Dorman & Deans, 2000; Friedman et al., 2002; Hammer et 
al., 1999). Oregano EO, thymol and carvacrol have all been shown to disrupt the 
bacterial cell membrane, causing increased permeability to the nuclear stain ethidium 
bromide (Lambert et al., 2001). Studies in Bacillus cereus have also shown carvacrol 
to interact with the cell membrane, dissolving the phospholipid bilayer, increasing 
membrane fluidity (Ultee et al., 2000; Ultee et al., 2002). Interaction with the lipid 
bilayer of the cytoplasmic membrane results in leakage of cellular material such as 
ions, ATP and nucleic acid (Helander et al., 1998; Trombetta et al., 2005).  
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5.1.3.2 Cinnamon – Cinnamomum zeylanicum (Synonym: Cinnamomum verum) 
Many species of cinnamon yield volatile oils on distillation (Chericoni et al., 2005). 
Variability in the composition of EOs from the same Cinnamomum species is 
common and is related to the geographical source of plant (Cheng et al., 2004). 
Cinnamomum zeylanicum is one of the worlds most commonly exported species of 
cinnamon and its primary constituents are cinnamaldehyde from the bark oil, eugenol 
from the leaf oil, and camphor from the root-bark oil (Wijesekera & Chichester, 
1978). Cinnamaldehyde, an aromatic aldehyde is the main component of bark extract 
(Ali et al., 2005) and has been demonstrated to display strong antibacterial activity 
against a range of bacterial pathogens including Helicobacter pylori (Ali et al., 2005), 
P. aeruginosa and  S. aureus (Bouhdid et al., 2010). Eugenol is also present in bark 
oil (but at lower concentrations) and has a similar range of activity to 
cinnamaldehyde, with activity against human pathogens such as E. coli, Listeria 
monocytogenes (Friedman et al., 2002), S. aureus and Klebsiella pneumonia 
(Prabuseenivasan et al., 2006).  
 
Cinnamaldehyde induces changes in the membrane but does not result in the 
disintegration of OM (Helander et al., 1998). Treatment of exponentially growing B. 
cereus cells with cinnamaldehyde results in filamentation and strong inhibition of cell 
separation (Kwon et al., 2003). Further studies have shown that cinnamaldehyde 
inhibits FtsZ which is responsible for the regulation of bacterial cell division 
(Domadia et al., 2007).  
5.1.3.3 Ginger (Zingiber officinale) 
Ginger is used in pharmaceutical, cosmetic, and food and beverage industries and it’s 
EO has applications as an analgesic, anti-inflammatory, and antirheumatic (de Melo et 
al., 2011). Ginger oil contains considerable concentrations of phenolic compounds 
including eugenol, gingerol and zingerone (Singh et al., 2008). The antibacterial 
activity of ginger EO is related to these phenolic compounds and although an exact 
mechanism of action has not been established it is likely to involve the synergistic 
action of all constituents. 
5.1.4 Green tea (Camellia sinensis) 
Camellia sinensis belongs to the ‘non-fermented’ class of tea in which the leaves are 
dried and steamed in the manufacturing process (Cabrera et al., 2006). The chemical 
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composition of green tea is complex and contains a diverse array of amino acids, 
carbohydrates, vitamins, minerals and pigments (Friedman, 2007). The polyphenol 
fractions have been widely investigated for their antimicrobial properties, of which 
the simplest compounds are catechins. Approximately 10% of green tea is made up of 
catechins, of which 4 main compounds are present; epicatechin (EC), epigallocatechin 
(EGC), epicatechin gallate (ECG), and epigallocatechin gallate (EGCG) (Hamilton 
Miller, 1995). Green tea catechins exert antimicrobial activity against human 
pathogens such as S. aureus, S. epidermidis, Vibrio cholerae (Toda et al., 1989), 
Clostridium spp. (Ahn et al., 1991) and P. aeruginosa (Yi et al., 2010). Similarly to 
EOs, several cellular targets have been proposed for green tea. Targets include the 
FabI and FabG reductase steps in the E. coli fatty acid elongation cycle (Zhang & 
Rock, 2004) and DNA gyrase (Gradisar et al., 2007). Certain green tea catechins 
(EGC and EGCC) can also inhibit bacterial efflux pumps Tet (K) (Roccaro et al., 
2004) and NorA (Gibbons et al., 2004), which reduced susceptibility to tetracycline 
and norofloxacin respectively. Green tea has also been shown to reverse methicillin 
resistance in methicillin-resistance S. aureus (MRSA), inhibiting the synthesis of 
penicillin binding protein 2’ (PBP2’; Yam et al., 1998).  
5.1.5 Candicidin  
Candicidin is a unique antimicrobial produced and formulated by Cultech Ltd., 
composed of a variety of EOs including; oregano, clove leaf oil, ginger oil and 
wormwood oil. The main antibacterial component of clove leaf oil derived from 
Eugenia carophyllus is eugenol (Farag et al., 1989) which shows activity against 
various pathogenic bacteria (Sanla-Ead et al., 2011). Clove oil possesses antioxidant 
properties and shows potential as a natural preservative or as a source of natural 
antioxidants for use in pharmaceutical applications (Chaieb et al., 2007). Wormwood 
oil is derived from Artemisia absinthium, and has antibacterial activity against 
pathogens such as K. pneumonia (Viljoen et al., 2006). The monoterpene ketone 
thujone is considered as the main ‘active ingredient’ (Lachenmeier, 2010) however 
limited information regarding its antibacterial application are available.  
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5.1.6 Synergy between plant antimicrobials and antibiotics 
Formulations of different antibacterial compounds that complement each others’ 
action offers a strategy to overcome the problem of antibiotic resistance 
(Hemaiswarya et al., 2008). For example, the combination of a ß-lactam antibiotic 
together with ß-lactamase inhibitor will render the ß-lactamase enzyme redundant 
allowing the antibiotic to remain active. Synergy is the term used to described when 
the combined effect of two compounds is greater than the sum of the effects of each 
compound alone (Berenbaum, 1978; Rand et al., 1993). Several examples in the 
literature have demonstrated successful combinations of plant antimicrobials with 
many different classes of antibiotics. Shiota et al. (2000) demonstrated that extract 
from the petals of Rosa canina (rose red) significantly increased the ß-lactam 
susceptibility of MRSA strains. Erybraedin and eryzerin isolated from the roots of 
Erythrina zeyheri (member of the Fabaceae plant family, found in South Africa) 
decreased the susceptibility of vancomycin resistant enterococci (VRE) to 
vancomycin (Sato et al., 2004). Furthermore, certain plant compounds have shown 
synergy with multiple antibiotics such as Punica granatum (pomegranate) which 
displayed a synergistic relationship with chloramphenicol, gentamicin, tetracycline, 
and oxacillin against MRSA (Braga et al., 2005).  
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5.1.7 Aims  
Cultech Ltd. produces various naturally derived compounds which are available in the 
form of EOs and emulsified powders. This study is the first to examine the action of 
naturally-derived plant EOs and plant compounds against S. aureus SCVs. As S. 
aureus SCVs are difficult to treat in the clinical setting and can be selected for in the 
presence of various antibiotics (Chapters 2 and 3), naturally derived compounds may 
offer an alternative method for treatment of SCV related infections. 
 
• Examine the susceptibility of a range of S. aureus parent and SCV strains to 
various EOs and green tea using a disc diffusion method. 
• Apply the CLSI broth dilution method(s) to obtain MIC and MBC values for plant 
antimicrobial powders against S. aureus parent and SCV strains.  
• Investigative time kill dynamics to validate plant antimicrobial MBC values. 
• Examine the ability of S. aureus parent and SCV strains to develop resistance to 
plant antimicrobial compounds. 
• Investigate synergistic relationships that may exist between plant antimicrobials 
and various classes of conventional antibiotics.  
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5.2 Material and methods 
5.2.1 Essential oils and powders  
Cinnamon bark, oregano and ginger oils and green tea (Cultech Ltd.) were examined 
for there antibacterial activity against S. aureus SCV and parent strains using a disc 
diffusion method. Emulsified powders of cinnamon bark and oregano oil as well as 
candicidin and green tea (Cultech Ltd.) were used for microdilution susceptibility 
testing. The major known antibacterial constituents of EOs and the emulsified 
powders used in this study are shown in Table 5.1. Stock solutions (100,000 mg/L) of 
the powders candicidin, cinnamon, green tea and oregano were prepared by dissolving 
1 gram of each powder in 10 mL of sterile deionised water. Suspensions were 
vortexed thoroughly for 5 min followed by centrifuged for 10 min at 10, 000 rpm. 
Dilutions of stocks were prepared in sterile deionised water and stock stored at 4°C 
for a maximum of 7 days. 
5.2.2 Bacterial strains  
Several reference methicillin sensitive S. aureus (MSSA) strains and well 
characterised MRSA strains were used to investigate the anti-staphylococcal effects of 
plant antimicrobials (Table 5.2). SCVs derived from these strains following antibiotic 
exposure, as well as laboratory constructed SCVs and a SCV human isolates were 
also examined (Table 5.3).  Strains were maintained at -80°C in Mueller Hinton (MH) 
broth supplemented with 8 % dimethyl sulfoxide (DMSO) and re-isolated on MH agar 
plates. 
5.2.3 Disc diffusion  
Disc diffusion method was carried out following guidelines from the British Society 
of Antimicrobial Chemotherapy (BSAC) standardised disc susceptibility testing 
method (Andrews & Susceptibility, 2009). Individual S. aureus colonies (3-4) were 
inoculated into cation adjusted Mueller Hinton broth (CAMHB) and incubated at 
37°C with shaking at 150 rpm.  Cultures were grown to the end of logarithmic phase 
and cell densities were adjusted to match the turbidity of a 0.5 McFarland standard at 
625 nm. Occasionally SCV strains failed to reach the densities required by the 
McFarland standard, in which case densities of parent strains were adjusted 
accordingly to ensure similar inoculum concentrations. A sterile cotton swab was 
dipped into the suspension and spread evenly over the surface of MH agar plate. This 
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procedure was shown to consistently produce semi confluent lawns recommend by the 
BSAC for susceptibility testing. Sterile filter discs (5mm diameter) were applied to 
the centre of the agar onto which 5 µL of plant antimicrobial stock solutions (100,000 
mg/L) were dispensed. Plates were allowed to dry for 10 minutes before being 
incubated (24 hours for parent and 48 hours for SCVs) at 37°C. Following incubation 
inhibition zones were measured digitally using IMAGE J (NIH). 
5.2.4 Determination of minimum inhibitory concentrations  
Minimum inhibitory concentrations (MICs) were determined according to Clinical 
Laboratory Standard Institute (CLSI) guidelines as described previously (section 
2.2.3). As no information regarding the susceptibility of S. aureus SCVs to plant 
antimicrobials was available, a wide range of plant antimicrobial concentrations were 
tested. Stocks of plant antimicrobials were used to prepare concentrations double the 
required concentration to allow for dilution by the inoculum.  
5.2.5 Determination of minimum bactericidal concentrations  
Non turbid wells from MIC experiments were used to determine MBCs as described 
previously (section 2.2.4).  
5.2.6 Time kill assays  
Time kill assays were performed for two reasons. Firstly, to confirm that 
concentrations obtain from well plate based MBC assays reached the required 
reduction in inoculum and secondly to assess the rate at which bactericidal activity 
was achieved. Overnight cultures of S. aureus parent and SCVs strains were prepared 
in CAMH broth and then inoculated into 50 mL of CAMHB (in 250 mL narrow neck 
conical flasks) to achieve a starting density of 5 x 105 CFU/mL. Required volumes of 
plant antimicrobial agents were then added so flasks contained bactericidal 
concentrations of plant antimicrobials and incubated at 37°C with shaking at 150 rpm. 
Samples were taken every 2 hours for 10 hours. Serial dilutions were performed in 
phosphate buffered saline (PBS) and dilutions were plated onto MH agar. Plates were 
incubated at 37°C and colonies were enumerated after 48 hours.  
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Table 5.1 Composition of the major antibacterial components of plant antimicrobials used in this investigation  
 
Essential oil/powder Antibacterial composition 
Candicidin powder 7.6 % (v/v) oregano oil 
3.6 % (v/v) clove leaf oil 
3.6 % (v/v) ginger oil 
3.6 % (v/v) wormwood oil 
 
Oregano oil 74.3 % (v/v) carvacrol 
0.35 % (v/v) thymol 
 
Oregano powder 
 
25 % (w/v) oregano oil emulsified with tapioca starch 
Cinnamon bark oil 70 % (v/v) cinnamaldehyde 
4.5 % (v/v) eugenol 
 
Cinnamon bark powder 
 
33 % (w/v) cinnamon bark oil emulsified with tapioca starch 
Green tea powder 
 
45 % EGCG 
Ginger oil 
 
84 % (v/v) gingerol 
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Table 5.2 MSSA and MRSA strains used in this study  
 
 
Strain Description Resistance(s)  Source/Reference 
ATCC 25923 S. aureus reference strain - ATCC 
NCTC 6571 S. aureus reference strain - NCTC 
MRSA COL Genome sequence early MRSA strain originally isolated in 
1960s 
TET, OX Dyke et al., 1966 (Dyke et al., 
1966); Gill et al., 2005 (Gill et al., 
2005) 
EMRSA 15 Epidemic MRSA type 15 – isolated in 1991, prevalent in 
UK hospitals  
OX Richardson & Reith, 1993 
OMB 299  Revertant of SCV isolated from wound infection  ERY University Hospital Münster, 
Germany  
N315 Genome sequenced MRSA strain isolated in 1982 ERY, NEO, OX Kuroda et al., 2001(Kuroda et al., 
2001) 
 
 
ATCC – American Type Culture Collection; NCTC – National Collection of Type Cultures; ERY- Erythromycin; NEO – Neomycin; OX – 
oxacillin; TET - Tetracycline  
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Table 5.3 S. aureus SCV strains used in this study  
 
Strain Description Auxotrophy   Source/Reference 
ATCC 25923 
SCVGEN 
SCV derived from ATCC 25923 following gentamicin 
exposure  
Hemin This study 
ATCC 25923 
SCVKAN 
SCV derived from ATCC 25923 following kanamycin 
exposure 
N/D This study  
NCTC 6571 
SCVGEN 
SCV derived from NCTC 6571 following gentamicin 
exposure 
Menadione This study 
NCTC 6571 
SCVTET 
SCV derived from NCTC 6571 following tetracycline 
exposure 
Menadione This study  
MRSA COL hemB Laboratory generated SCV mutant of MRSA COL  Hemin vonEiff et al., 1997  
MRSA COL menD Laboratory generated SCV mutant of MRSA COL  Menadione Bates et al., 2003  
EMRSA 15 
SCVGEN 
SCV derived from EMRSA15 following gentamicin 
exposure  
Menadione  This study 
EMRSA 15 
SCVNEO 
SCV derived from EMRSA15 following neomycin 
exposure 
N/D This study 
OMB 299 SCV SCV isolated from wound infection  Hemin University Hospital Münster, Germany 
N315 SCVGEN SCV derived from N315 following gentamicin exposure N/D This study 
N315 SCVTET SCV derived from N315 following tetracycline exposure Haemin This study 
 
 
N/D – No auxotrophy detected.  SCVs recovered following antibiotic exposure were previously confirmed as S. aureus via multiplex PCR.  
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5.2.7 Short-term resistance training by exposure to a single sub-lethal 
concentration of plant antimicrobials (Cooper et al., 2010) 
S. aureus strains ATCC 25923 and MRSA COL and their respective SCVs ATCC 
25923 SCVGEN and MRSA COL hemB were examined to test if resistance to the plant 
antimicrobials could be induced. 250 mL conical flask containing X 0.5 MIC (in 50 
mL CAMHB) candicidin, cinnamon bark, green tea and oregano powders were 
prepared. Starting densities of 5 x 105 CFU/mL were prepared by appropriate 
dilutions of overnight parent and SCV cultures. Flasks were incubated at 37°C with 
shaking at 150 rpm. On 10 successive days, similarly prepared flasks were inoculated 
with 40 µL from each preceding day’s culture. The MIC for each strain was 
determined every day preceding subculture to assess any change in susceptibility after 
continuous exposure.  
5.2.8 Effect of plant antimicrobials on antibiotic susceptibility of S. aureus  
The chequerboard method was used to determine the interactive effects between plant 
antimicrobials and antibiotics (White et al., 1996). The range of plant antimicrobial 
and antibiotic concentrations to be examined was determined in accordance with 
previously defined MIC values.  
 
Suspensions of cinnamon, green tea and oregano were prepared at four times the 
required final concentration in CAMHB, in order to allow for dilution by inoculum 
and antibiotic. Increasing concentrations of the plant antimicrobial suspensions (50 
µL volumes of each) were dispensed into each column of a microtitre plate, 
increasing from right to left (Figure 5.1). Increasing antibiotic solutions (50 µL 
volumes of each) were dispensed into each row, increasing in concentration from top 
to bottom. Optically adjusted S. aureus parent and SCV inoclua (1 x 106 CFU/mL) 
were prepared as described previously (section 2.2.3) and 100 µL inoculated into each 
individual well. This resulted in final total volume of 200 µL containing 5 x105 
CFU/mL. Control wells were prepared by replacing the plant antimicrobial and 
antibiotic with 100 µL of CAMHB. Microtitre plates were incubated statically at 37°C 
for a total of 24 hours for parent strains. The incubation period was extended to 48 
hours for SCV strains. Following incubation fractional inhibitory concentrations 
(FICs) and FIC indices (FICi) were calculated using the following formula, in order to 
determine the interactions between plant antimicrobial and antibiotics. 
 145 
 
FICi = FIC (Plant antimicrobial) + FIC (Antibiotic) 
 
Where:  
     MIC of plant antimicrobial in combination  
FIC (Plant antimicrobial)   =                    MIC of plant antimicrobial alone  
 
FIC (Antibiotic)             =                   MIC of antibiotic in combination 
        MIC of antibiotic alone 
 
Synergism was defined by a FICi ≤ 0.5. Indifference was defined as an FIC index of   
> 0.5 but of < 4. Antagonism was defined as an FIC index of >4 (White et al., 1996). 
 
 
S. aureus N315 and its corresponding SCV N315 SCVGEN are resistant to 
erythromycin, neomycin and oxacillin so these strains were chosen to investigate 
synergy with the plant antimicrobials in this study. S. aureus MRSA COL and its 
corresponding SCV MRSA COL hemB are resistant to oxacillin and tetracycline and 
therefore these strains were also selected to investigate synergy.  
 
5.2.9 Statistical analysis  
Analysis of significant differences between susceptibilities of SCV isolates and parent 
strains was performed using the statistical analysis described previously (section 
2.2.9.8).   
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Figure 5.1 Layout of plant antimicrobial and antibiotic solutions in 
chequerboard plates 
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5.3 Results 
5.3.1 Anti-staphylococcal effects of EOs and green tea  
5.3.1.4 Disc diffusion  
The antimicrobial action of candicidin, cinnamon bark, ginger grass, green tea and 
oregano oil against S. aureus SCVs and their parent strains was assessed using a 
simple disc diffusion method. Cinnamon bark oil, ginger grass, green tea and oregano 
oil antimicrobials produced inhibition zones in all SCVs and their respective parent 
strains examined (Figure 5.2). Candicidin showed no activity against all isolates 
examined. Oregano oil produced the largest inhibition zones in SCV and parent 
strains (mean 36 mm), followed by cinnamon bark oil (30 mm), green tea ( 17 mm) 
and ginger grass oil (11 mm). No significant difference was observed in diameter of 
inhibition zones produced by all plant antimicrobials in MRSA and MSSA strains (P 
= > 0.05). Mean inhibition zones produced by cinnamon bark oil (Figure 5.2 A), 
green tea (Figure 5.2 C) and oregano oil (Figure 5.2 D) were significantly greater in 
SCVs in comparison to inhibition zones in parent strains (P = < 0.05). No significant 
differences in the diameter of inhibition zones produced by ginger grass oil were 
detected between SCV and parent strains (P = > 0.05).  
5.3.1.5 Microdilution susceptibility   
Emulsified forms of candicidin, cinnamon bark oil, green tea and oregano oil were 
employed for microdilution testing against the same panel S. aureus SCV and parent 
strains. Although no guidelines to determine sensitivity and resistance for plant 
antimicrobials are available, all SCV and parent strains showed susceptibility to the 
concentrations examined (Table 5.4). Across the four compounds tested, per 
milligram green tea produced the lowest MICs (50 – 250 mg/L) in all S. aureus SCV 
and parent strains. Candicidin produced the highest MICs across all stains (2250 – 
3000 mg/L; Table 5.4). Comparison of MICs between SCV and parent strains 
demonstrated that SCVs were more sensitive than their parents to cinnamon bark, 
green tea and oregano which agreed with previous disc diffusion results. A trend in 
susceptibility of SCVs compared to parent strains to candicidin was not observed. 
MBCs correlated with previously determined MICs, with green tea producing the 
lowest mean MBCs followed by oregano and cinnamon bark respectively (Table 5.4). 
MBCs of cinnamon bark, green tea and oregano were lower in SCVs in comparison to 
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Figure 5.2 Antibacterial effects of various plant antimicrobials on S. aureus SCVs and their parent strains A) - Cinnamon bark oil          
B) - Ginger grass oil C) - Green tea D) - Oregano oil. Inhibition zones are the results of three independent replicates and three independent 
biological replicates. Error bars represent the standard error of the mean 
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Table 5.4 Plant antimicrobial MICs and MBCs (mg/L) of S. aureus SCVs and their parent strains  
Strain Candicidin 
MIC                  MBC 
Cinnamon Bark 
MIC                  MBC 
Green Tea 
MIC                 MBC 
Oregano 
MIC                 MBC 
ATCC 25923 3000 5500 2000 3250 175 1250 1250 2000 
ATCC 25923 SCVGEN 3250 6000 1250 2000 75 750 750 1500 
ATCC 25923 SCVKAN 3000 6250 1000 2500 75 750 750 1250 
NCTC 6571 2750 5000 2250 2750 150 1500 1500 2500 
NCTC 6571 SCVGEN 3000 5500 1750 2250 75 1000 1000 1500 
NCTC 6571 SCVTET 3250 6000 1750 2500 50 750 750 1250 
MRSA COL 2500 5750 2000 3250 250 1750 1750 2750 
MRSA COL hemB 2500 5750 1250 1750 125 1000 1000 1500 
MRSA COL menD 2500 6000 1000 1500 150 1000 1000 1750 
EMRSA 15 2250 5750 3000 3750 200 1500 1500 2250 
EMRSA 15 SCVGEN 2500 6000 2250 3000 125 1000 1000 1500 
EMRSA 15 SCVNEO 2500 5250 2500 3250 150 750 750 1250 
OMB 299 3250 6250 2500 3000 175 1750 1750 2500 
OMB 299 SCV 3000 6000 1750 2250 125 1500 1500 1750 
N315 3500 6000 3000 4000 150 1500 1500 2250 
N315 SCVGEN 3250 6250 2000 2750 125 1250 1250 1500 
N315 SCVTET 3500 6250 2250 2750 125 1000 1000 1250 
 
 
Modal MIC and MBC values are presented. Modal values were obtained from three independent replicates and three independent biological 
replicates. 
 
 150 
parent strains. Although green tea showed the lowest MIC and MBC values across 
the panel of strains examined, average MBCs were eight fold greater than MICs. 
Average MBCs for cinnamon bark, oregano and candicidin were 1.3, 1.5 and 2 
times greater than MIC values.  
5.3.1.6  Time kill assays   
Four plant antimicrobials (as above) were tested against S. aureus ATCC 25923 and 
MRSA COL and their corresponding parent SCVs to determine the rate at which 
plant antimicrobials achieved bactericidal activity using time kill assays (Figure 5.3). 
All previously determined MBCs (derived from the microtitre method above) 
achieved the required 99.9 % reduction (from the starting inoculum) required by the 
CLSI to be classed as bactericidal. Differences in the time required for bactericidal 
activity to be achieved varied between plant antimicrobials and difference between 
SCV and parent strains were also observed for certain compounds (Figure 5.3). 
Although all compounds examined achieved bactericidal activity within 10 hours, 
oregano (Figure 5.3 D) showed a substantially greater kill rate, reaching the 99.9 % 
reduction level in 4 hours for both SCV and parent strains. Green tea achieved the 
second most rapid time kill of between six and eight hours for SCV and parent strains 
respectively (Figure 5.3 C). Candicidin took 10 hours to achieve elimination of both 
SCV and parent strains. Differences in the time taken for green tea to exert the 
required reduction from the initial inoculum were apparent between SCV and parent 
strains. ATCC 25923 SCVGEN and MRSA COL hemB reached the bactericidal 
threshold within 6 hours where as both respective parent strains took a further 2 hours 
to reach the same reduction. Similar contrasting time kill kinetics were apparent when 
exposing SCV and parent cultures to cinnamon bark (eight hours for SCV and ten 
hours for parents). Uniform time kill kinetics were observed for candicidin between 
SCV and parent strains, which both reached the required reduction in 10 hours. 
Strains were also analysed for their responses to exposure to plant antimicrobials at 
previously defined MICs. All four plant antimicrobials over the 10 hour period 
showed no increase in viable cell count from the starting inoculum density. No 
increase in viable count is comparable with the original MIC determination. 
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Figure 5.3 Time kill curves of plant antimicrobials against S. aureus SCVs ATCC 25923 SCVGEN and MRSA COL hemB and their 
corresponding parent strains  A) – Candicidin; B) - Cinnamon Bark; C) - Green tea; D) – Oregano. Dotted line represents limit of detection. 
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5.3.1.7 Synergy between plant antimicrobials and antibiotics  
Synergistic relationships between three plant extracts (cinnamon, green tea and 
oregano) and four conventional antibiotics (erythromycin, neomycin, tetracycline and 
oxacillin) were examined in two S. aureus and SCV strains (Tables 5.5 and 5.6). 
Various synergistic relationships were observed with green tea displaying the largest 
number of synergistic relationship (three antibiotics). In the combinations in which 
synergy was reported the same trends were observed in SCV and parent strains. 
Cinnamon and oxacillin consistently showed a synergistic relationship achieving a FICi 
< 0.05 in both N315 and MRSA COL parent and SCV strains. All plant antimicrobial-
antibiotic indifferences observed in SCVs were also reported in corresponding parent 
strains. Green tea showed a synergistic relationship with both neomycin and oxacillin in 
N315 SCV its parent strain and with tetracycline and oxacillin in MRSA COL hem B 
and its parent strain. No antagonistic combinations (FICi > 4) were observed in all of 
the plant antimicrobial-antibiotic combinations tested (Tables 5.5 and 5.6). 
5.3.2 Resistance induction  
Two strains of S. aureus (one SCV and one parent of each) were exposed to sub lethal 
(X 0.5 MIC) concentrations of candicidin, cinnamon bark, green tea and oregano for 10 
days (Figure 5.4). An alteration of MIC of both SCV and their respective parent strains 
to all four plant antimicrobials was observed. MICs of all four strains tested displayed 
increasing MICs after exposure to candicidin, cinnamon bark and green tea. This was 
with the exception of MRSA COL exposed to green tea and oregano the MIC of which 
remained the same after 10 days continuous exposure (Figure 5.4). Exposure of SCVs 
and parent strains to green tea and candicidin produced small changes in MIC (0.26 and 
0.15 fold increase respectively) after 10 days. Exposure of ATCC 25923 parent and 
SCV strains to cinnamon saw a two fold increase in MIC. The two fold increase was 
apparent in the MRSA COL hemB mutant; however the parent strain showed a lower 
1.375 fold increase. Inversely exposure to oregano resulted in an increase in 
susceptibility in ATCC 25923 SCVGEN and parent strains as well as the MRSA COL 
hemB mutant.     
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Table 5.5 The effects of plant antimicrobials on erythromycin, neomycin and 
oxacillin susceptibility of S. aureus N315 SCVGEN and its corresponding parent 
strain expressed as FICi  
N315 SCVGEN 
 
Combination tested 
MICs (mg/L) 
 Plant Anti.      Antibiotic 
     
   FICi           Relationship  
Cinnamon  and 
erythromycin 
2000 64 1.39 Indifference a 
Cinnamon  and neomycin 2000 128 1.85 Indifference a 
Cinnamon and oxacillin 2000 64 0.20 Synergy b 
Green tea and erythromycin 125 64 2.15 Indifference a  
Green tea and neomycin 125 128 0.15 Synergy b 
Green tea and oxacillin 125 64 0.36 Synergy b 
Oregano and erythromycin 1250 64 2.8 Indifferencea  
Oregano and neomycin 1250 128 1.9 Indifferencea 
Oregano and oxacillin 1250 64 0.21 Synergy b 
 
N315 Parent  
 
Combination tested 
MICs (mg/L) 
 Plant Anti.      Antibiotic 
     
   FICi           Relationship  
Cinnamon  and 
erythromycin 
3000 64 1.25 Indifference a  
Cinnamon  and neomycin 3000 128 1.57 Indifference a 
Cinnamon and oxacillin 3000 64 0.41 Synergy b 
Green tea and erythromycin 150 64 2.5 Indifference a 
Green tea and neomycin 150 128 0.37 Synergy b 
Green tea and oxacillin 150 64 0.25 Synergy b 
Oregano and erythromycin 1500 64 1.72 Indifference a  
Oregano and neomycin 1500 128 2.1 Indifference a 
Oregano and oxacillin 1500 64 0.33 Synergy b 
 
Indifference (a) was defined as an FIC index of   > 0.5 but of < 4. Synergism (b) was defined by 
a FICi ≤ 0.5. Antagonism was defined as an FIC index of >4 (White et al., 1996). 
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Table 5.6 The effects of plant antimicrobials on oxacillin and tetracycline 
susceptibility of S. aureus COL hemB and its corresponding parent strain 
expressed as FICi  
 
MRSA COL hem B 
 
Combination tested 
MIC’s (mg/L) 
 Plant Anti.      Antibiotic 
     
   FICi           Relationship  
Cinnamon and oxacillin 1250 128 0.32 Synergy b 
Cinnamon and tetracycline 1250 64 1.57 Indifference a 
Green tea and tetracycline 125 64 0.32 Synergy b 
Green tea and oxacillin 125 128 0.22 Synergy b 
Oregano and tetracycline 1000 64 1.96 Indifference a 
Oregano and oxacillin 1000 128 0.17 Synergy b 
 
MRSA COL Parent  
 
Combination tested 
MIC’s (mg/L) 
 Plant Anti.      Antibiotic 
     
   FICi           Relationship  
Cinnamon and oxacillin 2000 128 0.27 Synergy b 
Cinnamon and tetracycline 2000 64 1.25 Indifference a 
Green tea and tetracycline 250 64 0.25 Synergy b 
Green tea and oxacillin 250 128 0.27 Synergy b 
Oregano and tetracycline 1750 64 2.15 Indifference a 
Oregano and oxacillin 1750 128 0.24 Synergy b 
 
Indifference (a) was defined as an FIC index of   > 0.5 but of < 4. Synergism (b) was defined by 
a FICi ≤ 0.5. Antagonism was defined as an FIC index of >4 (White et al., 1996). 
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Figure 5.4 Susceptibility of S. aureus SCVs ATCC 25923GEN and MRSA COL hemB and their corresponding parent strains 
following continuous exposure to plant antimicrobials A) - Candicidin B) - Cinnamon Bark C) - Green tea D) - Oregano  
A) B) 
C) D) 
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5.4 Discussion  
Disc diffusion has been implemented to assess the antimicrobial susceptibility of 
several different bacterial species to various EOs (Burt & Reinders, 2003; Kalemba & 
Kunicka, 2003). In this study disc diffusion was applied to a collection of S. aureus 
SCV and parent strains, and inhibitions zones measurements were successfully 
obtained for all plant antimicrobials except candicidin. EOs contain a mixture of 
several different components and their antibacterial effect is poorly understood 
(Holley & Patel, 2005). Consequently efforts have focused on identifying the 
individual components of EOs to develop an understanding of antibacterial activity.  
 
Oregano oil produced the largest mean inhibition zones in comparisons to the other 
EOs examined. The main component of the oregano oil used in this study was 
carvacrol, with the active compound making up 74.3% of the total composition. 
Carvacrol is responsible for the antibacterial activity of various EOs (thyme, savory as 
well as oregano) and has been shown to disrupt bacterial cell membranes (Lambert et 
al., 2001). The disruption of the cell membrane causes the leakage of cellular 
constituents resulting in bacterial death. SCVs were shown to be more susceptible to 
oregano compared to parent strains in both the disc diffusion and broth dilution 
method. This may be related to the differences in membrane potential (∆Ψ) and ATP 
availability. Studies in B. cereus have shown that exposure to carvacrol results in 
depletion of the intracellular ATP pool, however this was not attributed to leakage of 
ATP through the membrane (Ultee et al., 1999). Ultee et al. (1999) also showed that 
carvacrol induces membrane damage but concluded that ATP is not lost through this 
damage but is affected due the effect of carvacrol on ∆Ψ. SCVs have a reduced ∆Ψ as 
a direct consequence of their phenotype (Balwit et al., 1994), thus it can be postulated 
that carvacrol increases lethality in SCVs, as levels of ATP diminish at quicker rate in 
comparison to parent strains.  
 
The main component of the cinnamon bark used in study was cinnamaldehyde (70 % 
of total composition). All SCV and parent strains examined were shown to be 
susceptibile to preparations of cinnamon bark, with SCVs producing larger inhibition 
zones and lower MIC and MBC values. Although cinnamaldehyde acts on the 
bacterial membrane, unlike carvacrol treated cells, cells treated with cinnamaldehyde 
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do not show depletion of intracellular ATP or disintegration of the membrane 
(Helander et al., 1998). Cinnamaldehyde has been shown to inhibits FtsZ which is 
responsible for the regulation of bacterial cell division (Domadia et al., 2007) 
therefore it is surprising that SCVs show increased susceptibility to cinnamon. SCVs 
exhibited reduced rates of cell wall synthesis and an increase in cell wall thickness in 
comparison to parent strains, which results in reduced susceptibly to antibiotics that 
target cell wall synthesis. Slower rates of cell division would suggest that SCVs 
would exhibit reduced susceptibility to antimicrobials targeting the cell division 
process. Other cellular components may therefore be the target of cinnamaldehyde.  
 
Green tea exerts strong antibacterial activity against a range of bacterial pathogens, 
which is related to its composition of polyphenolic catechins, one of which is EGCG 
(Friedman, 2007). Several different targets for the antibacterial activity of green tea 
catechins have been published. Examples include the FabG and FabI reductase steps 
in the E. coli fatty acid elongation cycle (Zhang & Rock, 2004), cell division 
machinery (West et al., 2001) and DNA gyrase (Gradisar et al., 2007).  Similar to the 
effects of cinnamon and oregano SCVs were also more susceptible to green tea. As 
the exact mechanism of activity of green tea is yet to be eluded, the difference in 
susceptibility between SCV and parent strains in difficult to postulate. If green tea 
targets cell division or DNA gyrase, increased susceptibility in SCVs is striking as 
SCVs would be expected to be more susceptibile, due to the slower growth rate 
observed in many SCVs.   
 
Combined use of antibiotics with plant antimicrobial compounds may offer a strategy 
to overcome the problem of increasing antibiotic resistance through synergism; where 
the combined effect of two compounds is greater than the sum of the effects of each 
compound alone (Berenbaum, 1978; Rand et al., 1993). Many studies have proven the 
synergistic action of EO fractions from different plants with synthetic drugs as well as 
antifungal agents (Hemaiswarya et al., 2008). This study has identified synergistic 
relationships between several antibiotics and plant antimicrobials. Green tea displayed 
the highest number of synergistic relationships in both SCV and parent strains; 
include synergy with neomycin, oxacillin and tetracycline. The synergistic 
relationship between green tea and oxacillin has been explained by Zhao et al. (2001). 
EGCG of green tea directly binds to peptidoglycan on the cell wall interfering with 
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the integrity of the cell wall. The action of green tea directly facilitates the action of 
cell wall specific antibiotics, such as oxacillin.  
 
Tetracycline resistance in S. aureus is often related to active efflux of tetracycline thus 
reducing the accumulation of tetracycline molecules within the cell. One example of 
this efflux pump is the Tet(K) efflux pump, which is widespread in staphylococcal 
species. Synergy between the EGCG and tetracycline has been observed via the 
inhibition of the Tet(K) efflux pump, drastically decreasing the MIC of tetracycline 
(Roccaro et al., 2004).  The strain tested for green tea and tetracycline synergy in this 
study (MRSA COL) also possess the tetracycline efflux pump Tet(K) , confirming the 
inhibition of tetracycline efflux by green tea (Liu & Pop, 2009). Synergy between 
green tea and neomycin was also observed in S. aureus N315 SCV and the parent 
strain. Resistance to various aminoglycosides in S. aureus N315 is due to the 
presences of nucleotidyltransferases, enzymes that modifies the antibiotics rendering 
them inactive (Kuroda et al., 2001). The mode of synergy may involve green tea 
catechins, such as EGCG, inhibiting the activity or production of these modifying 
enzymes. EGCG can inhibit antibiotic modifying enzymes (Zhao et al., 2003) and in 
this case may inhibit activity of aminoglycoside modifying enzymes (AMEs), 
allowing an active aminoglycosides to exert antibacterial activity. The observation 
that green tea has a synergistic relationship with three separate antibiotic classes 
makes it an attractive candidate for further investigation. This is supported by 
evidence that the components of green tea have antibacterial activity against various 
human pathogens (Anand et al., 2006; Gordon & Wareham, 2010; Osterburg et al., 
2009) and are also active against S. aureus SCVs. SCVs display reduced susceptibility 
to cell wall specific antibiotics (such as ß-lactams) and protein synthesis inhibitors 
(aminoglycosides) as a direct result of their phenotype. Although the mechanisms 
surrounding the synergistic relationships may not be directly applicable to combating 
the reduced susceptibility mechanisms in SCVs, the susceptibility of SCVs to green 
tea may have potential in treatment of SCV infections.  
 
Among the other plant antimicrobials examined cinnamon and oregano both showed 
synergy with oxacillin. The literature provides several examples of other plant 
antimicrobials that present synergy with ß-lactam antibiotics. For example, baicalin (a 
flavonoid used in traditional Chinese medicine) has been shown to inhibit ß-lactamase 
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activity (Liu et al., 2000). Oxacillin is an example of a ß-lactam antibiotic that is 
resistant to the action of ß-lactamase enzymes, where the ß-lactam ring is protected 
from hydrolysis. Therefore if cinnamon and oregano are not involved in enzymatic 
inactivation, they may disrupt the integrity of the cell wall facilitating the action of ß-
lactam antibiotics in a similar manner to green tea.  
 
Bacterial resistance to antibiotics and biocides is well documented and patterns of 
resistance are closely observed by clinicians and healthcare workers. The European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) state that a clinically 
resistant organism is one in which the level of antimicrobial susceptibility has a high 
likelihood of clinical failure (EUCAST, 2009). Organisations such as EUCAST and 
the CLSI publish breakpoints that can be used in order to interpret whether an 
organism is susceptible or resistant to a certain antibiotic. Such guidelines are 
unavailable for plant antimicrobial compounds, mainly due to their lack of use in the 
clinical setting. The breakpoints stipulated by the CLSI usually specify an four to 
eight fold difference in MIC between sensitive and resistance organisms. For example 
S. aureus strains that are classified as susceptible to tetracycline have an MIC < 4 
mg/L where as strains classified as resistance have a MIC > 16 mg/L. Increases in 
MIC for candicidin, cinnamon, and green tea were detected although the largest 
increases across the panel of four strains was a doubling in the MIC against cinnamon 
of S. aureus ATCC 25923. Therefore none of the S. aureus strains examined in this 
study would meet the criteria for a ‘resistant’ classification.  
 
Classical mechanisms of resistance to antibiotics include enzymatic inactivation, 
efflux or modification of the target site (Almasaudi et al., 1991). Although these 
mechanisms may be applied to combat the antibacterial effects of plant 
antimicrobials, studies have shown a lack of resistance to plant antimicrobials such as 
garlic and honey (Cooper et al., 2010; Wood, 2009). It is likely that the bacterial 
resistance encountered today is due, in part, to the overuse of antibiotics in clinical 
and agricultural setting. The lack of resistance to plant antimicrobials may be partly 
due to the lack of implementation in treating bacterial infections and consequently the 
opportunity for bacteria to develop and evolve resistance mechanisms has not arisen. 
Another explanation may be the combination effects exerted by the different 
components of plant antimicrobials. EOs contain several groups of chemical 
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compounds resulting in multi-factorial antibacterial activity and therefore have several 
targets in the bacterial cell (Burt, 2004).  For instance, the main component of the 
cinnamon used in this study is cinnamaldehyde; however eugenol is also present at 
lower concentrations. The multi-target nature of plant antimicrobial compounds 
suggests resistance is less likely to occur in comparison to exposure to an individual 
antimicrobial agent.     
 
The problem of bacterial resistance to clinically important antibiotics has resulted in 
national and local surveillance networks being established to monitor antibiotic 
resistance trends (Nwosu, 2001). At present, plant antimicrobials are not used as 
systemic antibiotics due to their low level of activity, especially against Gram-
negative bacteria. The reported MIC is often orders of magnitude higher than those of 
common broad-spectrum antibiotics from bacteria or fungi (Tegos et al., 2002). The 
MICs of the plant antimicrobials assessed in this study are substantially higher than 
MICs for conventional antibiotics, although this study demonstrates that inhibition of 
aureus SCV and parent strains can be achieved. Additionally throughout the course of 
susceptibility testing it was observed that none of the plant antimicrobials examined 
selected for SCVs in parent strains. This is another advantageous characteristic of the 
plant antimicrobials examined as SCV selection can lead to persistent and recurrent 
infections. Whether or not these concentrations are achievable in the treatment of 
infections requires further investigation. An attractive option is the use of plant 
compounds as a topical agent for the treatment wounds or burns. Manuka honey is a 
plant derived antimicrobial that offer potentials in this particular application (Cooper 
& Molan, 1999; Cooper et al., 1999; Dunford et al., 2000). Plant antimicrobials may 
also be implemented in the decolonisation of patients who are known carriers of 
MRSA to prevent dissemination and spread of nosocomial infection (Caelli et al., 
2000; Dryden et al., 2004). Coupled with the lack of resistance and the synergistic 
combinations with several commonly used antibiotics, plant antimicrobials offer an 
attractive avenue for antimicrobial chemotherapy. More research is required to 
understand the complete molecular mechanism of the drug action in the presence and 
absence of the natural compounds, as well as the stability, selectivity and 
bioavailability of these natural products (Hemaiswarya et al., 2008). 
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5.5 Conclusions  
• S. aureus SCV and parent strains are susceptible to candicidin, cinnamon bark, 
ginger, green tea and oregano as confirmed by a combination of disc diffusion and 
microdilution methods. 
• S. aureus SCVs exhibit larger zones of inhibition and/or lower MIC and MBCs of 
candicidin, cinnamon bark, green tea and oregano.   
• Resistance to candicidin, cinnamon bark, green tea and oregano could not be 
induced in SCV or parent strains following short term exposure to MIC. 
• Cinnamon and oregano combined with oxacillin produces a synergistic 
relationship against S. aureus SCV and parent strains. 
• Green tea combined with neomycin, oxacillin and tetracycline produces a 
synergistic relationship S. aureus SCV and parent strains. 
 162 
6 CHAPTER 6: SMALL COLONY VARIANTS IN SPECIES OTHER 
THAN STAPHYLOCOCCUS AUREUS  
6.1 Introduction  
6.1.1 Small colony variants of bacterial species other than S. aureus  
SCVs have been extensively studied in Staphylococcus aureus, however SCVs have 
been isolated from a variety of other bacterial species have been isolated (Table 6.1). 
These species include important Gram-negative pathogens such as Pseudomonas 
aeruginosa and Gram-positive pathogens such as Enterococcus faecalis and 
Streptococcus pneumonia.  
6.1.1.1 Escherichia coli  
E. coli is rod shaped facultatively anaerobic bacterium that is a normal component of 
the intestinal flora of humans. Although E. coli is generally viewed as a commensal, 
certain strains have acquired virulence factors that allow colonisation of novel niches 
and the ability to cause disease in otherwise healthy hosts (Kaper et al., 2004). 
Different pathovars of E. coli have been described including enteropathogenic E. coli 
(EPEC), enterohaemorrhagic E. coli (EHEC), and uropathogenic E. coli (UPEC) 
(Croxen & Finlay, 2010). EPEC and EHEC cause disease in the small bowel and large 
bowel, respectively, where as UPEC colonises the bladder causing cystitis which can 
lead to kidney failure if left untreated. Comparison of a benign laboratory strain (K12) 
and an enterohaemorrhagic strain (O157:H7) identified the presence of 4.1 Mb 
sequence highly conserved between strains, regarded as the backbone of the E. coli 
chromosome (Hayashi et al., 2001). Genome analysis concluded that O157:H7 
diversified from a common lineage via the acquisition of foreign DNA, much of 
which encodes virulence related functions accounting for the difference in 
pathogenicity between strains.  
 
SCVs of E. coli have been isolated from patients suffering from prosthetic joint 
infections and chronic urinary tracts infections (Roggenkamp et al., 1998; Tappe et 
al., 2006). Analysis of isolates revealed they show E. coli SCV share characteristics 
associated with the conventional SCV phenotype observed in S. aureus including the  
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Table 6.1 Small colony variants isolated from various bacterial species  
 
CF - cystic fibrosis; PGFE – pulse field gel electrophoresis; MLST - multilocus sequence typing; SCV - small colony variant; WT - wildtype  
Species Source of isolation   Observations associated with SCV phenotype Reference 
Brucella abortus  Mouse model of infection  Slow growth rate, increased persistence in mouse model  Jacob et al., (2006) 
Burkholderia cepacia  Lung transplant in CF 
patient  
Increased serum resistance  Haussler et al., (2003a) 
Burkholderia 
pseudomallei 
In vitro exposure to 
ceftazidime, ciprofloxacin 
and gentamicin 
Identical biochemical, PFGE and electron microscopy 
profiles; reduced susceptibility to various antimicrobials  
Haussler et al., (1999a) 
Brucella melitensis  Bacterial endocarditis 
(blood culture) 
Reduced streptomycin susceptibility through 
development of SCV phenotype  
Hall & Spink (1947) 
Cryptococcus 
neoformans  
Chronic meningitis Negative result for cryptococcal antigen; implications in 
identification   
To et al., (2006) 
Enterococcus faecalis Amyloid arthropathy in 
chickens 
Identical PFGE and MLST profiles to WT; increased 
virulence and persistence 
Petersen et al., (2008) 
Enterococcus faecalis Chronic aortic valve 
endocarditis 
Identical PFGE profile to WT; auxotrophy for haemin; 
abnormal cell wall and cell size  
 (2009) Wellinghausen et al.,  
Neisseria gonorrhoea Gonorrhoea patient  Reversion to WT following subsequent culture  Morton & Shoemaker (1945) 
Salmonella enterica 
serovar Typhimurium 
Prolonged intracellular 
fibroblast infection 
Increased intracellular persistence; reduced virulence in 
mice model; reduced susceptibility to aminoglycosides  
Cano et al., (2003) 
Streptococcus 
pneumoniae  
Isolated from S. pneumonia 
biofilms during initial 
attachment phase 
Increased adherence, aggregation and biofilm formation  Allegrucci & Sauer (2007) 
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production of microcolonies, slow growth, reduced aminoglycoside susceptibility and 
auxotrophy. In cases of infection with E. coli SCVs, infection duration and persistence 
are increased (Roggenkamp et al., 1998; Sendi et al., 2010) which has been 
documented in patients with S. aureus SCV infection (Kahl et al., 1998; von Eiff et 
al., 1997a). Laboratory studies have shown that antimicrobial agents such as 
gentamicin can select for E. coli SCVs (Lewis et al., 1991). These variants showed 
similar characteristics associated with the SCV phenotype and auxotrophy for haemin 
was attributed to mutations in hemB.  
6.1.1.2 Pseudomonas aeruginosa  
P. aeruginosa is a rod shaped motile bacterium. On solid agar colonies often appear 
as green-blue in colour, characterised by the production of the pigments pyocyanin 
and pyoverdin (Pier & Ramphal, 2010). Genome sequencing of several P. aeruginosa 
strains has revealed the presence of a large genome (6.2 – 6.6 Mb) that permits 
nutritional versatility and environmental adaptability (Stover et al., 2000; Winstanley 
et al., 2009). A large proportion of genes in P. aeruginosa encode environmental 
sensors and transcriptional regulators that aid adaptational response to environmental 
fluctuations (Stover et al., 2000). P. aeruginosa is responsible for various community 
acquired infections (ear infections and keratitis), and is also the causative agent of 
nosocomial infections of the respiratory tract, urinary tract and burns (Rossolini & 
Mantengoli, 2005). Intrinsic resistance to a range of antimicrobial agents (quinolones, 
chloramphenicol, tetracycline, trimethoprim and sulphonamides) due the presence of 
multidrug efflux systems (Poole, 2001) results in limited treatment options for P. 
aeruginosa infections.                               
 
SCVs of P. aeruginosa have been isolated from in vitro exposure to aminoglycosides 
as well as experimental models of infection (Gerber & Craig, 1982; Gerber et al., 
1982). Common characteristics of SCVs included reduced uptake of aminoglycosides, 
reversion to the wildtype phenotype and changes in biochemical profiles. Chronic 
pulmonary infections in CF patients are also a source of P. aeruginosa SCVs. The 
link between the prevalence of SCVs in CF patients has been linked to the use of 
ventilator administered antimicrobials, which may induce the SCV phenotype 
(Haussler et al., 1999b). These isolates showed reduced susceptibility to 
antipseudomonal agents and are associated with reduced lung function in comparison 
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with patients infected with wildtype P. aeruginosa strains. P. aeruginosa SCVs also 
display many characteristics corresponding to niche adaptation with the lungs of CF 
patients. These characteristics include increased biofilm formation and increased 
association with a eukaryotic cell line (Haussler et al., 2003b). Auxotrophy for 
compounds such as haemin, menadione and thymidine has not been previously 
reported in P. aeruginosa SCVs.  
6.1.1.3 Staphylococcus epidermidis  
S. epidermidis is a member of the coagulase negative staphylococci (CoNS), which 
are differentiated from S. aureus by an inability to coagulate rabbit plasma (i.e. 
coagulase negative). S. epidermidis shares a core set of 1,681 open reading frames 
with S. aureus but lacks many of the genomic islands that encode virulence factors 
such as toxins (Gill et al., 2005). Recently the importance of S. epidermidis as an 
opportunistic pathogen has been recognised. Its natural niche on the human skin 
permits access through implanted devices resulting in S. epidermis being the most 
common source of infections associated with indwelling medical devices (Rogers et 
al., 2009). This opportunistic pathogen is one of most frequently recovered 
microorganisms in the hospital environment, showing high levels of incidence in 
nosocomial bloodstream infections, cardiovascular infections, and infections of the 
eye, ear, nose, and throat (Vuong & Otto, 2002). The affinity of S. epidermidis for 
foreign materials commonly used in modern medicine has further contributed to the 
increased incidence in nosocomial infections (Huebner & Goldmann, 1999). 
Antibiotic resistance is also prevalent in S. epidermidis and other coagulase negative 
CoNS. Recent surveillance studies in North America and the UK reported a high rate 
of ciprofloxacin, erythromycin penicillin, and oxacillin resistance (Hope et al., 2008; 
Streit et al., 2004). 
 
SCVs of S. epidermidis have been isolated from pacemaker-related infections (von 
Eiff et al., 1999), and SCVs of other CoNS species including S. capitis and S. 
lugdunensis have been isolated from prosthesis related infections (Seifert et al., 2005; 
von Eiff et al., 1999). Prosthetic device related infections caused by S. epidermidis 
SCVs respond poorly to antimicrobial chemotherapy, often resulting in the removal of 
the prosthesis. Similarly to S. aureus SCVs, identification of CoNS SCVs is a 
challenge due to their abnormal colony phenotypes, slow growth rate and altered 
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biochemical characteristics; amplification and sequence analysis of 16S rRNA is vital 
for accurate species identification (von Eiff et al., 1999). Recently a link has been 
postulated between CoNS SCVs and patients suffering from myalgic 
encephalomyelitis (known as chronic fatigue syndrome; CFS). CFS is a condition 
characterised by long periods of fatigue, short term memory loss and musculoskeletal 
pain (Fukuda et al., 1994). Increased carriage of CoNS on skin and the presence of 
atypical macrococci in blood cultures from CFS patients (unresponsive to antibiotic 
treatment) allude to the involvement of a SCV phenotype (Onyango et al., 2008; 
Tarello, 2001). The presence of a SCV phenotype may explain the persistence and 
duration of the disease as SCVs frequently persist within host cells and abate the 
immune response.   
 
The construction of a stable S. epidermidis hemB laboratory mutant (via allelic 
replacement) has aided the study of SCVs of this species. Stable S. epidermidis SCVs 
have permitted developments regarding the understanding of pharmcodynamic 
responses to antistaphylococcal agents (Wu et al., 2009). This approach has 
demonstrated that SCVs of S. epidermidis show reduced susceptibility to vancomycin 
in comparison to wildtype strains due to enhanced adhesion properties. Furthermore, 
increased capacity to form biofilms in S. epidermidis hemB mutants has been reported 
(Al Laham et al., 2007). Increased expression of icaA resulted in increased production 
of polysaccharide intracellular adhesin and the formation of large clusters of cells.   
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6.1.2 Aims  
SCVs of E. coli, P. aeruginosa and S. epidermidis have been isolated and 
characterised, however the majority of cases have been isolated from the clinical 
environment. The following work aimed to investigate whether various antimicrobial 
agents could select for SCVs in vitro and characterise these isolates to determine if an 
overlap was present between lab and clinically derived isolates through the following 
aims: 
 
• Examine the ability of several antimicrobial agents to select for SCVs in                  
E. coli, P. aeruginosa  and S. epidermidis. 
• Characterise any SCVs using species specific assays. 
• Determine antimicrobial susceptibility profiles of SCV isolates. 
• Analyse biofilm formation in SCV isolates.  
• Generate RAPD profiles for SCV isolates and compare parent RAPD profiles. 
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6.2 Materials and methods 
6.2.1 Bacterial strains and growth medium   
E. coli ATCC 25922 and NCTC 10418, P. aeruginosa ATCC 27853 and PAO1 and                   
S. epidermidis LTN (obtained from Heath Hospital, Cardiff) were all maintained on 
Mueller Hinton (MH) agar and grown in MH broth at 37°C with shaking (150 rpm) 
unless otherwise stated. All growth medium was obtained from Oxoid (UK), with the 
exception of purified agar which was obtained from Difco (UK). Additional 
components required for certain agar assays were obtained from Sigma (UK).  
6.2.2 Preparation of antimicrobial agents  
Ampicillin, ciprofloxacin, chloramphenicol, gentamicin, tetracycline were obtained 
from Sigma Aldrich (UK) and triclosan from Ciba Speciality Chemicals (Germany). 
Ciprofloxacin, chloramphenicol, gentamicin and tetracycline powders were dissolved 
in sterile deionised water. Saturated NaHCO3 solution was used to dissolve ampicillin 
and triclosan was dissolved in dimethyl sulfoxide. Reduced strength stocks were made 
where required in deionised water and all stock solutions were stored at 4°C for a 
maximum of 4 days.  
6.2.3 Determination of minimum inhibitory concentrations  
MICs were determined using Clinical Laboratory and Standards Institute (CLSI) 
guidelines as described previously (section 2.2.3).  
6.2.4 SCV selection assays  
Following the determination of MICs, strains that showed susceptibility were exposed 
to antimicrobial agents to examine their ability to select for SCVs in vitro. E. coli, P. 
aeruginosa and S. epidermidis cultures were prepared by inoculating 3-4 individual 
colonies into cation adjusted Mueller Hinton broth CAMHB and incubating at 37°C 
with shaking at 150 rpm. Cultures were grown to mid exponential phase and 
antimicrobial agents added at concentrations determined as the MIC in previous 
susceptibility testing (section 6.2.3). Following incubation for a further 6 hours, 100 
µL of culture was spread over the surface of a MH agar plate (containing X 2 MIC the 
selecting antimicrobial agent), using a sterile glass rod. Plates were incubated for 48 
hours at 37°C. The presence of colonies with altered phenotypic appearances were 
suspected as SCVs and chosen for further analysis.   
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6.2.5 Characterisation of SCVs  
6.2.5.1 Growth rate analysis 
Overnight cultures of E. coli, P. aeruginosa and S. epidermidis parent and SCV 
strains were used to inoculate 250 mL conical flasks containing 50 mL of MH broth at 
a starting density 1 X 105 CFU/mL. Flasks were incubated at 37°C with shaking (150 
rpm) for 48 hours. Optical density was measured at 580 nm and used to calculate lag 
time and growth rate. Lag time was recorded as the time taken for to the culture to 
reach the beginning of exponential growth from initial inoculation. Growth rate was 
calculated using the formula lnNT – lnNO/ TIME. Viable counts were obtained 
following the end of growth rate experiments by performing relevant serial dilutions 
in phosphate buffered saline (PBS) and enumerating cells on MH agar.  
6.2.5.2 Auxotrophy  
Auxotrophy profiles of E. coli, P. aeruginosa and S. epidermidis SCVs were 
determined as described previously (section 2.2.9.6).  
6.2.5.3 Antimicrobial susceptibility testing of SCVs 
Initially susceptibility testing was planned to be investigated via microdilution 
methods using CLSI guidelines. However the production of cellular aggregates and 
biofilms were frequently observed during microtitre susceptibility testing lead to 
inconsistencies and errors in observations. Therefore the British Society for 
Antimicrobial Chemotherapy (BSAC) standardised disc susceptibility testing method 
(section 5.2.3) was applied which improved result interpretation and consistency. Disc 
impregnated with antimicrobial agents were all obtained from Oxoid (UK). The 
antimicrobial discs used were 10 µg ampicillin, 30 µg chloramphenicol, 5 µg 
ciprofloxacin, 10 µg gentamicin, 30 µg tetracycline.  
6.2.5.4 S. epidermidis DNA extraction 
DNA extraction from S. epidermidis isolates was performed as described previously 
for S. aureus (section 2.2.7).  
6.2.5.5 E. coli and P. aeruginosa DNA extraction 
DNA was extracted using the GenElute Bacterial Genomic DNA Kit (Sigma Aldrich, 
UK), according to manufactures instructions. Overnight cultures were centrifuged at 
10,000 rpm in microfuge tubes to pellet cells. 180 µL of lysis buffer was used to 
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resuspend pellets and create a homogenous mixture. This was followed by the 
addition of 20 µL of Proteinase K, which was subsequently incubated for 30 minutes 
at 55°C. Manufactures specific lysis C solution (200 µL) was then added and 
incubated for a further 10 minutes at 55°C. DNA binding columns were optimised for 
binding using ethanol followed by the addition of the previously prepared lysate. 
Samples were centrifuged at 8,000 rpm for 1 minute, followed by 2 additional 
washing steps before eluting bound DNA by the addition of 200 µL manufactures 
elution solution. Finally, samples were centrifuged for 1 minute at 10,000 rpm and the 
remaining eluate (regarded as pure genomic DNA) was stored at 4ºC until required.  
6.2.5.6 Biofilm formation assay 
SCVs isolated from E. coli, P. aeruginosa and S. epidermidis were analysed for the 
ability to form biofilms using a standardised multiwell microtitre plate assay (O'Toole 
et al., 1999). Overnight cultures of SCV and parent strains were adjusted to 1 x 106 
CFU/mL in fresh medium (Luria Broth for E. coli and P. aeruginosa and tryptone soy 
broth for S. epidermidis) supplemented with 0.5 % glucose and 200 µL was dispensed 
into wells of 96 microtitre well plates (Fisher, UK). Microtitre plates were incubated 
at 37°C for 48 hours and subsequently stained with 0.1 % safranin (dissolved in H2O 
and filter sterilised). Biofilms were stained for 15 minutes at room temperature before 
being washed twice with PBS to remove unattached cells and residual dye. To elute 
safranin from biofilms 200 µL of solvent was added to individual wells (95% ethanol 
for P. aeruginosa and S. epidermidis and 80% ethanol, 20% acetone for E. coli) and 
incubated at room temperature for 30 minutes. Subsequently optical density was 
measured at OD490 using a DYNEX Technologies MRX® Microplate Absorbance 
Reader with RevelationTM application programme.   
6.2.5.7 Cell-surface hydrophobicity  
The microbial adhesion to hydrocarbons assay described previously (section 4.2.5) 
was used for determine cell-surface hydrophobicity.  
6.2.5.8 Random amplified polymorphic DNA analysis  
RAPD was carried out as described previously (section 3.2.5.9) with the inclusion of 
the additional primers 228 (5’-GCTGGGCCGA-3’) and 270 (5’-TGCGCGCGGG-3’).  
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6.2.6 Characterisation of P. aeruginosa SCVs  
P. aeruginosa is a motile organism therefore various motility assays were employed 
to compare flagella and pili activity in SCV and parent strains.  
6.2.6.1 Swarming assay (Rashid & Kornberg, 2000) 
Swarming plates (0.5% purified agar, 8 g/L nutrient broth, 5 g/L glucose) were 
prepared and allowed to dry overnight before being used. SCV and parent strains were 
adjusted to 1 X 106 CFU/mL in PBS and 5 uL inoculated onto the centre of swarming 
agar plates. Plates were incubated at 30°C for 48 hours and the furthest branching 
point from the initial point of inoculation measured.   
6.2.6.2 Swimming (Rashid & Kornberg, 2000) 
SCV and parent strains were adjusted to 1 X 106 CFU/mL in PBS and used to 
inoculate tryptone swim plates (10 g/L tryptone, 5 g/L NaCl, 0.3 % purified agar). 
Tryptone swim plates were inoculated with the use of a sterile toothpick and 
incubated at 30°C for 48 hours. Swimming motility was assessed by examining the 
circular turbid zone formed by the bacterial cells migrating away from the initial point 
of inoculum.  
6.2.6.3 Twitching (Darzins, 1993; Deziel et al., 2001) 
SCV and parent strains were adjusted to 1 X 106 CFU/mL in PBS and used to 
inoculate thin (3 mm) LB agar plates. Using a sterile toothpick cells were stabbed into 
the agar so the toothpick reached the Petri dish surface. Bacterial growth at the 
interface between the plastic surface and the agar was measured by removing agar and 
staining with 1 % crystal violet. Twitching motility was determined by measuring the 
diameter of the crystal violet stained area.  
6.2.6.4 Pyocyanin assay (Schaber et al., 2004) 
SCV and parent strains were grown in glycerol alanine minimal (GA) medium (1 % 
glycerol, 6 g/L L-alanine, 2 g/L MgSO4, 0.1 g/L K2HPO4, and 0.018 g/L FeSO4) to 
investigate pyocyanin production. Overnight SCV and parent cultures were 
centrifuged at 10,000 rpm for 5 minutes and the supernatant collected. Individual 
strain supernatants (5 mL) were mixed with 5 mL chloroform and left at room 
temperature for 5 minutes to allow separation. To the lower organic layer 1.5 ml             
0.2 M hydrochloric acid was added and the pyocyanin-rich organic layer was 
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separated. The absorbance of the extracted layer was measured at OD520 to quantify 
pyocyanin production.  
6.2.6.5 Elastin Congo red assay   
To quantify elastolytic activity the method of Schad et al., (1987) was applied. 
Supernatants of SCV and parent strains grown in LB were collected as described 
previously (section 6.2.6.4) and 100 µL added to 2 ml of 10 mM NaHPO4 containing 
30 mg elastin Congo red (Sigma Aldrich, UK). The mixture was incubated at 37 °C 
for 14 hours, centrifuged at 10,000 rpm for 5 minutes and released Congo red 
measured at 495 nm. 
6.2.7 Characterisation of E. coli SCVs  
6.2.7.1 Biochemical analysis  
API 20E strips (Biomerieux, France) were used to compare biochemical profiles 
between E. coli SCV and parent isolates. A direct colony suspension of SCV and 
parent cells was prepared in API suspension medium (Biomerieux, France), and 200 
µL used to inoculate CIT, GEL and VP reactions (in order to fill both tube and 
cupule) with 100 µl being added to all remaining tubes. Anaerobic conditions were 
created by the overlaying of mineral oil to ADH, LDC, ODC, H2S and URE tests. 
Wildtype test strips were incubated at 37°C for 24 hours where as the incubation 
period was extended to 48 hours for SCV isolates. Following incubation various tests 
required the addition of reagents which can be found in the Appendix. The catalogue 
of the enzymatic reactions tested and resulting colour changes are seen in Appendix 1.   
6.2.7.2 Swimming motility 
Swimming agar used for P. aeruginosa (section 6.2.6.2) was used to assay swimming 
motility in E. coli SCVs and parents.  
6.2.8 Characterisation of S. epidermidis SCVs  
6.2.8.1 Catalase production 
Catalase production was determined by the addition of 10 uL hydrogen peroxide 
(Sigma, UK) to glass slides containing a homogenous mixture of several                              
S. epidermidis colonies. The production of bubbles was indicative of catalase activity.  
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6.2.8.2 Biochemical analysis  
API Staph strips (Biomerieux, France) were used as described previously (section 
2.2.9.1). 
6.2.9 Statistical analysis  
Analysis of significant differences between characteristics of SCV isolates and parent 
strains were performed as described previously (section 2.2.9.8).  
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6.3 Results  
6.3.1 SCV selection 
E. coli ATCC 25922 and NCTC 10418 strains showed susceptibility to ampicillin, 
ciprofloxacin, chloramphenicol, gentamicin, tetracycline and triclosan and thus all 
were analysed for their ability to select for SCVs (Table 6.2). P. aeruginosa ATCC 
27853 and PAO1 however displayed resistance (MIC > 32 mg/L) to ampicillin, 
chloramphenicol, tetracycline and triclosan. Both strains were sensitive to gentamicin 
and ciprofloxacin which were used in SCV selection assays (Table 6.2). Finally,              
S. epidermidis LTN showed susceptibility to chloramphenicol, gentamicin and 
tetracycline, which were employed in SCV selection assays.  
 
SCVs were successfully isolated from E. coli, P. aeruginosa and S. epidermidis. 
Gentamicin was the only antimicrobial agent that selected for SCVs in all three 
species. Furthermore, SCVs were recovered after exposure of E. coli to ciprofloxacin 
and chloramphenicol and S. epidermidis with tetracycline. Exposure to ampicillin, and 
triclosan did not result in the detection of SCVs from any of the species examined. 
Although the species examined exhibit morphological differences on solid agar, when 
observing SCVs, colonies with a smaller diameter (in comparison to parent strains) 
were consistently observed in all three species (Figure 6.1). E. coli and P. aeruginosa 
SCV colonies also appeared less mucoid. SCV were named to reflect the selecting 
antimicrobial. For example P. aeruginosa PAO1 SCVGEN was selected for after 
exposure of strain PAO1 in the presence of gentamicin.  
6.3.2 Auxotrophy profiles 
Auxotrophy for haemin, menadione and thymidine was tested for in SCVs isolated 
from E. coli, P. aeruginosa and S. epidermidis (Table 6.3). Autotrophy for haemin 
was detected in all E. coli SCVs recovered from both ATCC 25922 and NCTC 10418. 
Menadione auxotrophy was observed in S. epidermidis LTN SCVs. Auxotrophy was 
not detected in any of the gentamicin selected SCVs isolated from P. aeruginosa 
ATCC 25922 or PAO1. Furthermore, no auxotrophy was detected in SCVs isolated 
following exposure to ciprofloxacin and no SCVs isolated showed auxotrophy for 
thymidine.  
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Table 6.2 Minimum inhibitory concentrations of E. coli, P. aeruginosa and S. epidermidis parent strains  
 
 
 
 Ampicillin Chloramphenicol Ciprofloxacin Gentamicin Tetracycline Triclosan 
E. coli 
ATCC 25922 
1 2 0.125 0.25 0.5 0.125 
E. coli 
NCTC 10418 
2 4 0.25 0.25 1 0.125 
P. aeruginosa 
ATCC 27853 
> 32 > 32 0.5 1 > 32 > 32 
P. aeruginosa  
PAO1 
> 32 > 32 1 2 > 32 > 32 
S. epidermidis 
 LTN 
> 32 4 > 32 0.5 1 4 
 
 
Modal MIC values are presented. Modal values were obtained from three independent replicates and three independent biological replicates. 
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A1)
A2)
B1)
B2)
C1)
C2)
 
 
Figure 6.1 Morphological differences between wildtype and SCV strains A1) - E. coli ATCC 25922; A2) - E. coli ATCC 25922 SCVGEN;                  
B1) - S. epidermidis LTN; B2) - S. epidermidis LTN SCVGEN; C1) - P. aeruginosa PAO1; C2) - P. aeruginosa PAO1 SCVGEN. Colony 
diameters are reduced in all SCVs. Additionally a loss of a mucoid appearance in E. coli ATCC 25922 SCVGEN and loss of pyocyanin 
production in P. aeruginosa PAO1 SCVGEN is also apparent.  
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6.3.3 Growth profiles 
All SCVs isolated produced dissimilar growth profiles to parent strains (Table 6.3). A 
significant decrease in growth rate and an increase in the duration of lag time was 
observed in all SCV in comparison with parent strains (P = < 0.01) For example, lag 
time duration for E. coli was 1.64 hours, in comparison to an average 4.43 hour lag 
time observed in SCV isolates (Table 6.3). Similar extension of lag times was 
observed in P. aeruginosa and S. epidermidis SCVs. The longest increased in lag time 
was observed in E. coli SCVs selected for in the presence of ciprofloxacin. Reduced 
maximum cell density was consistently observed amongst SCVs from all species. 
Wildtype strains consistently reached > 109 CFU/mL where as all SCV strains 
produced significantly lower final cell density in comparison (P = < 0.01).  
6.3.4 Antibiotic susceptibilities  
The BSAC disc diffusion method was used to examine the susceptibility of E. coli, P. 
aeruginosa and S. epidermidis SCV and parent strains. E. coli SCVs (selected for in 
the presence of chloroamphenicol, ciprofloxacin and gentamicin) produced 
significantly smaller zones of inhibition for all 5 antibiotics tested (Figure 6.2), 
including those targeting cell wall synthesis (ampicillin), DNA replication 
(ciprofloxacin) and protein synthesis (chloramphenicol, gentamicin and tetracycline) 
(P = < 0.05).  E. coli SCVs selected in the presence of ciprofloxacin (E. coli SCVCIP) 
displayed the most pronounced degree of reduced susceptibility, producing the 
smallest inhibition zones for every antimicrobial agent examined.  
 
Due to the intrinsic resistance of P. aeruginosa to various antimicrobial agents, 
susceptibility profiles were only determined for gentamicin and ciprofloxacin.            
P. aeruginosa SCVGEN produced significantly smaller zone of inhibition for 
gentamicin (P < 0.01). Mean zones of inhibition for ciprofloxacin were smaller but 
not statistically significantly (Figure 6.2). S. epidermidis SCVs showed a significant 
reduction in the diameter of inhibition zones for gentamicin (P = < 0.01).                     
S. epidermidis LTN SCVTET produced significantly smaller zones of inhibition when 
exposed to the antibiotic that had selected for them (tetracycline). 
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Table 6.3 Auxotrophy profiles and growth characteristics of E. coli, P. aeruginosa, S. epidermidis SCV and parent strains  
 
Strain/isolate Auxotrophy  Lag time duration 
(hours) 
Growth rate  Maximum cell density 
(CFU/mL) 
E. coli ATCC 25922 N/T 1.70 0.88 5.2 X 109 
E. coli ATCC 25922 SCVCHL Haemin 4.08 0.27 5.8 X 108 
E. coli ATCC 25922 SCVCIP N/D 4.80 0.20 7.2 X 107 
E. coli ATCC 25922 SCVGEN Haemin 4.13 0.24 5.0 X 108 
E. coli NCTC 10418 N/T  1.58 0.85 3.2 X 109 
E. coli NCTC 10418 SCVCHL Haemin 4.23 0.31 1.5 X 108 
E. coli NCTC 10418 SCVCIP N/D 4.87 0.22 9.5 X 107 
E. coli NCTC 10418 SCVGEN Haemin 4.53 0.27 2.6 x 108 
P. aeruginosa ATCC 27853 N/T 2.15 0.81 5.1 x 109 
P. aeruginosa ATCC 27853 SCVGEN N/D 5.91 0.36 3.6 x 107 
P. aeruginosa PAO1 WT N/T 2.06 0.77 2.8 X 109 
P. aeruginosa PAO1 SCVGEN N/D 5.68 0.41 6.3 X 107 
S. epidermidis  LTN N/T 2.20 0.81 7.5 X 109 
S. epidermidis LTN SCVGEN Menadione  5.21 0.34 2.2 X 108 
S. epidermidis LTN SCVTET Menadione  5.46 0.30 4.3 X 108 
 
N/D – not detected; N/T – not tested 
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Figure 6.2 Inhibition zones of E. coli, P. aeruginosa, S. epidermidis SCV and parent strains measured by disc diffusion Results represent 
the mean of three independent replicates and three independent biological replicate. Error bars represent standard error  
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6.3.5 Biofilm formation and cell-surface hydrophobicity  
E. coli, P. aeruginosa and S. epidermidis all formed biofilms using the multiwell 
biofilm assay. S. epidermidis produced the greatest biofilm mass, where as E. coli and 
P. aeruginosa produced biofilm at similar levels (Figure 6.3). SCVs of E. coli, P. 
aeruginosa and S. epidermidis showed increased biofilm formation in comparison to 
parent strains regardless of the selecting antibiotic (P = < 0.01; Figure 6.3). No 
significant difference in cell-surface hydrophobicity was observed between S. 
epidermidis parent and SCV isolates (P = > 0.05; Figure 6.3). SCV isolates of E. coli 
and P. aeruginosa however displayed a significant increase in cell surface 
hydrophobicity in comparison with parent strains (P = < 0.01).  
6.3.6 RAPD profiles  
RAPD primers 228 and 272 produced reproducible complex banding patterns for both 
E. coli and S. epidermidis. SCV isolates for both species showed identical RAPD 
profile regardless of the selecting agents, indicating clonality (Figures 6.4 and 6.5).            
P. aeruginosa RAPD profiles lacked the banding complexity seen in E. coli and S. 
epidermidis however parent and SCV isolates produced identical RAPD profiles with 
primers 268 and 270 (Figure 6.5).   
6.3.7 Characterisation of P. aeruginosa SCV isolates  
Various agar based motility assays were applied to P. aeruginosa SCVGEN isolates to 
examine flagella and type IV pili activity. Twitching motility was measured by crystal 
violet staining growth at the interface between the plastic surface of a Petri dish and 
the agar. P. aeruginosa SCVs isolated from PAO1 and ATCC 25923 strains showed a 
significant increase in the diameter of this zone correlating to an increase in twitching 
motility (P = < 0.01; Figure 6.6). Using the swarming motility assay parent strains 
demonstrated far reaching irregular branching patterns. In contrast SCV strains failed 
to produce the complexity of branching patterns observed and a significant reduction 
in branching diameter was observed (P = < 0.01; Figure 6.6). Similarly SCV isolates 
were also deficient in swimming motility producing smaller diameter concentric rings 
(P = < 0.01; Figure 6.6) in comparison to parent strains. Elastase activity was 
measured via the release of Congo red from Congo red bound elastin. SCVs produced 
significantly lower elastolytic activity in comparison to parent strains (P = < 0.05; 
Figure 6.6). On agar plates P. aeruginosa SCV isolates appeared deficient in
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Figure 6.3 Biofilm formation (A) and cell-surface hydrophobicity (B) in E. coli, P. aeruginosa, S. epidermidis SCV and parent strains 
Results represent the mean of three independent replicates and three independent biological replicate. Error bars represent standard error  
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Figure 6.4 E. coli SCV and parent RAPD profiles L - Hyperladder 1; 1 - E. coli ATCC 25922; 2 - E. coli ATCC 25922 SCVCIP; 3 - E. coli 
ATCC 25922 SCVCHL; 4 - E. coli ATCC 25922 SCVGEN. RAPD analysis of E. coli SCVs selected in the presence of various antimicrobials 
displayed identical profiles in comparison to parent strain. 
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Figure 6.5 S. epidermidis and P. aeruginosa SCV and parent RAPD profiles L - Hyperladder 1; 1 - S. epidermidis  LTN; 2 - S. epidermidis  
LTN SCVGEN; 3 - S. epidermidis  LTNTET;  A1 - P. aeruginosa PAO1; A2 - P. aeruginosa PAO1 SCVGEN.  RAPD analysis of S. epidermidis 
SCVs selected in the presence of gentamicin and tetracycline and P. aeruginosa SCVs selected in the presence of gentamicin displayed identical 
profiles in comparison to parent strain.   
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pyocyanin production (Figure 6.1). Although the presence of pyocyanin was 
visualised with increasing incubation, quantitative analysis confirmed SCVs were 
significantly deficient in pyocyanin production (P = < 0.01). Parent strains produced 
an absorbance of 0.31 (±0.08) in comparison to an average of 0.11 (± 0.05) in SCV 
strains.  
6.3.8 Characterisation of E. coli SCV isolates  
Biochemical analysis of wildtype E. coli demonstrated the production of                              
β-galactosidase through the hydrolysis of ortho-nitrophenyl-galactopyranoside          
(Table 6.4). The production of β-galactosidase facilitates the hydrolysis of lactose 
which is a common characteristic of E. coli. All E. coli SCV isolates showed an 
absence of β-galactosidase activity even after prolonged incubation. SCVs were 
negative for mannitol fermentation, for which the wildtype was positive. Other 
differences between SCVs and wildtype were seen in an inability to produce indole 
(SCVCIP and SCVGEN), and inability to ferment sorbitol (SCVCIP and SCVGEN) and 
melibioise (SCVCIP). Motility assays revealed that all E. coli SCV regardless of the 
selecting antimicrobial were deficient in swimming motility (Figure 6.7). A 
significant reduction in the mean average diameter was observed in SCV isolates in 
comparison to parent strains (P < 0.01) 
6.3.9 Characterisation of S. epidermidis SCV isolates  
S. epidermidis SCVs (SCVGEN and SCVTET), produced different biochemical profiles 
in comparison to parent strains (Table 6.5). Fermentation of maltose and lactose was 
not observed in both SCV isolates as well as a lack of production alkaline phosphatase 
production. Addition of hydrogen peroxide to wildtype strains resulted in rapid 
bubbling indicative of the action of catalase. However all SCV isolates showed a 
weak catalase response. As the assay did not allow a quantitative parameter all SCVs 
were regarded as weakly catalase positive. 
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Figure 6.6 Characteristics of P. aeruginosa SCVs A) - Twitching motility; B) - Swarming motility; C) - Swimming motility; D) - Elastolysis 
activity. Results represent the mean of three independent replicates and three independent biological replicate. Error bars represent standard error  
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Table 6.4 Biochemical analysis of E. coli ATCC 25922 SCVs 
 
 
 Parent  E. coli SCVCIP E. coli SCVCHL E. coli SCVGEN 
ONPG + - - - 
ADH - - - - 
LDC + + + + 
ODC + + + + 
CIT - - - - 
H2S - - - - 
URE - - - - 
TDA - - - - 
IND + - + - 
VP - - - - 
GEL - - - - 
GLU + + + + 
MAN + - - - 
INO - - - - 
SOR + - + - 
RHA + + + + 
SAC - - - - 
MEL + - + + 
AMY - - - - 
ARA + + + + 
 
 
+ - Positive (enzyme activity, fermentation of carbohydrate); - = Negative (lack of enzyme activity, inability to ferment carbohydrates). 
Differences between SCV and parents are highlighted in grey. 
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Figure 6.7 Swimming motility of E. coli SCV and parent strains. E. coli SCVs produced reduced zones of swimming motility in both strains 
examined. Results represent the mean of three independent replicates and three independent biological replicate. Error bars represent standard 
error 
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Table 6.5 Biochemical profiles of S. epidermidis LTN SCVs  
 
 
 Parent  S. epidermidis SCVGEN S. epidermidis SCVTET 
GLU + + + 
FRU + + + 
MNE + + + 
MAL + - - 
LAC + - - 
TRE - - - 
MAN - - - 
XLT - - - 
MEL - - - 
NIT + + + 
PAL + - - 
VP + + + 
RAF - - - 
XYL - - - 
SAC + + + 
MDG - - - 
NAG - - - 
ADH + + + 
URE + + + 
 
 
+ - Positive (enzyme activity, fermentation of carbohydrate); - = Negative (lack of enzyme activity, inability to ferment carbohydrates). 
Differences between SCV and parents are highlighted in red 
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6.4 Discussion 
This study on E. coli, P. aeruginosa and S. epidermidis illustrates that SCV formation 
can be readily promoted by commonly used antibiotics. Although not all antibiotics 
examined result in the selection of SCVs, SCV selection with antibiotics 
(ciprofloxacin, chloramphenicol and tetracycline) that have previously not been 
known to select for SCVs, was observed.  
 
Regardless of the bacterial species all SCVs isolated produced atypical phenotypic 
characteristics in comparison with parent strains and therefore phenotypic 
identification is prone to misidentification. Phenotypic variation has been well studied 
in P. aeruginosa and is known to produce a diverse array of morphological 
characteristics (Hogardt & Heesemann, 2010). P. aeruginosa is easily recognisable 
when grown on solid agar due to the production of pyocyanin, which was shown to be 
attenuated in SCVs. The atypical morphology and slow growth rate of SCVs may lead 
to them being misidentified or the determination of a culture negative in the 
laboratory testing. Similar problematic issues may arise during phenotypic 
identification of E. coli SCVs. Due to abnormalities in carbohydrate utilisation and 
growth profiles, SCVs can be misidentified when grown on selective differential 
medium  (Kipp et al., 2005). MacConkey agar is commonly used for the identification 
of lactose fermenting Gram-negative bacteria. The utilisation of lactose in the medium 
results in an acidification of pH and a subsequent colour change. However all E. coli 
SCV isolates were unable to utilise lactose which may lead to misidentification.  
 
These results underline the importance of molecular identification as gold standard. In 
this study RAPD analysis was applied to determine whether SCVs showed clonality 
with parent strains. Consistent and easily interpretable banding patterns were 
produced confirming clonality between SCVs and parents. These results are similar to 
the findings found in RAPD profiles generated from S. aureus SCVs recovered 
following exposure to tetracycline (Chapter 3). RAPD analysis has been applied to          
P. aeruginosa isolates recovered from patients suffering from CF (Mahenthiralingam 
et al., 1996). Many of these isolates displayed alteration in colonial morphology and 
motility but continued to produce a consistent RAPD fingerprints. The RAPD profiles 
generated in this study are in agreement with the work of Mahenthiralingam et al., 
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(1996), as the various differences alterations observed in SCVs do not correspond to a 
change in RAPD profiles. Although RAPD strain typing is highly discriminatory, the 
technique is subject to variability between laboratories. There are alternative PCR 
identification methods which could also be employed to aid SCV identification. 
Several P. aeruginosa specific gene targets are available but ecfX (which encodes an 
extracytoplasmic function sigma factor) has been demonstrated to be both 
discriminatory and reliable (Lavenir et al., 2007). Multiplex PCR protocols are 
available for the identification of E. coli (Toma et al., 2003) which allows 
differentiation of different E. coli pathovars. Finally multiplex PCR allowing 
identification of S. epidermidis as well as differentiation from S. aureus (Zhang et al., 
2004) would permit accurate determination of S. epidermidis SCV isolates.  
 
P. aeruginosa is intrinsically resistant to many antimicrobial agents (most β-lactams 
the older quinolones, chloramphenicol, tetracycline, macrolides, and rifampin) and 
thus very few antipseudomonas agents are available (Rossolini & Mantengoli, 2005). 
The observation that gentamicin can select for SCVs is thus important as it remains 
one of the few agents available to treat P. aeruginosa infection. SCVs have been 
implicated in persistent and recurrent infections (Roggenkamp et al., 1998; von Eiff et 
al., 1998) and thus treatment with gentamicin (and possibly other aminoglycosides) 
may present risks through the selection of SCVs. Several antibiotics were also able to 
select for SCVs of E. coli and S. epidermidis. Although these species do not show 
intrinsic resistance to the same degree as P. aeruginosa, antibiotic resistance in 
isolates has become apparent (Arciola et al., 2005; Mathai et al., 2001). The 
observation that various antibiotics can select for the SCV phenotype therefore has 
implications in treatment and management of infections.  
 
The bacterial signal molecule cyclic-diguanylate GMP (c-di-GMP) has been linked to 
SCV phenotype in P. aeruginosa (Meissner et al., 2007). c-di-GMP controls several 
cellular functions in many bacteria, but is principally related to the regulation and 
transition of the motile to the sessile form (Jenal & Malone, 2006). Further 
investigation has shown that the yfiBNR genes in P. aeruginosa produce a signalling 
molecule that regulates c-di-GMP levels in P. aeruginosa (Malone et al., 2010). 
Disruption of the YfiR (which regulates YfiN and subsequently c-di-GMP) leads to 
the production of the SCV phenotype through increased c-di-GMP production. 
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Antibiotics such as aminoglycosides influence the expression of c-di-GMP (Hoffman 
et al., 2005), which may explain the ability of gentamicin to select for SCVs. Parallels 
can be drawn between this mechanism and the alternative sigma factor, sigma B (σB) 
in S. aureus which influences formation of the SCV phenotype (Mitchell et al., 
2010a). It is feasible that σB activity governs SCV formation in S. epidermidis as 
comparison of σB between the two species show a similar organisation although there 
are variations in their role and function (Kazmierczak et al., 2005).  
 
The identification of auxotrophy in E. coli and S. epidermidis SCVs confirmed 
disruption of the bacterial electron transport chain (ETC). Auxotrophy is a common 
occurrence in SCV isolates recovered from antibiotic exposure (Balwit et al., 1994; 
Lewis et al., 1991). The resulting defects in electron transport result in major energy 
deficiencies resulting in atypical colony morphologies and growth profiles. Although 
auxotrophy was not detected in P. aeruginosa, SCV isolates shared characteristics 
with SCVs from other species, suggesting defects in ETC are responsible for the SCV 
phenotype. Haemin and menadione both play roles in P. aeruginosa electron transport 
(Matsushita et al., 1980), therefore defects in other components of the ETC may be 
responsible for the SCV phenotype. E. coli and S. epidermidis SCVs also displayed 
atypical biochemical characteristics in comparison to parent strains. This is an 
agreement with previous analysis in E. coli (Lewis et al., 1991) and S. epidermidis 
SCV (Al Laham et al., 2007) This may be attributed to interruption of the ETC and 
inability to utilise the tricarboxylic acid cycle (TCA cycle; Proctor, 2006).  
 
P. aeruginosa is a motile organism that can move via the process of swarming and 
swimming; both functions are dependant on the action of flagella (Henrichsen, 1972). 
The observations in this study suggest that P. aeruginosa SCVs are flagella deficient 
in comparison to parent strains. P. aeruginosa flagella have been shown to be an 
important virulence factor, and are required for the establishment of respiratory tract 
infections (Feldman et al., 1998). The loss of flagella activity may relate to an 
adaption after infection has been established, which has been observed in P. 
aeruginosa recovered from CF patients (Luzar et al., 1985; Starkey et al., 2009). The 
findings presented in this study suggest that exposure of P. aeruginosa to gentamicin, 
results in the production of the SCV phenotype similar to that observed in CF, which 
serves as an environmental adaptation.  
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The various physiological changes that have been reported in P. aeruginosa isolates 
from CF patients are often the result of adaptation to the CF lung (Smith et al., 2006; 
Sriramulu et al., 2005). P. aeruginosa SCVs recovered from CF patients have been 
shown to exhibit similar characteristics suggesting the SCV phenotype may play a key 
role in the pathogenesis of P. aeruginosa lung infection (Haussler et al., 2003b). 
Although the P. aeruginosa SCVs isolates in this study share characteristics with CF 
SCV isolates, this study additionally reports reduction in pyocyanin production and 
elastolytic activity. Pyocyanin mediates tissue damage and necrosis during lung 
infection (Lau et al., 2004). This stimulates the immune system which increases the 
number of macrophages, CD4 (+) T cells and neutrophils at the site of infection 
(Caldwell et al., 2009). Elastase is a zinc metalloprotease secreted by P. aeruginosa 
that causes tissue destruction during infection due to its proteolytic activity 
(Galloway, 1991). The reduced activity of these virulence factors shares common 
features with S. aureus SCVs which show reduced production of certain virulence 
factors (Tuchscherr et al., 2010). Reduction in virulence factors in the CF lung serves 
as an adaptation to a less aggressive lifestyle geared towards persistence (Hogardt & 
Heesemann, 2010) which P. aeruginosa SCVs are suited to. The SCV phenotype may 
serve as a survival mechanism to respond to a change in environment (exposure to 
antibiotics), similar to adaptations that occur in the CF lung.  
 
Disc diffusion assays were used to provide a measure of antimicrobial susceptibility. 
All SCVs (regardless of bacterial species or selecting agent) showed a reduction in 
susceptibility to gentamicin. Auxotrophy was defined in the majority of SCV isolates, 
confirming that disruption of the ETC is present in these isolates. Disruption of the 
ETC results in a decreases in the uptake of gentamicin. The isolates in which 
auxotrophy were not detected, reduced gentamicin susceptibility may be attributed to 
disruption of the ETC, since they share many characteristics with the auxotrophic 
SCV isolates. E. coli and S. epidermidis SCVs also showed reduced susceptibility to a 
variety of different classes of antimicrobial agents in comparison to parent strains. An 
explanation for this reduced susceptibility is the reduced growth rate observed in all 
SCV isolates. Antibiotics target various bacterial cellular processes, including protein, 
DNA and cell wall synthesis and thus altered rates of bacterial growth rate coincides 
with the response to antimicrobial agents (Tuomanen et al., 1986). As SCV isolates 
displayed reduced growth rate these processes work at a slower rate thus reducing 
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susceptibility. This is supported by the observation that E. coli SCVCIP showed the 
slowest growth rate in comparison to other E. coli SCV isolates and the greatest 
reduction in susceptibility to all antibiotics examined.   
 
Hydrophobicity is an important factor in bacterial adhesion to surfaces and to each 
other (van Loosdrecht et al., 1987). Increased hydrophobicity has been attributed to 
the abundance of pili in both E. coli (Drumm et al., 1989) and P. aeruginosa (Speert 
et al., 1986). As E. coli and P. aeruginosa SCVs isolated in this study displayed 
increased hydrophobicity, it is postulated that these SCVs show an increased 
abundance of pili in comparison to parent strains. This is further supported by the 
increase in twitching motility observed in P. aeruginosa SCVs as twitching motility 
in P. aeruginosa is dependent on the action of pilli (Bradley, 1980) and mutants 
defective in pili production are deficient in twitching motility (Shan et al., 2004).  The 
increase in the abundance of pili may increase the capacity of SCVs to form biofilms. 
P. aeruginosa mutants that are deficient in the synthesis of type IV pili are also 
deficient in the formation of biofilms on abioitic surfaces (O'Toole & Kolter, 1998). 
Similarly in E. coli, mutants deficient in pili production are also deficient in biofilm 
formation (Pratt & Kolter, 1998). Although both of these studies show the crucial 
importance of pili in biofilm formation it is important to note that the deficiencies in 
different type pili systems impacts on different stages of biofilm development. 
Nevertheless the data shown in this study suggest that the presence of pili may be 
linked to biofilm formation in P. aeruginosa SCVs. An increased abundance of pili 
has been reported in P. aeruginosa SCVs isolated from CF patients and linked to 
biofilm formation (Haussler et al., 2003b) adding evidence to the links proposed.  
 
In contrast, S. epidermidis SCVs displayed no difference in cell surface 
hydrophobicity in comparison with parent strains but still showed an increased 
capacity to form biofilms. The σB mediated selection mechanism proposed previously 
correlates with the enhanced biofilm capacity in S. epidermidis SCVs. Previous 
studies have demonstrated that S. epidermidis mutants constitutively expressing σB 
displayed increased production of polysaccharide intracellular adhesin (PIA) therefore 
increasing biofilm formation (Jager et al., 2009). Increased expression of σB can be 
proposed as the genetic mechanism for increased biofilms formation in S. epidermidis 
SCVs. Biofilm formation in S. epidermis is considered as one of the organism’s key 
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virulence factors in mediating device associated infections (McCann et al., 2008). A 
switch to the SCV phenotype may facilitate persistence through the increased capacity 
to form biofilms.  
 
The production of the SCV has been linked to persistence and survival in S. aureus 
(Proctor et al., 2006). SCVs isolated from diverse bacterial species that inhabit many 
different environments share similar characteristics that have come to be associated 
with the SCV phenotype. The SCV phenotype appears to be a common mechanism 
utilised by bacteria to permit survival in the presence of antimicrobial compounds 
which subsequently permits persistence via reduced antimicrobial susceptibility and 
biofilm formation. The switch from a fast growing virulent phenotype to a slow 
growing SCV seems a small price to pay for survival. 
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6.5 Conclusions  
 
• Exposure of E. coli to ciprofloxacin and chloroamphenicol and S. epidermidis to 
tetracycline results in selection for SCVs. 
• Exposure of E. coli, P. aeruginosa and S. epidermidis to gentamicin results in 
selection for SCVs. 
• E. coli, P. aeruginosa and S. epidermidis SCVs share known characteristics with 
SCVs including atypical colony morphology and growth profiles. 
• E. coli and S. epidermidis SCVs are auxotrophic for compounds which have roles 
in electron transport. 
• Susceptibility to various antimicrobial agents is reduced in SCVs. 
• E. coli and P. aeruginosa SCVs have an increased capacity to form biofilms 
which appears to be related to increased abundance of pili. 
• RAPD analysis confirmed SCVs show clonality with parent strains. 
• E. coli and S. epidermidis SCVs display atypical biochemical profiles.  
• P. aeruginosa SCVs are deficient in swarming and swimming motility, as well as 
deficient in the production of virulence factors; elastase and pyocyanin.   
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7 CHAPTER 7: GENERAL CONCLUSIONS AND DISCUSSION 
 
7.1  Conclusions 
The work presented in this study aimed to investigate the ability of various 
antimicrobials to select for S. aureus SCVs and investigate their capacity to form 
biofilms as well as examine their susceptibility to a range of plant antimicrobial 
compounds. Antibiotic selection for SCVs in other bacterial species was also 
examined and these isolates were characterised and their capacity to form biofilms 
investigated. In this chapter the general conclusions of each main area of work will be 
reiterated with respects to the aims mentioned in Chapter 1.  
 
• Various aminoglycosides can select for S. aureus SCVs at a range of 
concentrations. 
• The formation of SCVs is a hindrance to accurate aminoglycoside susceptibility 
testing, which led to the development of a ‘minimum SCV prevention 
concentration’, which ensures eradication rather than SCV selection at higher 
concentrations.  
• Variations in carbohydrate utilisation, carotenoid production, levels of 
intracellular ATP, mutation frequency and rates of reversion are apparent between 
SCVs selected at different aminoglycoside concentrations. 
• Members of the tetracycline family of antibiotics can select for S. aureus SCVs 
• Tetracycline selected SCVs show attenuated catalase, coagulase and heamolysis 
activity and reduced production of extracellular DNase and lipase and reduced 
susceptibility to various antimicrobial agents.  
• S. aureus SCVs show increased biofilm formation in comparison to parent strains 
which appears to be linked to increased production of polysaccharide intracellular 
adhesin. 
• S. aureus SCV and parent biofilms show reduced susceptibility to various 
antimicrobial agents in comparison to planktonic cells.  
• The reduction in antimicrobial susceptibility is further pronounced in S. aureus 
SCV biofilms which is linked to reduced antimicrobial penetration through             
S. aureus SCV biofilms.  
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• S. aureus SCV and parents are susceptible to various plant antimicrobial 
compounds of which SCVs are more susceptible to cinnamon bark, green tea and 
oregano.  
• Resistance to plant antimicrobials was not detected following continuous exposure 
of S. aureus SCVs to sub lethal concentrations. 
• Various plant antimicrobials display a synergistic relationship against S. aureus 
with various antibiotics including oxacillin, neomycin and tetracycline.  
• Gentamicin can select for SCVs in Escherichia coli, Pseudomonas aeruginosa 
and S. epidermidis. Additionally exposure of E. coli to ciprofloxacin and 
chloramphenicol and S. epidermidis to tetracycline selected for SCVs. 
• SCVs from these bacterial species share characteristics with S. aureus SCVs 
including altered growth and biochemical profiles, auxotrophy for compounds 
involved in electron transport, reduction in virulence factors and reduced 
antimicrobial susceptibility. 
• All SCVs showed an increased capacity to form biofilms compared to their parent 
strains. 
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7.2 General discussion  
7.2.1 Identification and treatment of SCV infections   
Despite the observation that S. aureus SCVs are often associated with  infections 
commonly caused by biofilms,  planktonic cells are still of the utmost importance in 
species and strain identification and determining  susceptibility profiles in clinical 
laboratories. However the identification of SCVs is riddled with difficulty. It is well 
documented that identification of S. aureus SCVs is difficult and automated systems 
can misidentify SCVs (Seifert et al., 1999; Spanu et al., 2005). Atypical growth rates 
can lead to their presence being missed on agar plates and their atypical phenotypic 
and enzymatic characteristics can also lead to misidentification. In this study 
multiplex PCR was successfully employed for the identification of S. aureus SCVs. 
Molecular identification of SCVs has been applied previously and proved successful 
(Sendi et al., 2006; von Eiff et al., 1999). RAPD fingerprinting also showed that SCV 
isolates showed clonality with parent strains. Although molecular diagnostics may 
increase expense compare with conventional diagnostic microbiology it overcomes 
the uncertainty that may surround the identification of SCVs.  
 
In order for susceptibility testing to be performed cultivation is required. When 
investigating SCVs in species other than S. aureus conventional CLSI microdilution 
susceptibility proved difficult due to the formation of biofilms in microtitre plates. 
However the use of disc diffusion method of susceptibility overcame these associated 
problems. Again these issues highlight difficulties during susceptibility testing of 
SCVs. Molecular determination of resistance determinants such as mecA may prove 
useful for determining SCV susceptibility. Furthermore, the instability of the SCV 
phenotype represents further challenges. SCVs may be the causative agent of 
infection, but the subsequent cultivation may result in reversion to the parent 
phenotype which may have implications for the chosen treatment regime. Taking into 
account these issues, an awareness of the SCV phenotype (particularly in the diseases 
they have been associated with such as CF and osteomyelitis) may aid accurate 
diagnostics and change treatment course.  
 
Research presented here documents for the first time for the tetracycline class of 
antibiotics to select for S. aureus SCVs. The SCV phenotype represents a novel 
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mechanism for reduced tetracycline susceptibility in S. aureus. As the uptake of 
tetracycline is partially energy dependent (McMurry & Levy, 1978) and attributed in 
part to the presence of a proton motive force (Smith & Chopra, 1984), the reduced 
susceptibility to tetracycline in SCVs may be related to reduced uptake. Tetracycline 
and other tetracycline antibiotics have been successfully applied for the treatment of 
MRSA infections (Ruhe et al., 2005). A follow up of patients in the latter study would 
have provided an interesting observation to determine if any relapse of infection were 
reported.  This would perhaps correlate with the presence of SCVs. Although the 
selection of SCVs does not result in a large reduction in antimicrobial susceptibility, 
the finding that tetracycline can select for S. aureus (and also S. epidermidis) SCVs 
may have implications in its clinical use. Investigating the ability of the recently 
developed tigecycline to select for SCVs would be an interesting further investigation.  
 
Exposure to several aminoglycosides at a wide range of concentrations also resulted 
in the selection of S. aureus SCVs. Although gentamicin has a long history of SCV 
selection this study was the first to address concentration dependent selection. 
Interestingly the concentration of selecting aminoglycoside impacts on the 
characteristic of the SCV selected for and a clear correlation between 
aminoglycosides concentration and SCV characteristics are apparent. The observation 
that a broad range of concentrations selects for S. aureus SCVs is also an important 
finding. The concentrations examined range from bacteriostatic to bactericidal; 
however the distinction between bacteriostatic and bactericidal activity can often be 
arbitrary in the clinical sense. Achieving bactericidal activity is crucial for the 
effective treatment of various bacterial infections (Pankey & Sabath, 2004). As 
aminoglycosides are considered as bactericidal agents, they may be employed a high 
concentrations to treat infection. However the use of bactericidal concentrations can 
select for a SCV population, hence the development of the term ‘minimum SCV 
prevention concentration’. This ensures eradication of wildtype and thwarts the 
selection of SCVs.  
7.2.2 SCV and persisters   
Some overlap exists between the SCV phenotype and a state of bacteria termed 
persisters which are often recovered following antibiotic exposure. Persisters have 
been described as a ‘subpopulation of dormant cells that have been implicated in a 
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range of chronic and recurrent infections through their ability to survive antibiotic 
treatments’ (Jermy, 2011). Although persisters are antibiotic tolerant, they differ from 
antibiotic resistance mutants as their antibiotic tolerance is not hereditary and can be 
reversed when grown in the absence of antibiotics (Jayaraman, 2008). Persisters have 
also been implicated in chronic infectious diseases, including cystic fibrosis (CF) 
patients infected with Pseudomonas aeruginosa and Candida albicans in oral thrush 
patients (Lewis, 2010). The observation that SCVs have also been implicated in 
persistent infections suggests that some similarities exist between the two phenotypes. 
Some overlap in gene expression profiles in SCVs and persisters is apparent; for 
instance, expression of stress response proteins (heat shock, SOS response) and 
operons involved in oxidative phosphorylation (NADH dehydrogenase, ATP 
synthase, and cytochrome O-ubiquinole oxidase) are altered in persisters (Keren et al., 
2004). Similarly in S. aureus SCVs alteration in the expression of genes with 
functions in electron transport and global regulators involved in stress response and 
virulence are altered (Moisan et al., 2006; Seggewiss et al., 2006). An important 
contrasting characteristic between SCVs and persisters is growth rate. SCVs are 
metabolically active although they exhibit atypical growth profiles. On the other hand 
persisters are regarded as non-growing, dormant cells that exist as a distinct 
physiological state (Balaban et al., 2004; Shah et al., 2006).  
 
SCVs and persisters have been associated with antimicrobial resistance. Although 
SCVs and persisters do not follow classical resistance mechanisms, there are 
differences in the mechanisms that contribute to reduced antibiotic 
susceptibility/tolerance. In persisters of Escherichia coli toxin-antitoxin (TA) modules 
and other genes block translation in protein synthesis (Keren et al., 2004). This results 
in the shutting down of cellular processes and targets which antimicrobial agents 
required to be active in order to effective. The non-dividing state results in the 
tolerance observed in persisters. In SCVs however, reduced susceptibility to 
antimicrobial agents rather than tolerance is observed. A perturbed electron transport 
chain results in a reduced membrane potential and uptake of positively charged 
antimicrobials such as aminoglycosides is reduced. Defects in electron transport result 
in a slower growing phenotype however cellular processes are still active in contrast 
to persisters. As such, it is important to document that although persisters and SCVs 
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can both be linked to recurrent and refractory infections and some overlap exists 
between the states, they must be viewed as separate entities.   
7.2.3 Biofilm formation in SCVs  
In this study SCVs from several bacterial species displayed an increased capacity for 
biofilm formation in comparison to parent strains. Biofilms have been suggested to be 
the root of many chronic and persistent infections and are associated with increasing 
healthcare cost and morbidity. Furthermore, approximately 60% of bacterial 
infections are thought to involve biofilms (Costerton et al., 1999) yet the role of SCVs 
in these biofilm-related infections remains largely unknown. The ability of SCVs to 
form biofilms has clear implications in biofilm associated infections. It is well 
documented that bacteria present in biofilms showed a reduced growth rate which 
contributes to reduced antimicrobial susceptibility (Mah & O'Toole, 2001). Nutrient 
limitation and oxygen limitation is thought to be responsible for slow growth rate in 
biofilms (Brown et al., 1988). The SCV phenotype and the biofilm phenotype appear 
to share similarities. SCVs were not detected from parent biofilms, however it is 
important to note that SCVs are frequently unstable and reversion during plate 
counting may have meant SCVs went undetected. SCVs were shown to disseminate 
from S. aureus parent biofilms that had been exposed to antimicrobials and their 
growth characteristics and biofilm forming capacity suggest the SCV phenotype 
permits an optimised phenotypic state for biofilm growth and proliferation of 
biofilms. Couple with their reduced growth rate and reduced antimicrobial 
susceptibility the formation of a SCV phenotype serves as an adaptive plasticity.  
7.2.4 Novel biofilm treatment strategies  
This study also demonstrates the reduced antimicrobial susceptibility of biofilms. 
Biofilms displayed reduced susceptibility to various antimicrobials which we 
observed in several wildtype S. aureus strains. However, biofilms formed by SCV 
isolates showed further reduced susceptibility in comparison. One of the novel 
approaches to treating biofilm associated infections is the use of bacteriophage. 
Bacteriophages are viruses that infect bacteria and can follow a virulent lytic or 
lysogenic lifestyle. The use of bacteriophage to control device associated infections 
offers several advantages over antimicrobial agents. Firstly, whilst older biofilms are 
more difficult to eradicate using conventional antimicrobials, bacteriophage treatment 
 202 
is not affected by biofilm age (Amorena et al., 1999; Hanlon et al., 2001). Hanlon et 
al., (2001) also documented that biofilm thickness and the presence of polysaccharide 
did not limit the diffusion of phage through biofilms, which in the study antibiotic 
penetration has a direct impact on antimicrobial susceptibility. Finally, bacteriophage 
can be engineered to express biofilm degrading enzymes. The treatment of biofilms 
with such degrading enzymes, such as dispersin B (which causes hydrolysis of 
glycosidic linkages in biofilm polysaccharide) can eradicate bacterial biofilms (Itoh et 
al., 2005) and use of bacteriophage expressing these enzymes enabled high levels of 
anti-biofilm activity (Lu & Collins, 2007). Bacteriophage K (a member of the 
Myoviridae phage family) has been shown to inhibit various clinically isolated S. 
aureus strains and other staphylococcal species (O'Flaherty et al., 2005), although it 
has yet to be tested on biofilms formed by S. aureus. Bacteriophage K has been 
demonstrated to reduce biofilm mass in biofilms formed by S. epidermidis (Cerca et 
al., 2007). The engineering of bacteriophage K to produce biofilm degrading enzymes 
such as dispersin B may offer an attractive option to combat SCV biofilms. Other 
novel approaches for the eradication of staphylococcal biofilms include the inhibition 
of quorum sensing (Balaban et al., 2007) and the impregnation of biomaterials with 
novel antibacterial compounds (such as usnic acid, a secondary lichen metabolite) to 
inhibit biofilm formation (Francolini et al., 2004).  
7.2.5 The SCV phenotype as a survival strategy  
An overview of the research presented here and a review of the literature implicates 
the role of the SCV phenotype as survival mechanism in S. aureus and other bacterial 
species. The ability to switch to an altered phenotype in the presence of antimicrobial 
agents is clearly favourable if it permits survival. SCVs ‘trade in’ many characteristics 
that are associated with rapid growth in order to survive in unfavourable conditions. 
Various reports of phenotypic switching have been reported in the literature including 
the formation of persisters, in the presence of antibiotics. Other examples include 
variation of membrane surface lipoprotein antigens in Mycoplasma bovis 
(Lysnyansky et al., 1996) and altered expression of surface determinants in 
Burkholderia pseudomallei (Chantratita et al., 2007). Formation of the SCV 
phenotype in S. aureus can also be viewed as a phenotypic switching system which 
appears to be strongly influenced by the alternative sigma factor, σB (Mitchell et al., 
2010a). The observation that SCVs characteristics correlates to the concentration of 
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the selecting aminoglycoside suggests that σB is influenced in a concentration 
dependent manner. Rates of reversion in SCV isolates showed differentiation with 
SCVs selected a higher concentrations remaining stable. In these variants σB may 
constantly upregulated thus locking them into the SCV phenotype. The influence of 
σ
B
 and the locking in of the SCV phenotype has been observed in S. aureus SCV 
isolated from CF patients (Mitchell et al., 2008). Clearly σB plays an important role in 
the SCV phenotype in S. aureus SCVs and their selection in the presence of 
aminoglycosides. Various other antimicrobial agents are known to select for S. aureus 
SCVs and it would be interesting to monitor the expression of σB (via  real time PCR) 
to determine whether these antibiotics influence the expression of the global regulator 
and are involved in SCV formation.  
7.2.6 Novel antimicrobials for S. aureus and SCVs 
The ability of S. aureus to develop resistance to variety of antimicrobial agents and 
the ability to switch to the SCV phenotype results in diminishing therapeutic options 
for treatment of these infections caused by these organisms. As discussed previously 
the difficulties surrounding antibiotic resistance and the lack of novel antibiotics in 
development have worrying implications in the healthcare setting. Cinnamon bark, 
ginger grass, green tea and oregano all have activity against S. aureus as demonstrated 
via disc diffusion and broth dilution methods. Broth dilution testing revealed S. 
aureus SCVs to be more susceptible to cinnamon bark, green tea and oregano which 
is encouraging as SCV show reduced susceptibility to various antimicrobial agents. 
Another significant observation was that none of the plant antimicrobials examined 
showed selection for S. aureus SCVs, which taking into consideration of previous 
finding may be a consideration in the treatment of S. aureus infection. Although the 
plant antimicrobials concentrations that were inhibitory are a lot higher than the 
concentrations of commonly used antibiotics, this research also highlights their 
possible use in combination with antibiotics. Various synergistic relationships were 
observed thus there is that these plant antimicrobials offer a novel avenue to combat 
antibiotic resistance.  
 
The susceptibility of S. aureus SCVs to plant antimicrobials may have applications in 
the treatment of biofilm associated infections. For example carvacrol and eugenol are 
effective against biofilms formed by E. coli O157:H7 and Listeria monocytogenes 
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(Perez-Conesa et al., 2011). Specifically carvacrol and thymol can inhibit the first 
step in biofilm formation (initial adherence) in S. aureus (Nostro et al., 2007). The 
application of these compounds to biomaterials such as catheters and prosthetics may 
provide a useful strategy to block biofilm formation. 
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APPENDIX 1 
 
Enzymatic Reactions of API STAPH Test Strip 
 
Result Tests Substrates  Reactions/Enzymes 
Negative Positive 
0 No Substrate negative Control red/orange - 
GLU 
FRU 
MNE 
MAL 
LAC 
TRE 
MAN 
XLT 
MEL 
D-glucose  
D-fructose 
D-mannose  
maltose 
lactose  
D-trehalose  
D-mannitol  
xylitol 
D-melibiose  
 
 
acidification due to 
carbohydrate 
utilization 
 
 
 
red 
 
 
 
yellow 
NIT potassium nitrate  reduction of nitrate to 
nitrite 
colourless-Light 
pink 
red/purple* 
PAL Β-naphthyl-acid 
phosphate 
 
alkaline phosphatase yellow violet# 
VP sodium pyruvate  acyl-methyl-carbinol 
production 
colorless/light 
pink 
pink/violet^ 
RAF 
XYL 
SAC 
MDG 
NAG 
raffinose  
xylose  
sucrose  
α-methyl-D glucoside 
N-acetyl-glucosamine 
 
acidification due to 
carbohydrate 
utilization 
 
 
red 
 
 
yellow 
ADH arginine  arginine dihydrolase yellow orange-red 
URE urease urease yellow red-Violet 
 
*1 drop of the reagents NIT-1 and NIT-2 was added, and left for 10min before result being read. 
# 1 drop of the reagents ZYM A and ZYM B were added, and left for 10min before result being 
read. 
^1 drop of the reagents VP-1 and VP-2 was added, and left for 10 min before result being read. 
ADH and URE- Anaerobic conditions needed for these reactions. This was achieved by filling up to 
the cupule meniscus with mineral oil. 
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API Staph medium (composition per litre) 0.5 g yeast, 10 g bactopeptone, 5 g NaCl, 10 mL 
trace elements  
 
Enzymatic Reactions of API E Test Strip 
 
Result  Tests   Substrate   Reactions/Enzymes 
Negative     Positive  
ONPG 
2-nitrophenol-ßD-
galactopranoside 
ß-galactosidase colorless Yellow 
ADH 
        L-arginine arginine dihydrolase yellow red/orange 
LDC 
L-lysine lysine decarboxylase yellow red/orange 
ODC 
L-omithine omithine decarboxylase yellow red/orange 
CIT 
trisodium citrate citrate utilisation yellow blue/green 
H2S 
sodium thiosulfate H2S production colorless black deposit 
URE 
urea urease yellow red/orange 
TDA 
L-tryptophane tryptophane deaminase yellow red* 
IND 
L-tryptophane indole production yellow red ring# 
VP 
sodium pyruvate acetoin production colorless pink/red^ 
GEL 
gelatin gelatinase no diffusion diffusion of pigment 
GLU 
D-glucose fermentation/oxidation blue/green yellow 
MAN 
D-mannitol fermentation/oxidation blue/green yellow 
INO 
inositol fermentation/oxidation blue/green yellow 
SOR 
D-sorbitol fermentation/oxidation blue/green yellow 
RHA 
L-rhamnose fermentation/oxidation blue/green yellow 
SAC 
D-sucrose fermentation/oxidation blue/green yellow 
MEL 
D-melibose fermentation/oxidation blue/green yellow 
AMY 
amygdalin fermentation/oxidation blue/green yellow 
ARA 
L-arabinose fermentation/oxidation blue/green yellow 
 
*1 drop of the TDA reagent added and result read immediately   
# 1 drop of the JAMES reagent added and result read immediately   
^1 drop of the reagents VP-1 and VP-2 was added, and left for 10 min before result being read. 
ADH, LDC, ODC, H2S and URE - Anaerobic conditions needed for these reactions. This was achieved by 
filling up to the cupule meniscus with mineral oil. 
 
